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Dry powder coating of pharmaceutical dosage forms has been investigated as an 
alternative method to commonly used liquid based coating techniques. Eudragit® L 100-
55 and Eudragit® L 30 D-55 have been employed in enteric film coatings using aqueous 
dispersions, organic solutions and compression coating. However, the copolymer has not 
been investigated in dry powder coating applications.  
 Initially, formulation factors and processing parameters were investigated for the 
dry powder coating of chlorpheniramine maleate tablets using Eudragit® L 100-55 as the 
delayed release polymer. Powder coating was studied as a method to prevent the 
migration of an ionizable, highly water soluble model drug into the polymeric film during 
the coating process. Eudragit® L 100-55 was pre-plasticized with triethyl citrate (TEC) 
using hot-melt extrusion and subsequently ground into a fine powder. Polyethylene 
glycol 3350 (PEG 3350) was used as a primer and low melting coating excipient to 
 viii
enhance coating powder adhesion and to improve film formation. The powder coating 
process was performed in a modified laboratory scale spheronizer.  
 For the dry-powder coating of sodium valproate tablets different subcoating 
materials were investigated to improve powder adhesion to the substrate and to reduce 
the level of Eudragit® L 100-55 required for gastric resistance. PEG 3350 and Methocel® 
K4M were incorporated in the Eudragit® E PO and Eudragit® RL PO subcoating 
formulations as pore forming materials. The miscibility of the PEG 3350 and Methocel® 
K4M in the film coating was correlated with their ability to function as pore forming 
agent. 
 The film formation process of thermally cured Eudragit® L 100-55 dry-powder 
coatings was characterized. The influence of film additives on relative melt viscosity, 
surface free energy of the polymer and the mechanical properties of powder-cast films 
was studied.  
The influence of Eudragit® E PO in Eudragit® L 100-55 film coatings applied by 
a dry powder coating technique on the drug release mechanism was investigated. 
Calculation of the Flory-Huggins interaction parameter based on solubility parameters 
and different analytical techniques demonstrated immiscibility of the copolymers at 
processing conditions. A broad range of pH dependent theophylline release profiles were 
obtained as a function of the polymer blend ratio. 
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Chapter 1: Introduction 
1.1 DRY COATING OF PHARMACEUTICAL DOSAGE FORMS 
1.1.1 Coating of pharmaceutical dosage forms 
 
Dry coating of pharmaceutical dosage forms has been widely investigated as 
alternative to liquid based coating techniques. Sugar coating is a time-consuming process 
that is difficult to standardize and that requires highly skilled operators. Organic solvent 
based coating techniques are connected with environmental and safety related concerns. 
Other disadvantages include the relatively low polymer concentration of the coating 
formulation and from a toxicological standpoint, possible solvent residues in the final 
product. Aqueous coating has been widely used for the coating of pharmaceutical dosage 
forms. However, the process is not applicable for water-sensitive drugs. It has been 
reported that highly water-soluble drugs can migrate into the film coating, interfere with 
film formation and result in a premature drug release [1]. Another disadvantage is the 
slow drying rate. Usually slower spray rates and higher coating bed temperatures are used 
in aqueous coating compared to organic solvent based processes. Residual moisture was 
shown to affect the storage stability of the final product [2]. Water can cause hydrolysis 
reactions of active pharmaceutical ingredients and as plasticizer it may affect the 
permeability of the film coating. Bose and Bogner recently reviewed different solvent-
free pharmaceutical coating techniques including compression coating, hot-melt coating, 
supercritical fluid coating, electrostatic spray powder coating, dry powder coating, and 
photocurable coatings [3]. 
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1.1.2 Compression coating 
 
 The manufacturing process for compression coated dosage forms consists of two 
steps: compression of the core which is followed by a second compression of the outer 
layer around the core. The process is mainly used for the coating of tablets. Correct 
centering of the inner core is essential for a controlled drug release. Typical materials 
used for compression coating include polyethylene oxide, hydroxypropyl 
methylcellulose, carboxymethylcellulose, sodium alginate, and chitosan [3]. Upon 
contact with dissolution media or physiological liquids these materials forms a gel-like 
matrix. Erosion and diffusion of the swollen coating control the drug release rate. 
Important formulation considerations include the compactability of the outer layer 
material and bonding between core tablet and outer layer.  
Mixtures of Eudragit® RS PO and Eudragit® S 100 were investigated for the 
compression coating of tablets to apply a seal coat onto constant-rate regulated release 
tablets [4]. The coating formulation consisted of granulated blends of Eudragit® RS PO 
(520g), Eudragit® S 100 (138g), triethyl citrate (35g), and magnesium stearate (7g). After 
curing of the compression coated tablets at 80ºC for 1 hour, the polymer coating was 
shown to be porous, allowing dissolution medium to enter the core tablet. NMR analysis 
was used to study the diffusion of water into the compression coated tablet.  
Eudragit® L 100-55 was investigated alone or in combination with hydroxypropyl 
cellulose (HPC) and magnesium stearate for the compression coating of tablets 
containing nattokinase [5]. No additional plasticizer was listed in the manuscript. The 
coating was shown to prevent denaturation of the enzyme in gastric juice and the gastric 
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resistance was improved in the presence of HPC and reduced in combination with 
magnesium stearate. 
One-Step Dry-Coating Technology (OSDrC®) is used to manufacture 
compression coated dosage forms in a single step [6, 7]. Rotary tableting machines with 
variable double-punch configuration were employed to coat Eudragit® L 100-55 onto 
core tablet containing either 5-fluorouracil or acetaminophen. The coating formulation 
contained Eudragit® L 100-55 (79%), magnesium aluminometasilicate (10%), triethyl 
citrate (10%), and magnesium stearate (0.6%) [6]. Prior to powder blending, the 
plasticizer triethyl citrate was adsorbed onto magnesium aluminometasilicate [6]. The 
tablets were not cured but stored at room temperature for 24 hours with desiccant prior to 
analysis. The compression coated tablets were acid resistant for 24 hours in No.1 fluid 
(pH 1.2) and thus complying with JP XIII. After 4 hours in No.1 fluid, the tablets were 
transferred to No.2 fluid (pH 6.8) and acetaminophen was rapidly released after 
approximately two more hours lag time [6]. The release of 5-fluorouracil was affected 
both in acid and buffer when Eudragit® L 100-55 was combined with chitosan [7]. 
Chitosan in Eudragit® L 100-55 compression coatings acted as pore forming agent in 
No.1 fluid. In No.2 fluid, chitosan delayed the release of 5-fluorouracil. The effect was 
dependent on the chitosan concentration. 
 
1.1.3 Hot-melt coating 
 
 Lipids, waxes, polyethylene glycol are materials that have been investigated for 
the hot-melt coating of pharmaceutical dosage forms to obtain taste-masking or sustained 
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drug release.  Recommended properties for the coating excipients encompass a melt 
viscosity of less than 300 centipoise and a melting point below 80ºC for flow and 
sprayability of the coating material [3] and is thus not used for Eudragit® polymers. One 
major stability concern of hot-melt coated dosage forms is the polymorphism of some 
employed coating excipients.  
  
1.1.4 Supercritical fluid coating 
 
 Supercritical carbon dioxide can be used as solvent and anti-solvent in 
pharmaceutical coating applications. Supercritical fluid coating is mainly employed for 
the coating of drug particles. One formulation requirement is the insolubility of the core 
material in the supercritical fluid. Since most polymers have insufficient solubility in 
supercritical fluids, cosolvents are additionally used or the supercritical fluid is used as 
anti-solvent [3, 8]. Eudragit® RL 100 was investigated for the coating of silica 
nanoparticles employing an anti-solvent process [8]. Due to the limited solubility of the 
acrylic polymer in supercritical carbon dioxide, Eudragit® RL PO was dissolved in 
acetone. The spraying of the supercritical anti-solvent in the nanosuspension resulted in 
polymer nucleation on the silica nanoparticles. Since the process employed organic 




1.1.5 Photocurable coating  
 
 Photocurable coating technology is based on free-radical polymerization, initiated 
by UV or visible light and is hence not applicable for photosensitive drugs [3]. The 
coating formulation is based on liquid monomers, photoinitiator and/or photosensitizer. 
Bose and Bogner investigated siloxanes and methacrylates. The addition of pore formers 
such as sodium starch glycolate, lactose, and sodium chloride resulted in an increase in 
drug release rate. The toxicological profile of the coating excipients has not been 
established for all employed materials. Also possible chemical reactions with active 
pharmaceutical ingredients or core excipients have not been discussed. 
 
1.1.6 Initiated chemical vapor deposition 
 
 Initiated chemical vapor deposition was investigated to apply methacrylic acid 
copolymers similar to Eudragit® L 100-55 onto silicon flats and three-dimensional 
particles [9]. The process involved free radical polymerization without any liquid or 
solvent phase. Adsorption of polymerized monomers from its vapor onto a cooled surface 
resulted in a polymer coating. Tert-butyl peroxide was used as radical initiator and 
methacrylic acid and ethyl acrylate as comonomers in different ratios. When ethylene 
dimethacrylate was used as alternate comonomer, the cross-linking agent tert-amyl 
peroxide was used as radical initiator. Ibuprofen microcrystals that were coated using 
initiated chemical vapor deposition did not possess sufficient gastric resistance. However, 
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silicon surfaces that were coated with methacrylic acid and ethylene dimethacrylate were 
stable at pH 1.2 and did not show any fluorescein release over 90 minutes. 
 
1.1.7 Electrostatic spray powder coating 
 
 Electrostatic powder coating has been widely used in the metal finishing industry. 
Initially the coating powder particles are charged (potential difference to earth). The 
adhesion of the coating powder to a grounded substrate is followed by heat curing or IR 
radiation [3]. All used excipients must be characterized by some conductivity. 
Conductive properties can be obtained in pharmaceutical dosage forms with the use of 
materials possessing polar functional groups such as quaternary ammonium groups (i.e. 
cetrimide, benzalkonium chloride), by the incorporation of ionic salts, or high humidity 
treatment [3, 10]. Phoqus Pharmaceuticals, Ltd. developed scale-up and technology 
transfer strategies for the electrostatic dry powder deposition onto tablet cores [11]. 
However, there is little peer-reviewed literature on the technique. Electrostatic coating of 
pharmaceutical dosage forms with Eudragit® polymers, namely Eudragit® RS and 
Eudragit® E, have been claimed in several US patent applications [10, 12-15]. In addition 
to Eudragit® RS, the coating formulation may contain high molecular weight 
polyethylene glycol, polyethylene oxide, hydroxypropyl cellulose, xylitol, colorants and 
pigments such as aluminum lakes or titanium dioxide, disintegrants like sodium starch 
glycolate or croscarmellose sodium, wetting agents as sodium lauryl sulfate and glidants 
like colloidal silicon dioxide or glycerol monostearate [13]. The coating powder for 
electrostatic coating was obtained by wet granulation, followed by fluid bed drying and 
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micronization using a fluid energy mill. The mean particle size of the coating powder was 
approximately 10µm. Both sides of the tablet cores were coated separately using 
specialized equipment. Polymer particle fusion was completed with a curing step above 
130ºC for 5 seconds employing IR radiation. Both Eudragit® RS and Eudragit® E 
formulation were also investigated to layer active pharmaceutical ingredients onto tablet 
cores using an electrostatic powder coating technique [15].  
 
1.1.8 Dry powder coating 
 
 Thermosetting powder coatings have been investigated since the 1950s when for 
the first time powdered polyethylene was coated onto a preheated metal surface using a 
fluidized bed process [16]. In 1999 the first manuscript on the dry powder coating of oral 
pharmaceutical dosage forms was published by Obara et al. [17]. Hydroxypropyl 
methylcellulose acetate succinate (HPMCAS) was used as the enteric polymer with a 
particle size of not more than 10µm. The coating of pancreatin beads consisting of sugar 
seeds, corn starch, and low-substituted hydroxypropyl cellulose (L-HPC®) and placebo 
tablets containing spray-dried lactose, corn starch and L-HPC® was investigated in the 
study. The tablet cores were coated with hydroxypropyl methyl cellulose prior to 
application of the enteric polymer using an aqueous process to avoid penetration of the 
plasticizer into the core. Obara et al. used a centrifugal granulator for preliminary studies, 
a lab-scale ventilated pan coater, and a fluidized bed for the coating process. During the 
coating process, the exhaust air temperature which approximately corresponds to the bed 
temperature was kept at 42ºC and was increased to 50ºC during the curing phase. 
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HPMCAS was pre-blended with talc in a 10:3 ratio. The plasticizer triethyl citrate was 
combined with acetylated monoglycerides in a 3:2 ratio to reduce the necessary 
plasticizer level and increase coating efficiency. Acetylated monoglycerides 
demonstrated a low contact angle with HPMCAS which was directly correlated with an 
increased coating efficiency. The triethyl citrate level was 30% based on the dry polymer 
weight. Plasticizer dispersion and polymer powder were separately delivered into the 
coating bed, however powder feed and plasticizer spray started and ended 
simultaneously. As part of the curing process, an aqueous HPMC solution was applied 
onto the coated cores to increase the gastric stability, before the beads and tablets were 
dried with heated air until the exhaust temperature reached 50ºC. The aim of Obara’s 
study was to shorten the processing time of coating processes by using a formulation with 
a higher polymer concentration. The final goal, to develop a completely liquid free 
process, was not achieved since water was still required during the curing phase to 
promote film formation [17]. Higher coating levels were required to ensure gastric 
resistance (25% polymer weight gain for dry coated beads compared to 18% for aqueous 
coating). However, the processing time was shortened to approximately one third 
compared to an aqueous coating process. Also physical stability of the dry coated tablets 
was comparable to ones prepared using an aqueous process after storage at 40ºC for 6 
months. Both formulations showed a slight increase on disintegration time at pH 6.8.  
Pearnchob et al. adapted the process that was developed by Obara et al. for 
Eudragit® RS PO and ethylcellulose [18, 19]. Prior to dry powder coating, the model drug 
propranolol HCl was layered onto nonpareils using hydroxypropyl methyl cellulose as 
binder and polyethylene glycol 4000 as plasticizer. Eudragit® RS PO was micronized, 
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obtaining a mean particle size of 9.4µm compared to 159.2µm of the bulk polymer. Talc 
was employed as glidant to improve flow of the polymer powder and was characterized 
with a mean particle size of 17.4µm. The polymer/talc mixture (1:1 w/w) was fed 
separately while the plasticizer was bottom-sprayed into a fluidized bed coater. The 
optimum plasticizer type and concentration was determined employing the minimum 
softening temperature. Different plasticizers were investigated for the coating with 
Eudragit® RS PO including triethyl citrate, acetyl tributyl citrate, as well as acetylated 
monoglycerides and each was combined with a 10% hydroxypropyl methyl cellulose 
aqueous solution to prevent agglomeration of the pellets. The fraction of plasticizer in the 
emulsion was 36.8 to 75.0% w/w. The optimum plasticizer level was determined to be 
40% based on the polymer weight. More hydrophilic plasticizers such as triethyl citrate 
were shown to increase the drug release rate. Higher plasticizer levels generally 
decreased the drug release rate. The product temperature was kept between 34 and 36ºC 
during the coating process. Coating thicknesses between 50 and 100µm, corresponding to 
9.9 and 19.6% weight gain, resulted in sustained release profiles. The Eudragit® RS PO 
coated pellets were oven-cured at 40ºC and 60ºC up to 24 hours to complete film 
formation and to avoid drug release rate changes over storage. The drug release rate did 
not change over three years of storage at room temperature when Eudragit® RS PO 
coated pellets were cured at 60ºC for two hours and acetylated monoglycerides was 
employed as plasticizer at a 40% level. 
Similar studies were performed using ethylcellulose as extended release polymer 
with a Dv50 of 6.1µm [18]. The polymer/talc ratio was reduced to 10:3 for ethylcellulose. 
The amount of plasticizer in the emulsion with hydroxypropyl methyl cellulose aqueous 
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solution was between 50 to 75% w/w. Acetylated monoglycerides were shown to be the 
most effective plasticizer for ethylcellulose and to further reduce the drug release rate 
compared to triethyl citrate and acetyl tributyl citrate. The optimum plasticizer level was 
determined to be 40% w/w based on the polymer weight. Due to the high glass transition 
temperature of ethylcellulose of 130ºC, the product temperature was increased to 45 to 
47ºC during the coating process. Following coating, the pellets were oven-cured at 60 or 
80º for 2 or 24 hours. Curing at high humidity (100% RH) conditions accelerated film 
formation, resulted in a faster decrease in drug release, and may be employed to shorten 
curing times. Physical stability of the ethylcellulose dry powder coated pellets was 
confirmed over storage at room temperature over 3 years. 
Pearnchob et al. also compared the dry powder coating process to conventional 
liquid-based coating techniques [20]. Besides Eudragit® RS PO and ethylcellulose, 
shellac was included in the study. Higher plasticizer concentrations, curing, and higher 
coating levels were generally required in dry powder coating processes compared to 
aqueous and organic solvent based coating techniques to obtain comparable drug release 
profiles as shown in Table 1.1. Similar coating levels required shorter processing times in 
dry powder coating applications such that total coating times were still shorter, although 
higher coating levels were necessary to control the drug release rate. 
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 Ethylcellulose Eudragit® RS PO 




Plasticizer TEC TEC TEC TEC TEC 
Plasticizer 
level 
20% 25% 40% 20% 40% 
Product 
temperature 
29-31ºC 41-43ºC 45-47ºC 31-33ºC 34-36ºC
Coating level 5% 5% 20% 20% 20% 
Coating time 111min 44min 30min 171min 41min 
 
Table 1.1: Formulation and processing parameters for the coating of pellets with 
ethylcellulose and Eudragit® RS PO employing organic solvent based, aqueous, dry 
powder coating processes [20]. 
 
 
Kablitz et al. modified the process that was introduced by Obara et al. by using a 
three-way nozzle to deliver polymer and plasticizer dispersion jointly into the coating bed 
[21]. The coating process was performed in a rotary fluid bed. HPMCAS with a median 
particle size of 5.4µm was used as functional polymer. Talc was eliminated from the 
coating formulation since it was identified to disturb film formation. Colloidal silicon 
dioxide was used as an alternative anti-tack agent employing a concentration of 
approximately 1% based on the polymer weight. It was applied as overcoat after the 
coating process was completed. The coating efficiency increased when talc was replaced 
with colloidal silicon dioxide and when the plasticizer was combined with acetylated 
monoglycerides in a 7:3 ratio. An increased coating efficiency was directly correlated 
with an improved gastric resistance. A triethyl citrate concentration in the talc-free 
formulations of 23 to 24% based on the polymer weight resulted in a glass transition 
temperature of free films that were sprayed onto celluloid spheres of 42.5±0.6ºC. The 
coating process was performed at a product temperature of 40 to 42ºC [21]. During the 
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curing step the product temperature was raised to 53 to 55ºC. Curing of the dry coated 
pellets was demonstrated to be an essential step of the process. Drug release from 
uncured pellets followed zero order kinetics in acidic media and did not show an enteric 
release profile due to incomplete coalescence of the polymer particles. Approximately 
50% of drug were released from uncured pellets after 2 hours in 0.1N hydrochloric acid. 
A 25% coating level and curing for 45 minutes provided the necessary gastric resistance. 
The drug release rate did not change after 6 months of storage; however, the storage 
conditions were not further specified in the publication.   
The interparticle forces acting between HPMCAS and HPMCAS containing 
triethyl citrate and acetylated monoglycerides were determined using atomic force 
microscopy [22]. Acetylated monoglycerides was shown to be immiscible with 
HPMCAS using DSC and thus did not penetrate into the polymer. Since it remained on 
the surface, the adhesion force was shown to be highest between HPMCAS and 
acetylated monoglycerides containing formulations [22]. This effect was directly 
correlated to an increased coating efficiency. However, acetylated monoglycerides did 
not plasticize the polymer and did not promote film formation and was thus combined 
with triethyl citrate. 
Kablitz et al. characterized the film forming process using scanning electron 
microscopy and dissolution studies using the same dry coating technique as described 
above [23]. To facilitate wetting of the pellets, the plasticizer dispersion was sprayed for 
30 seconds onto the cores. The product temperature was kept at 25 to 26ºC to avoid 
premature film formation during the coating process. The pellets were then cured in an 
oven at temperatures up between 25 and 95ºC up to 24 hours. The glass transition 
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temperature of a film cast from an organic solution of the same formulation was 
characterized by a glass transition temperature of 51.7±3.3ºC. Different curing times and 
temperatures were investigated. As mentioned previously, polymer particle fusion occurs 
mainly during the curing phase of the coating process [21]. It was proposed, that prior to 
uptake into the polymer, the liquid plasticizer exerts capillary forces between the polymer 
particles [23]. During the curing phase, after absorption of the plasticizer into the 
polymer, viscous flow and particle deformation were anticipated to cause polymer 
particle sintering and coalescence. Curing at 55ºC for 45 minutes was determined to be 
the optimum curing conditions to obtain an enteric release profile since lower 
temperatures required longer curing times and higher temperatures caused sticking of the 
pellets. Kablitz et al. concluded that the glass transition temperature is the key parameter 
to determine the optimum curing conditions.  
 Cerea et al. and Zheng et al. developed a new dry coating technique for the 
coating of tablets [24, 25] in which the use of solvents or water was circumvented. Cerea 
et al. used Eudragit® E PO for taste masking and moisture protective coating of 
theophylline tablets [24]. Besides the model drug, the cores contained microcrystalline 
cellulose, lactose monohydrate, PVP K-30, magnesium stearate, and fumed silica. A 
laboratory scale spheronizer was modified for the dry coating process, employing a 
smooth stainless steel disc with 45º edges to ensure tumbling of the core tablets and avoid 
loss of coating powder. The optimum rotation speed was shown to be 190 rpm to 
facilitate tablet movement and prevent unnecessary friability of the tablet cores. The bed 
temperature was regulated using an infrared lamp as heat source and controlled using a 
digital temperature probe. The optimum bed temperature for the coating with Eudragit® E 
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PO was 55 to 60ºC. The glass transition temperature of Eudragit® E PO was determined 
to be 50±3ºC. Coating temperatures below 50ºC did not result in sufficient polymer 
adhesion whereas temperatures above 70ºC resulted in irregular polymer layering. The 
batch size was 50 g of tablets. Eudragit® E PO was pre-blended with 10% talc based on 
the polymer weight and fed onto the pre-heated tablet cores employing a single screw 
powder feeder at a rate of 0.5 g/min. Prior to coating, the coating powders were passed 
through a 100 mesh sieve. Curing of the coated tablets in a static oven on Teflon plates at 
80ºC for 12 hours completed film formation. Optimum curing conditions were 
determined using free powder-cast films according to transparency of the film, film 
thickness, as well as surface and cross-sectional morphology using SEM analysis. 
Coating levels of 7 mg/cm2, 10 mg/cm2, and 14 mg/cm2 of Eudragit® E PO resulted in a 
delay in drug release in pH 6.8 buffer. However no delay was occurring in pH 1.0 
medium with more than 90% theophylline released after 30 minutes for the three 
investigated coating levels. The incorporation of hydrophilic polymers including 
Methocel® K4M, PVP K-90, glycerol monostearate, and polyethylene glycol 3350 in a 
10% ratio based on the polymer weight decreased the lag time for drug release in buffer. 
In acidic medium only the addition of hydroxypropyl methyl cellulose was shown to 
reduce the drug release rate. The addition of low-melting coating excipients such as 
glycerol monostearate and polyethylene glycol were demonstrated to enhance coating 
powder adhesion. 
 Zheng et al. adapted the dry coating method developed by Cerea at al. as 
described above [25]. The process was modified for the acrylic polymers Eudragit® RS 
and RL PO for sustained release film coatings. The original process consisted of three 
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steps: pre-heating of the tablets, powder layering, and curing. The modified method for 
Eudragit® RS and RL PO, in contrast, required pre-plasticization of the polymer and 
priming of the pre-heated tablets to improve coating powder adhesion. Eudragit® RS/RL 
in a ratio of 95:5 was pre-plasticized with 5 to 15% triethyl citrate based on the polymer 
weight using hot-melt extrusion to avoid the separate spraying of the plasticizer. 
Following extrusion, the polymer was cut into pellets and ground into a fine powder, 
using a cryogenic process. The processed Eudragit® RS/RL PO was mixed with talc in a 
10% ratio based on the weight of the polymer and directly fed onto the core tablets. The 
same equipment was used as by Cerea et al. and also the feeding rate of the coating 
powder was kept at 0.5 g/min. The coating bed temperature varied according to the 
plasticizer level between 55 to 60 for 15% triethyl citrate and 80 to 85ºC for 0% triethyl 
citrate. Similarly, curing was performed in a static oven at 80ºC, however, the curing time 
was increased to 24 hours for complete film formation of Eudragit® RS/RL PO films. The 
Dv50 of the processed polymers with different plasticizer levels was 65 to 71µm. Smaller 
particles were demonstrated to accelerate polymer particle coalescence. A 3% weight 
gain cetyl alcohol primer that formed a molten layer on the core tablets was shown to 
modify the hydrophobicity of the tablet surfaces. Improved wetting of the core tablets for 
Eudragit® RS/RL resulted in an increase coating powder adhesion. The theophylline 
tablet cores were composed of model drug, microcrystalline cellulose, lactose 
monohydrate, PVP K-30, magnesium stearate, and fumed silica. The drug release rate 
from theophylline tablets dry coated with pre-plasticized Eudragit® RS/RL PO was 
shown to be dependent on curing temperature, curing time, plasticizer level, coating 
level, and particle size of the ground polymer. A polymer weight gain of 8% resulted in a 
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sustained release profile with a lag time of about 2 hours and approximately 70% 
theophylline were released after 12 hours. Physical stability of the dry coated tablets was 
confirmed in closed HDPE containers at 25ºC/60%RH and 40ºC/75%RH over a period of 
3 months.  
 
 
1.2 PRINCIPLES OF COATING POWDER ADHESION 
 
Sufficient powder particle adhesion is essential in dry-coating processes. True 
contact between two surfaces can only occur for ideally smooth surfaces since surface 
roughness acts as adhesion barrier [26]. The deformation of surface asperities improves 
the contact between surfaces. The Johnson, Kendall, Roberts theory (JKR theory) is used 
to determine the contact area between two atomically smooth spheres that are pressed 
into contact [27]. The diameter of the area is a function of external force, surface 
attractions, and elastic properties of the deformed particles [28].  
Kendall distinguished different principles of adhesion by the range of action of 
adhesion force as two spheres are separated [26]: molecular adhesion, electrostatic 
adhesion, liquid drop adhesion and suction pad. Molecular adhesion force falls off in 
nanometer range. Electrostatic adhesion reduces with the square of the separation 
distance from the centers of the two spheres. Both liquid drop and suction pad are 
characterized by a long-range action of the adhesive forces. In the suction pad model the 
atmospheric pressure holds surfaces together, which stays constant when the surfaces are 
separated. The similar mechanism applies to the liquid bridge adhesion model.  
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The Laplace pressure in the interpenetrating liquid acts on the surfaces of two 
particles, pulling them together [29]. Liquid bridges fill gaps between the particles and 
reduce the surface roughness of the particles such that capillary attraction, surface tension 
and viscous resistance of the liquid inhibit rapid separation [30, 31]. Rough surfaces 
result in insufficient atomic contact. A liquid bridge increases the attractive force due to 
capillary pressure although it results in a decrease of solid/solid molecular adhesion. A 
molten priming layer as used by Zheng et al. [25] may promote liquid bridge adhesion of 
the polymer particles in a powder coating process. Also the techniques as used by Obara 




1.3 CHEMICAL STRUCTURE AND PROCESSING PARAMETERS OF EUDRAGIT® 
POLYMERS 
1.3.1 Commercial forms of Eudragit® polymers 
 
Eudragit® S 100, Eudragit® L100-55, Eudragit® RS PO, Eudragit® E PO and 
mixtures of pre-plasticized Eudragit® RS and RL PO have been studied in dry coating 
applications. Eudragit® polymers have been widely used as aqueous and organic solvent 
based coating for pharmaceutical dosage forms and as matrix materials in wet-
granulation, spray-drying, and hot-melt extrusion processes. Dosage forms based on 
Eudragit® polymers have been widely investigated for oral, buccal, sublingual, 
transdermal, rectal, and vaginal applications.  
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Eudragit® polymers are copolymers based on acrylate and methacrylate and their 
esters. They are commercially available as organic solutions E 12.5, L 12.5, and S 12.5; 
as aqueous dispersions including L 30 D-55, FS 30 D, NE 30 D, NE 40 D, NM 30 D and 
RL/RS 30 D; as granules like RS 100, RL 100, and E 100; or as powder such as L 100-
55, L 100, S 100, RS PO, RL PO, E PO [32]. Most of the Eudragit® polymers are listed in 
the European Pharmacopoeia, the United States Pharmacopoeia and the National 
Formulary, as well as the Japanese Pharmacopoeia. 
 
1.3.2 Chemistry of Eudragit® polymers 
 
 Since the backbone of Eudragit® polymers is formed by carbon atoms it is stable 
in the presence of water, oxygen, light, digestive enzymes, and body fluids [33]. 
Eudragit® polymers are not metabolized and absorbed in the digestive tract [34]. The 
methyl pendant group of the methacrylate additionally stabilizes the molecule, resulting 
in a more rigid and brittle polymer, while the polymerization of acrylic monomers 
produce more flexible materials [33]. The methyl side group also increases the 
hydrophobicity of the polymer, as present in Eudragit® E polymers. Due to the methyl 
group, methacrylic acid is a weaker acid (pKa 4.66) compared to acrylic acid (pKa 4.25) 
[33].  
After treatment with dilute acids or bases over 6 weeks, hydrolysis of less than 
0.3% of the ester groups in polymethacrylic esters has been reported [35]. Ester groups in 
acrylic ester copolymers are more likely subject to hydrolysis. As powder or granular 
form, Eudragit® polymers did not show a loss of functional groups after storage for up to 
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5 years [2]. Side chain degradation of Eudragit® polymers was shown to occur above 
150ºC, depolymerization and cross-linking of the main chain above 180ºC [2]. Neutral 
and anionic copolymers were demonstrated to be more heat-stable that cationic ones.  
The melt viscosity of Eudragit® polymers is dependent on the molecular weight 
and the amount of methacrylic acid in the molecule. High methacrylic acid contents were 
shown to increase while high concentrations of acrylic esters were demonstrated to 
decrease the melt viscosity of Eudragit® polymers [33]. 
  
1.3.2.1 Eudragit® L 100, S100, FS 30 D, L 30 D-55, and L 100-55 
 
Eudragit® L, S, and FS polymers are gastroresistant and enterosoluble methacrylic 
copolymers with free carboxylic acid groups. Eudragit® L 30 D-55 and Eudragit® L 100-
55 are based on methacrylic acid and ethyl acrylate in a 1:1 ratio, soluble above pH 5.5 
and thus used for the delivery of drugs to the upper small intestine. The average 
molecular weight is approximately 250,000 [32]. The commercial product contains 
additionally 0.7% sodium lauryl sulfate and 2.3% polysorbate 80 based on solid 
substances. Eudragit® L and S contain methacrylic acid and methyl methacrylate. Since 
Eudragit® L contains higher amounts of methacrylic acid (approximately 50:50 compared 
to approximately 30:70 for Eudragit® S) it is soluble above pH 6.0 while Eudragit® S 
starts to dissolve above pH 7.0. The average molecular weight of Eudragit® L and S is 
approximately 135,000 [32]. Eudragit® FS 30 D is based on methacrylic acid, methyl 
acrylate as well as methyl methacrylate and is soluble above pH 7.0. The fraction of free 
carboxyl groups to ester groups is about 1:10. The average molecular weight is 
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approximately 220,000. Combinations of Eudragit® S and L 100 [34] and Eudragit® FS 
30 D can be used for pH dependent colonic delivery.  
Not only the amount of free carboxylic groups influences the pH-dependent 
solubility of Eudragit® L, S, FS and L 55. The exchange of methyl methacrylate as 
present in Eudragit® L 100 with ethyl acrylate as in Eudragit® L 100-55 results in a 
decrease of the dissolution pH. The dissolution is also dependent on the pKa value of the 
acid component and on the ionic strength of the dissolution media and is accelerated in 
the presence of divalent and trivalent ions such as phosphate and citrate [33]. 
Dissociation of the salts at the interface between enteric coating and core due to water 
penetration through the enteric coating may affect the microenvironmental pH. As a 
result, active pharmaceutical ingredients or excipients based on a strong acid and a weak 
base can improve the gastric resistance of enteric coated dosage forms and may delay the 
release in buffer whereas salts composed of a weak acid and a strong base may decrease 
the stability of the enteric coating in gastric fluid [33]. Non-ionic subcoatings were 
recommended to prevent this phenomenon [33].  
 
1.3.2.2 Eudragit® E PO, E 100, and E 12.5 
 
Eudragit® E is a cationic copolymer composed of dimethylaminoethyl 
methacrylate and neutral methacrylic esters in a 1:1 ratio. The average molecular weight 
is approximately 150,000 [32]. The tertiary amino group in Eudragit® E makes the 
polymer gastrosoluble and applicable for taste masking. The polymer is soluble below pH 
5 due to salt formation of the tertiary amino group of Eudragit® E, which is present in a 
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high quantity in the polymer [34]. Above pH 5 Eudragit® E polymers absorb water and 
swell due to the presence of the hydrophilic amino groups causing disintegration of the 
coating even at high pH [34].   
Eudragit® E films are characterized by very low water permeability compared to 
Eudragit® RL PO and hydroxypropyl methyl cellulose coatings and are thus employed as 
moisture protective coatings. The addition of hydrophilic excipients including 
polyethylene glycol, lactose, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, 
and microcrystalline cellulose were recommended to increase the permeability of 
Eudragit® E film coatings [32].  
 
1.3.2.3 Eudragit® NE 30D/40D and Eudragit® NM 30 D  
 
The neutral methyl and butyl esters of Eudragit® NE and NM polymers result in 
insoluble, permeable (pH independent) formulations. The average molecular weight of 
Eudragit® NE is approximately 800,000. Due to its high flexibility, Eudragit® NE 30 D 
does not require the addition of plasticizer. The average molecular weight of Eudragit® 
NM 30 D is approximately 600,000 [32]. 
 
1.3.2.4 Eudragit® RS/RL PO, RS/RL 100, and RS/RL 30 D 
 
Eudragit® RL and RS polymers are insoluble, swellable, and permeable (pH 
independent) polymers due to trimethylammonioethyl methacrylate functional groups. 
The average molecular weight is approximately 150,000 [32]. The quarternary 
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ammonium groups in Eudragit® RL and RS increase the hydrophilicity and permeability 
of the polymer. The molar fraction of the quaternary ammonium groups to neutral 
methacrylic acid ester groups is 1:20 (approximately 50 mEq/100g) for Eudragit® RL and 
1:40 (approximately 25 mEq/100g) for Eudragit® RS and influence the swellability as 
well as permeability of the polymers. The water permeability of Eudragit® RL is 
approximately twice as high as the permeability of Eudragit® RS PO [33]. The ratio of 
RL and RS, which are miscible in all ratios, can be modified to adjust the drug release 
profile [34, 36]. Thin Eudragit® RL coatings (10 – 30 µm) were also recommended as 
fast-disintegrating protective coatings due to a high diffusion rate of dissolved drug 
through the film [37]. Diffusion through Eudragit® RS films was reduced compared to 
Eudragit® RL films and was dependent on molecular size of the drug and steric effects. 
The diffusion rate of phenyl propanolamine was about 8 times fold increased through a 
RL membrane (approximate thickness 25 µm) compared to an RS membrane [37]. The 
factor was 3 for chlorpheniramine maleate using the same experimental set-up.   
Penetration of dissolution medium into the core followed by diffusion of 
dissolved drug through pores into the surroundings was proposed as drug release 
mechanism from dosage forms that were coated with Eudragit® RL/RS mixtures [38]. 
The pores in Eudragit® RL films were shown to be larger than in Eudragit® RS films. The 
release from dosage forms that were formulated with Eudragit® RL and RS is pH 
independent due to ionization of the quarternary ammonium group at all pH levels 
occurring in the digestive tract [36]. However, the drug release was shown to be 
dependent on ionic strength and buffer species of the dissolution medium [36, 39, 40].  
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1.3.3 Formulation and processing parameters for Eudragit® polymers 
 
 The addition of plasticizers reduces the glass transition and minimum film-
formation temperature of hard and brittle Eudragit® polymers to prevent cracking and 
splitting of the film coating [2, 41]. Most commonly used are triethyl citrate, triacetin, 
propylene glycol, and polyethylene glycol [37]. More hydrophobic plasticizers include 
tributyl citrate, dibutyl phthalate, and tertiary butyl acetate. The usual plasticizer level for 
aqueous coating applications is 10 to 20% based on the dry polymer weight [33, 37]. 
Higher levels of 40 to 50% of triethyl citrate may be required for Eudragit® L100 and S 
100 [41].  
Talc, magnesium stearate, and glycerol monostearate have been used to reduce 
the tackiness of the film coating during processing. Talc was also shown to improve the 
smoothness of the film coating [37]. A talc content of 25% based on the weight of the dry 
polymer weight was sufficient in aqueous coating applications. The addition of 50% talc 
resulted in opaque film coatings, however, the spray rate may be increased [37]. Glycerol 
monostearate was usually used in a concentration of 2 to 15%.  
Several hydrophilic and hydrophobic film additives including sucrose, lactose, 
microcrystalline cellulose, poly (vinyl pyrrolidone), poly (vinyl alcohol), and 
polyethylene glycol have been investigated to modify the drug release rate from dosage 
forms that were coated with Eudragit® polymers [33, 35, 36]. 
 Eudragit® L 100 and Eudragit® L 100-55 were shown to have an ion exchange 
capacity of approximately 6 mEq/g. The ion exchange capacity of Eudragit® S 100 was 
determined to be approximately 3.5 mEq/g [37]. Drugs may adsorb to the polymer, but 
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will be eluted upon contact with digestive fluids. Acids like salicylic acid were shown to 
adsorb to Eudragit® RL/RS in water or alkaline media [42]. Also Eudragit® E 100 was 
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Chapter 2: Research Outline 
 
2.1 OVERALL OBJECTIVE 
 
The overall objective was to develop a powder coating process using Eudragit® L 
100-55 for the coating of tablets, to investigate formulation factors, and processing 
parameters on product performance and to characterize the film forming mechanisms. 
Eudragit® L 100-55, an anionic acrylic copolymer, has been studied for the compression 
coating of tablets as well as aqueous and organic solvent based film coating of 
pharmaceutical dosage forms. However, it has not been investigated for dry powder 
coating applications. The coating process itself is based on a water and solvent-free 
technique that was developed by Cerea and Zheng et al. in 2004 to circumvent limitations 
of the established aqueous and organic coating systems for pharmaceutical products [1, 
2]. The dry powder coating process was successfully employed for the acrylic polymers 
Eudragit® RS/RL PO and Eudragit® E PO for the coating of tablets. The powder coating 
process consisted of three steps, namely priming, powder layering and curing. To avoid 
the separate spraying of the plasticizer, polymers with a high glass transition temperature 
were pre-plasticized using a hot-melt extrusion process and subsequently ground into a 
fine coating powder using a cryogenic process.   
 
 30
2.2 SUPPORTING OBJECTIVES 
 
2.2.1 Investigation of the Influence of Processing Parameters and Formulation 
Factors on the Drug Release from Tablets Powder-coated with Eudragit® L 100-55 
 
Migration of active pharmaceutical ingredients into the film coating has been 
reported for aqueous dispersion based coating applications [3]. In chapter 4, powder 
coating technology was investigated as a method to prevent the migration of the 
ionizable, highly water soluble drug chlorpheniramine maleate (CPM) into the film 
coating. Formulation factors such as plasticizer level and coating additives were 
investigated and the optimum processing parameters including coating and curing 
conditions were determined. The coating powder characteristics as well as interactions 
between film components and the active ingredient were investigated using differential 
scanning calorimetry (DSC). The drug release properties as well as the physical stability 
of the coated tablets during storage at accelerated conditions were studied using 
dissolution and high performance liquid chromatography (HPLC). 
 
2.2.2 Investigate the Influence of Polymeric Subcoats on the Drug Release 
Properties of Tablets Powder-coated with Pre-plasticized Eudragit® L 100-55 
 
 The coating of sodium valproate tablets with Eudragit® L 100-55 employing dry-
powder coating technology was investigated in chapter 5. Sodium valproate is a 
hygroscopic drug and affects the microenvironmental pH of the hydrated core during 
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dissolution [4]. The influence of polymeric subcoats on the release of sodium valproate 
from tablets that were powder coated with pre-plasticized Eudragit® L 100-55 was 
studied using dissolution testing and HPLC. Since both Eudragit® RL PO and Eudragit® 
E PO are insoluble at pH 6.8 and delay the drug release during the buffer stage of the 
USP enteric test, pore forming agents were added to the subcoating formulation. The 
miscibility of pore forming agents in the functional polymers and the effect of the 
incorporation into the subcoat on the drug release rate were investigated using dissolution 
testing, HPLC and DSC. Interfacial interactions between tablet surface and coating 
powder are complex and were shown to be dependent on interfacial tension, wetting and 
adhesion [5]. Wetting properties and spreading of the primer polyethylene glycol 3350 
(PEG 3350) over the tablet cores were investigated using solubility parameters. 
 
2.2.3 Study of the Influence of Additives on Melt Viscosity, Surface Tension, and 
Film Formation of Dry Powder Coatings  
 
The main factors that determine polymer particle fusion and leveling of a 
polymeric film that was applied using a dry coating technique are surface tension and 
melt viscosity of the polymer [6, 7]. In chapter 6, both parameters were determined for 
Eudragit® L 100-55. Since the incorporation of coating excipients was shown to affect 
both melt viscosity and surface tension, the influence of additives on both parameters and 
on film formation of Eudragit® L 100-55 coatings was studied. Mechanical testing was 
used to evaluate puncture strength and elongation of free powder-cast films as a function 
of progress in film formation. 
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2.2.4 Characterize the Properties of Theophylline Tablets Dry Powder Coated 
with Eudragit® E PO and Eudragit® L 100-55 
 
 In chapter 7, the influence of Eudragit® E PO in Eudragit® L 100-55 film coatings 
applied by a dry powder coating technique on the drug release mechanism of 
theophylline from tablets was analyzed. Due to the different pH-dependent solubility 
properties of the polymers, complexes of both materials were used in sustained release 
dosage forms [8]. Physical blends and micronized extrudates of different polymer ratios 
were investigated for the powder-coating of theophylline tablets employing dissolution 
testing and UV analysis. The miscibility of the two polymers was studied and interactions 
were characterized using DSC, Fourier transform infrared spectroscopy (FT-IR), and 
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Eudragit® L 100-55, Eudragit® RL PO, and Eudragit® E PO were donated by Evonik 
Industries AG (Piscataway, NJ). Chlorpheniramine maleate USP (CPM), sodium 
valproate, anhydrous theophylline USP, lactose monohydrate NF, and magnesium 
stearate NF were purchased from Spectrum Chemical Mfg. Corp. (Gardena, CA). 
Triethyl citrate NF (TEC) was donated by Vertellus Materials Inc. (Greensboro, NC). 
Talc USP (Imperial 500) was supplied by Luzenac America, Inc. (Centennial, CO). 
Polyethylene glycol (PEG) 3350 NF and hydroxypropyl methylcellulose (Methocel® 
K4M) were obtained from The Dow Chemical Company (Midland, MI). Microcrystalline 
cellulose (MCC, Avicel® PH-200 and PH-101) was donated by FMC BioPolymer 
(Newark, DE). Polyvinylpyrrolidone K-30 (PVP, Kollidon® 30) was supplied by BASF 
Corp. (Mt. Olive, NJ). Colloidal silicon dioxide (Cab-O-Sil® M-5P) was donated by 




3.2.1 Coating powder preparation 
 
 Eudragit® L 100-55 and Eudragit® RL PO were pre-plasticized using a method 
reported by Zheng et al. [1] for the pre-plasticization of Eudragit® RS / RL PO blends. 
Polymer and different concentrations of the plasticizer triethyl citrate (TEC) were mixed 
using a high shear mixer. The powder blend was hot-melt extruded employing a single 
screw extruder (Randcastle Model RC 0750, Cedar Grove, NJ) using a cylindrical die 
with an inner diameter of 6mm. For the extrusion of Eudragit® L 100-55, the temperature 
zones were set to: zone 1 = 80ºC, zone 2 = 110ºC, zone 3 = 115ºC, and die = 120ºC and 
for Eudragit® RL PO to: zone 1 = 80ºC, zone 2 = 105ºC, zone 3 = 115ºC, and die = 
125ºC. Different ratios of Eudragit® E PO and Eudragit® L 100-55 that contained 30% 
TEC based on the weight of the enteric polymer were extruded at the following 
temperatures: zone 1 = 65ºC, zone 2 = 110ºC, zone 3 = 115ºC, and die = 120ºC. The 
extrudate was subsequently cut into pellets with a Randcastle RCP-2.0 pelletizer and then 
cryogenically ground into a fine powder using a CF Mikro-Bantam Cryogenic Grinder 
(Micron Powder Systems, Summit, NJ). To obtain a more uniform particle size 
distribution and exclude fines and large particles, the ground pre-plasticized polymer was 
sieved by mechanical shaking for 15 minutes. The particle size fraction between 100 and 
200 mesh (75 - 150μm) was used for the dry powder coating experiments. 
 
 36
3.2.2 Tablet preparation and characterization 
 
 The API such as chlorpheniramine maleate (CPM), theophylline, or sodium 
valproate, fillers including microcrystalline cellulose, lactose monohydrate NF, and the 
binder Kollidon® K 30 were mixed in a V-shape blender (Model Yoke, Patterson-Kelley 
Co., East Stroudsburg, PA) or a low shear mixer for 15 minutes. Following the addition 
of the magnesium stearate and colloidal silicon dioxide, the mixture was blended for an 
additional 5 minutes. The tablets were compressed either on a rotary press (Model FJS-
B2 Stokes, Bristol, PA) or a single stage press (Stokes F press, Bristol, PA) using deep 
concave 5 mm punches. The tablet hardness was measured using a hardness tester (WTP-
3, Heberlein &. Co. AG, Wattwil, Switzerland). The disintegration time was determined 
according to USP 29 using a USP Disintegration Tester (Vankel Industries Inc., 
Chatham, NJ). The tablet friability was tested according to USP 29 with a Tablet 
Friability Apparatus (Vankel Industries Inc., Chatham, NJ). 
 
3.2.3 Powder coating process 
 
 Powder coating of the tablets was performed according to the method reported by 
Cerea et al. (2004) and Zheng et al. (2004) in a modified laboratory scale spheronizer 
(Model 120, G.B. Caleva, Dorset, UK) [1, 2]. The batch size was 40 g of tablets. The 
rotation speed of the spheronizer was adjusted for each coating formulation and varied 
between 170 and 220 rpm. The coating bed temperature was dependent on formulation 
and the plasticizer content of the coating powder and maintained between 65 and 75ºC. 
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The temperature of the coating bed was monitored by measuring the surface temperature 
of the tablets using a Fluke 61 Infrared Thermometer (Fluke Corporation, Everett, WA). 
Some formulations required the addition of the anti-tack agent talc and the low-melting 
coating excipient polyethylene glycol 3350 (PEG 3350). The feeding rate of the coating 
powder onto the tablets cores was dependent on the capacity of the coating powder to 
adhere, which decreased with increasing coating levels. Following the application of the 
priming layer of molten PEG 3350, the polymer mixture was fed onto the tablet surfaces 
at a feeding rate of about 3 g/min until a polymer weight gain of 7% to 10% was 
obtained. The powder-feeding rate was then reduced to 0.5 g/min. Since all coating 
formulations exhibited poor flow properties, the powder mixtures were manually fed onto 
the tablet surfaces. After completion of the coating process, the tablets were subsequently 
cured either in the operating spheronizer for or in a static oven on Teflon trays at different 
temperatures for varying times 
 
3.2.4 Drug release study 
 
 Dissolution testing was performed using the USP 29 or USP 30 Apparatus 2 
(Vankel VK 6010; Vankel Industries Inc., Cary, NC). The dissolution media were 
maintained at 37 °C and agitated at 50 rpm. Samples were withdrawn by an autosampler 
(Vankel VK 8000; Vankel Industries Inc., Cary, NC). The drug release rate of the model 
drugs from powder-coated tablets was investigated using different dissolution media. A 
modified USP 29 Drug Release Standard for Enteric-Coated Articles, Method B was 
employed by placing coated tablets initially in 900 mL 0.1N HCl for two hours, followed 
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by 4 hours in 900 mL pH 6.8, 50 mM phosphate buffer. Furthermore, the USP Drug 
Release Standard for Enteric Coated Articles, Method A was used to characterize the 
release properties of the coated tablets. Following two hours dissolution in 750 mL, 0.1N 
HCl, 250 mL of 0.2M tribasic sodium phosphate solution were added to the dissolution 
vessel to adjust the pH of the dissolution medium to 6.8 ± 0.05. The drug release study 
was then resumed for 2 more hours. Alternatively, in vitro dissolution testing was 
conducted to investigate the theophylline release rate from powder-coated tablets in 
either 900 mL of 0.1N HCl or in 900 mL pH 6.8, 50 mM phosphate buffer for 12 hours.  
 
3.2.5 HPLC analysis 
 
 The plasticizer content in the extrudates and free films as well as the 
concentration of the model drug in the dissolution medium were determined using a 
Waters high performance liquid chromatography (HPLC) system (Waters, Milford, MA) 
equipped with a photodiode array detector (Model 996). Prior to analysis, all samples 
were filtered using 0.2μm or 0.45μm nylon filters. The samples were injected by an 
autosampler (Model 717plus), and Empower® Version 5.0 software was used to collect 
and analyze the data. 
 The TEC content was analyzed at a wavelength of 210 nm using an ODS-3 3μm, 
150mm × 4.6mm column (Alltech Inertsil™, Deerfield, IL, USA) at a column 
temperature of 30 ± 2ºC. Prior to HPLC analysis, processed polymer or powder cast film 
samples were initially dissolved in 50 mM pH 7.4 buffer and then 1:2 diluted with 50mM 
pH 2.5 phosphate buffer to precipitate the polymer from the solution. The injection 
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volume was 50 μL. The mobile phase contained a mixture of acetonitrile and pH 2.5 10 
mM phosphate buffer in volume ratios of 55:45. The flow rate of 1 mL/min resulted in a 
retention time of 4.0 min for TEC. Linearity was demonstrated in the concentration range 
of 100 to 500 μg/mL (R2 > 0.999).  
 An ODS-3 3 μm, 150 mm × 4.6 mm column (Alltech Inertsil™, Deerfield, IL, 
USA) was used to detect CPM at a wavelength of 260 nm. The column temperature was 
maintained at 40 ± 2ºC. The injection volume was 50 μL. The mobile phase contained a 
mixture of water:methanol:triethylamine in volume ratios of 675:325:4.5. The retention 
time of CPM was 9.5 min at a flow rate of 1mL/min. Linearity was demonstrated from 2 
to 50 μg/mL (R2 > 0.999).  
 The injection volume for theophylline was 40 μL. The mobile phase consisted of 
water:acetonitrile:glacial acid in volume ratios 845:150:5 and 1.156 g/L of sodium 
acetate trihydrate. The flow rate was 1 mL/min, and the retention time of theophylline 
was 4 minutes. Linearity was confirmed from 1 to 60 μg/mL (R2 > 0.999). 
 A wavelength of 210 nm was employed to analyze the sodium valproate 
concentration in the dissolution samples. A Phenomenex Luna C18(2), 3 μm, 150 mm × 
4.6 mm column (Phenomenex Inc., Torrance, CA) was used at a column temperature of 
30 ± 2ºC. The injection volume was 50 μL. The mobile phase contained a mixture of 
sodium phosphate monobasic and acetonitrile in a volume ratio of 63:37. The pH of the 
mobile phase was adjusted to 2.3 using phosphoric acid. A flow rate of 1 mL/min 
resulted in a retention time of 18 min for sodium valproate. Linearity was demonstrated 
from 4 to 100 μg/mL (R2 > 0.999). 
 
 40
3.2.6 UV analysis 
 
 UV Analysis was conducted to analyze dissolution samples for theophylline 
content using a μQuant (Bio-Tek® Instruments Inc., Winooski, Vermont) at the detection 
wavelength 278 nm. Prior to analysis, the samples were filtered using 0.45 μm nylon 
filters and diluted with an equal volume of dissolution medium. Linearity was 
demonstrated from 1 to 25 μg/mL (R2 > 0.999). SPSS Version 15.0 was used to 
statistically analyze the dissolution results. 
 
3.2.7 Particle size analysis 
 
 Laser light diffraction was used to analyze the particle size distribution of the 
coating powders with a Malvern Mastersizer S (Malvern Instrument Limited, Malvern, 
Worcestershire, UK). Dv 10, Dv 50, and Dv 90, the cumulative percent undersize, were 
determined using the diffractive index of Eudragit® L 100-55 (nD20 = 1.3899) and the 
approximate diffractive index of Eudragit® E PO (nD20 = 1.3899) in purified water (nD20 = 
1.3300).  
 
3.2.8 Residual moisture analysis 
 
 A MF-50 Moisture Analyzer (A&D Engineering, Inc., Milpitas, CA) was 
employed to determine the loss on drying of the coating powder. A sample of 2 g was 
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dried to a constant weight, as defined by a weight change of less than 0.05% per minute 
at 110ºC. 
 
3.2.9 Contact angle measurements 
 
 Sample compacts were prepared at a 500kg or 1000kg compression force using a 
Carver Laboratory Press (Model M, ISI Inc., Round Rock, TX). 3 μL of water, ethylene 
glycol or diiodomethane were placed onto the surface of the compacts with a 
microsyringe. The contact angle was determined by measuring the tangent to the curve of 
the sessile droplet using a Goniometer (Model No. 100-00-115, Ramé-Hart Inc., 
Mountain Lakes, NJ) within 5 seconds after drop deposition. The measurements were 
performed in a series of 3 samples.  
 
3.2.10 Film preparation 
 
 Free films were prepared from different coating powder formulations using 
Teflon coated aluminum dishes with a Teflon coated lid. The powder was either powder-
cast or compressed into films using a compression force of 10 kN on 22 cm2 of film for 3 
minutes (Carver Laboratory Press, Model M, ISI Inc., Round Rock, TX). All samples 
were subsequently cured in a static oven at 60ºC at a reduced compression force of 
approximately 10 N. 
Film samples of 3x3 mm were immersed in 15 mL of 0.1N HCl and shaken at 100 
rpm at 37ºC for 2 hours using a Lab-Line® Orbit Environ-Shaker (Lab-Line Inctruments 
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Inc., Melrose Park, IL). A volume of 5 mL 0.2M tribasic sodium phosphate solution was 
added to adjust the pH of the dissolution medium to 6.8 ± 0.05 and the film dissolution 
was continued for 2 more hours. 
 
3.2.11 Mechanical testing 
 
 Mechanical testing of powder-cast films was performed using a puncture test that 
was adapted from a method previously described by Bodmeier et al. [3]. A Chatillon 
Universal Tension / Compression Tester Model TCD-200 (Ametek, Largo, FL) was 
employed with a DFGS 50 digital force gauge to analyze puncture strength and 
elongation of powder-cast films. Prior to analysis, the film specimen was mounted onto 
the open mouth of a film holder that consisted of an aluminum cup with an inner diameter 
of 15 mm and an upper mounting plate. The puncture probe (length, 31 mm; diameter, 6 
mm; dome shaped probe end) was lowered toward the center of the film specimen at a 
crosshead speed of 10 mm/min. The load and deflection at maximum were used to 
determine the maximum puncture strength and % elongation (puncture strength = F/Acs, 
where F is the load and Acs is the cross-sectional area in the path of the cylindrical 
opening; % elongation = [{(R2 + D2)1/2 – R}/R]·100, where R is the radius of the film and 
D is the deflection of the probe). SPSS Version 15.0 was used for the statistical analysis 
of the data.  
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3.2.12 Differential scanning calorimetry 
 
 To characterize the thermal properties of the melt extrudates and powder cast 
films, modulated differential scanning calorimetry (MDSC) was conducted using a 
Thermal Advantage Model 2920 (TA Instruments, New Castle, DE) equipped with 
Universal Analysis 2000 software. Ultrahigh pure nitrogen was used as the purge gas at a 
flow rate of 150 ml/min. Prior to analysis, the samples were sealed in aluminum pans (Kit 
0219-0041, Perkin-Elmer Instruments, Norwalk, CT). The temperature ramp rate was 
either 3°C/min or 5°C/min at a modulation rate of ±1.00°C every 60 seconds. The reverse 
heat flow of the second heating cycle was used to determine the inflection glass transition 
temperature. Linear peak integration was used to determine the heat of fusion. 
 To study potential interactions between excipients and the model active 
pharmaceutical ingredients, conventional differential scanning calorimetry (DSC) was 
used employing the same instrument as described above. The samples were heated from 
50ºC to 300ºC using a temperature ramp rate of 10ºC/min. The raw materials were 
analyzed as well as physical mixtures. The heat flow of the first heating cycle was used to 
determine the melting points and heat of fusion values.  
 
3.2.13 Thermogravimetric analysis 
 
The thermal stability of the coating excipients and a powder-cast film was 
investigated using thermogravimetric analysis (TGA). A sample of approximately 10 mg 
was equilibrated to 50ºC and then heated at a temperature ramp rate of 10ºC/min to 
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800ºC. At isothermal conditions, the equilibration of the sample to 50ºC was followed by 
heating to 60ºC and the temperature was then kept constant for 6 hours. 
 
3.2.14 Relative melt viscosity 
 
A Haake MiniLab-Compounder (Thermo-Fisher Scientifc Inc., Waltham, MA) 
was used in the cycle mode to determine the mixing torque for Eudragit® L 100-55 
containing various amounts of TEC and PEG 3350. The screw speed was set to 10 rpm. 
The temperature range was adjusted for each formulation. The maximum temperature did 
not exceed 125ºC to avoid side chain degradation of the polymer [4]. The torque cut off 
value occurred at 550 Ncm. 
 
3.2.15 Scanning electron microscopy 
 
 The morphology of the surface and cross-section of powder-cast films and coated 
tablets was analyzed by scanning electron microscopy (SEM) using either a Hitachi, 
Model S-4500 FE (Hitachi, London UK) operated at 10 kV and 20 mA or a LEO 1530 
Gemini scanning electron microscope (Zeiss/LEO, Oberkochen, Germany) operated at 10 
kV. The samples were sputter coated with either gold/palladium (60:40) using a Ladd 
Benchtop Sputter Coater (Ladd Research, Winston, VT) or with platinum/palladium 
(80:20) using a Cressington Sputter Coater 208 HR equipped with a Thickness Controller 
MTM 20 (Cressington Scientific Instruments Ltd., Watford, UK). 
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3.2.16 Fourier transform infrared spectroscopy 
 
To characterize interactions occurring between model drugs and excipients, 
Fourier transform infrared spectroscopy was conducted using a Nicolet Magna IR-560 
FT-IR spectrometer. Prior to analysis, the samples were compressed with potassium 
bromide into pellets under vacuum using a compression pressure of 10 tons. 
 
3.2.17 1H and 13C nuclear magnetic resonance spectroscopy  
 
1H and 13C nuclear magnetic resonance spectroscopy (1H and 13C NMR) was 
performed to investigate possible interactions between model drug and excipients. For 
NMR analysis, the sample was dissolved in deuterium dioxide containing 3-
(trimethylsilyl)-propionic acid-D4, sodium salt (TSP) as the internal standard. The NMR 
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Chapter 4: Investigation of the Influence of Processing Parameters and 
Formulation Factors on the Drug Release from Tablets Powder-coated 
with Eudragit® L 100-551 
 
Abstract: 
 The aim of this study was to develop a dry powder coating process for 
chlorpheniramine maleate (CPM) tablets using Eudragit® L 100-55 as the delayed release 
polymer. Powder coating, a water and organic solvent-free process, was investigated as a 
method to prevent the migration of an ionizable, highly water soluble model drug into the 
polymeric film during the coating process. Eudragit® L 100-55 was pre-plasticized with 
triethyl citrate (TEC) using hot-melt extrusion at levels of 20, 30, and 40%, based on the 
polymer weight. The extrudate was subsequently cut into pellets and cryogenically 
ground into a fine powder. Talc was incorporated into the coating powder as an anti-tack 
agent. PEG 3350 was used as a primer for the powder coating of tablets with pre-
plasticized Eudragit® L 100-55. The addition of polyethylene glycol 3350 (PEG 3350) to 
the pre-plasticized Eudragit® L 100-55 was necessary to enhance the adhesion of the 
coating powder to the tablet cores. PEG 3350 also improved film formation and 
coalescence of the polymeric particles due to its plasticization effects on the acrylic 
polymer. For comparison, theophylline tablets were also coated with pre-plasticized 
Eudragit® L 100-55. Theophylline was selected as a less water soluble model drug. The 
powder coating process was performed in a modified laboratory scale spheronizer. The 
                                                 
1 Significant portions of this chapter were taken from: Sauer, D., W. Zheng, L.B. Coots, and J.W. McGinity, Influence 
of processing parameters and formulation factors on the drug release from tablets powder-coated with Eudragit L 100-
55. European Journal of Pharmaceutics and Biopharmaceutics, 2007. 67: p. 464-475. 
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drug release rate was dependent both on TEC content and the coating level. The stability 






 Although widely employed in other industrial applications since the 1950s, dry 
powder coating was not described in the pharmaceutical literature until the late 1990s. 
The primary advantage of this process is that it circumvents many limitations of 
established organic and aqueous coating systems for pharmaceutical products. The 
traditional use of organic solvents in coating processes creates environmental, 
toxicological, and safety-related concerns. Problems of aqueous coating are primarily due 
to the limited applicability for water-sensitive active ingredients [1], the migration of 
drugs into the polymer coatings during processing [2], and the physical aging of the 
polymeric films that leads to changes in the drug release rate during product storage [3-
5].  
 The first approach to powder-coat pharmaceutical dosage forms was reported by 
Obara and coworkers in 1999 [6]. The process involved the direct application of 
polymeric particles and the simultaneous spraying of a mixture of a plasticizer and 
acetylated monoglyceride onto drug containing cores. An aqueous hydroxypropyl 
methylcellulose (HPMC) solution was applied during the curing step to improve film 
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formation [6]. Pearnchob et al. modified the technique using an aqueous HPMC solution 
in combination with a plasticizer, while still separately feeding the polymer powder onto 
the solid substrates during the coating process [7-9]. Investigations from these researchers 
encompassed cellulose derivatives, the acrylic polymer Eudragit® RS, and shellac [7-9]. 
Both methods [6-9] required a minimal amount of water, and it was demonstrated that 
dry-powder coating compared to aqueous coating procedures generally required higher 
coating levels, higher plasticizer concentrations, and higher processing temperatures. 
Nevertheless, the processing time in dry-powder coating operations was significantly 
shorter due to the high solids content of the coating mixture. Recently the dry coating 
method developed by Obara was modified by Kablitz et al. by replacing the anti-tacking 
agent talc with colloidal silicon dioxide and eliminating the use of water in the curing 
step [10]. 
 A novel water and solvent-free powder coating technique was developed by Cerea 
et al. and Zheng et al. in 2004 [11, 12]. This dry coating technique did not utilize water or 
any other liquid during the entire coating process. The process was successfully applied 
for the acrylic polymers Eudragit® RS PO, Eudragit® RL PO, and Eudragit® E PO for the 
coating of tablets to modify the drug release rate. Dry powder coating was shown to 
prevent the aging of the polymeric film, a phenomenon which has been reported for 
aqueous coated dosage forms during storage. The powder coating process itself consisted 
of three steps, namely, priming, powder layering, and curing. To facilitate the direct 
application of the acrylic polymers onto the solid substrates, the solid Eudragit® RS PO  
and Eudragit® RL PO powders were pre-plasticized using a hot-melt extrusion process. 
The extrudates were subsequently cryogenically ground into a micronized coating 
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powder [12]. The pre-plasticization step was not needed for Eudragit® E PO due to the 
low glass transition temperature of this polymer [11]. 
 Eudragit® L 100-55, an anionic copolymer, is based on methacrylic acid and ethyl 
acrylate in a 1:1 ratio and has not been studied in dry powder coating applications. Its 
glass transition temperature was reported to be within the range of 124 to 129ºC [13, 14].  
 The objective of the present study was to investigate the properties of 
chlorpheniramine maleate (CPM) and theophylline tablets that were powder-coated with 
pre-plasticized Eudragit® L 100-55. CPM is a freely water soluble drug. It was reported 
that CPM pellets required higher coating levels of the enteric polymer than pellets 
containing theophylline, a less soluble drug, in order to pass the dissolution specification 
in acidic media due to the migration of the drug into the Eudragit® L 30 D-55 coating [2]. 
Powder coating, a water and organic solvent-free process, was employed as a method to 
prevent the migration of the highly water soluble drug CPM into the film coating. The 
drug release properties of the powder-coated tablets as well as storage stability under 
accelerated storage conditions were studied. Film formation and surface morphology of 
powder-coated tablets were characterized, and the function and influence of the primer on 






 Eudragit® L 100-55 was donated by Degussa Corp. (Piscataway, NJ). 
Chlorpheniramine maleate USP/NF, anhydrous theophylline USP, magnesium stearate 
NF, and lactose monohydrate NF were purchased from Spectrum Chemical Mfg. Corp. 
(Gardena, CA). Triethyl citrate NF (TEC) was donated by Morflex Inc. (Greensboro, 
NC). Talc USP (Imperial 500) was supplied by Luzenac America, Inc. (Centennial, CO). 
Polyethylene Glycol (PEG) 3350 NF was donated by The Dow Chemical Company 
(Midland, MI). Microcrystalline cellulose (MCC, Avicel® PH-101) was donated by FMC 
BioPolymer (Newark, DE). Polyvinylpyrrolidone K-30 (PVP, Kollidon® 30) was 
supplied by BASF Corp. (Mt. Olive, NJ). Colloidal silicon dioxide (CAB-O-SIL® M-5P) 





4.3.1 Coating powder preparation and characterization 
 
 The pre-plasticization process for Eudragit® L 100-55 was based on the method 
reported by Zheng et al. [12] for Eudragit® RS and Eudragit® RL PO. After combining 
Eudragit® L 100-55 with TEC (20, 30, or 40% based on the polymer weight) in a high 
shear mixer, the powder blend was extruded using a single screw extruder (Randcastle 
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Model RC 0750, Cedar Grove, NJ). The extruder temperature zones were set to: zone 1 = 
80ºC, zone 2 = 110ºC, zone 3 = 115ºC, and die = 120ºC. A cylindrical die with an inner 
diameter of 6mm was used. The extrudate was subsequently cut into pellets with a 
Randcastle RCP-2.0 pelletizer and then cryogenically ground into a fine powder using a 
CF Mikro-Bantam Cryogenic Grinder (Micron Powder Systems, Summit, NJ).  To obtain 
a more uniform particle size distribution and exclude fines and large particles, the ground 
pre-plasticized polymer was sieved by mechanical shaking for 15 minutes. The particle 
size fraction between 100 and 200 mesh (75 - 150μm) was used for the dry powder 
coating experiments. 
 Laser light diffraction was employed to analyze the particle size distribution of 
the coating powder using a Malvern Mastersizer S (Malvern Instrument Limited, 
Malvern, Worcestershire, UK). Dv 10, Dv 50, and Dv 90, the cumulative percent 
undersize, were determined using the diffractive index of Eudragit® L 100-55 (nD20 = 
1.3899). The measurements were performed in triplicate in purified water (nD20 = 
1.3300).  
 The TEC content in the extrudates was determined at a wavelength of 210 nm 
using a Waters high performance liquid chromatography (HPLC) system (Waters, 
Milford, MA) equipped with a photodiode array detector (Model 996). Depending on the 
TEC concentration, 500 mg (20 and 30% TEC) or 300 mg (40% TEC) of processed 
polymer were initially dissolved in 50 mM pH 7.4 buffer and then 1:2 diluted with 50 
mM pH 2.5 phosphate buffer to remove the polymer from the solution (n = 3). The 
samples were filtered using 0.2 μm nylon filters prior to analysis. 50 μL samples were 
injected by an autosampler (Model 717plus), and Empower® Version 5.0 software was 
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used to collect and analyze the data. An ODS-3 3 μm, 150 mm × 4.6 mm column (Alltech 
Inertsil™, Deerfield, IL, USA) was employed at a column temperature of 30 ± 2ºC. The 
mobile phase contained a mixture of acetonitrile:pH 2.5 10 mM phosphate buffer in 
volume ratios of 55:45. The flow rate of 1 mL/min resulted in a retention time of 4.0 min 
for TEC. Linearity was demonstrated in the concentration range of 100 to 500 μg/mL (R2 
> 0.999).  
 A MF-50 Moisture Analyzer (A&D Engineering, Inc., Milpitas, CA) was used to 
determine the loss on drying of the coating powder. A sample of 2 g was dried to a 
constant weight, as defined by a weight change of less than 0.05% per minute at 110ºC. 
 
4.3.2 Differential scanning calorimetry 
 
 To characterize the thermal properties of the melt extrudates, modulated 
differential scanning calorimetry (MDSC) was conducted using a Thermal Advantage 
Model 2920 (TA Instruments, New Castle, DE) equipped with Universal Analysis 2000 
software. Ultrahigh pure nitrogen was used as the purge gas at a flow rate of 150 ml/min. 
The polymeric film or polymer powder samples were sealed in aluminum pans (Kit 0219-
0041, Perkin-Elmer Instruments, Norwalk, CT). The temperature ramp rate was 3°C/min 
at a modulation rate of ±1.00°C every 60 seconds. The initial temperature was at least 
30ºC below the expected glass transition temperature. The final temperature exceeded the 
glass transition temperature by a minimum of 10ºC. The reverse heat flow of the second 
heating cycle was used to determine the inflection glass transition temperature. 
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 To study any potential interactions between PEG 3350 and the model active 
pharmaceutical ingredients (API), conventional differential scanning calorimetry (DSC) 
was used employing the same instrument as described above. The samples were heated 
from 50ºC to 300ºC using a temperature ramp rate of 10ºC/min. The raw materials were 
analyzed as well as physical mixtures of API and PEG 3350 in ratios of either 1:1, 1:2 or 
1:10. The heat flow of the first heating cycle was used to determine the melting points 
and heat of fusion values.  
 
4.3.3 Tablet preparation  
 
 The compositions of CPM and theophylline tablets appear in Table 4.1. The API, 
Avicel® PH 101, lactose monohydrate, and the binder were mixed in a V-shape blender 
(Model Yoke, Patterson-Kelley Co., East Stroudsburg, PA) for 15 minutes. Following the 
addition of the magnesium stearate and colloidal silicon dioxide, the mixture was blended 
for an additional 5 minutes. The tablets were compressed on a rotary press (Model FJS-
B2 Stokes, Bristol, PA) using deep concave 5 mm punches and characterized by their 
dimensions and weight (Table 4.1). The tablet hardness was measured on a hardness 
tester (WTP-3, Heberlein &. Co. AG, Wattwil, Switzerland). The disintegration time was 
determined according to USP 29 using a USP Disintegration Tester (Vankel Industries 
Inc., Chatham, NJ). The tablet friability was tested according to USP 29 with a Tablet 
Friability Apparatus (Vankel Industries Inc., Chatham, NJ). 
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4.3.4 Powder coating process 
 
 Powder coating of the tablets was performed according to the method reported by 
Cerea et al. (2004) and Zheng et al. (2004) in a modified laboratory scale spheronizer 
(Model 120, G.B. Caleva, Dorset, UK) [11, 12]. The batch size was 40 g of tablets. The 
rotation speed of the spheronizer was set to 220 rpm. The bed temperature was dependent 
on the plasticizer content of the coating mixture and maintained at 80-85ºC, 70-75ºC, or 
70-75ºC using coating powders containing either 20, 30, or 40% TEC based on the 
polymer weight, respectively. The temperature of the coating bed was monitored by 
measuring the surface temperature of the tablets using a Fluke 61 Infrared Thermometer 
(Fluke Corporation, Everett, WA). Both talc and PEG 3350 were added in a 10% ratio to 
the coating powder based on the weight of the ground extrudate. The feeding rate of the 
coating powder onto the tablets cores was dependent on the capacity of the coating 
powder to adhere, which decreased with increasing coating levels. Following the 
application of the primer subcoat, the polymer mixture containing pre-plasticized 
Eudragit® L 100-55 was fed onto the tablet surfaces at a feeding rate of about 3 g/min 
until a polymer weight gain of 7% was obtained. The powder-feeding rate was then 
reduced to 0.5 g/min. Due to the poor flow properties of the coating formulation, the 
powder mixture was manually fed onto the tablet cores. After completion of the coating 
process, the tablets were subsequently cured either in the operating spheronizer for 6 
hours or in a static oven on Teflon trays at 60ºC for 24 hours. To prevent sticking during 
the stability test at 25ºC/60% RH and 40ºC/75% RH, the cured tablets were over-coated 
with 2% talc based on the weight of the coated tablets in the spheronizer. 
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4.3.5 Contact angle measurements 
 
Polymer sample compacts were prepared at a 500 kg compression force using a 
Carver Laboratory Press (Model M, ISI Inc., Round Rock, TX). 3 μL of water were 
placed onto the surface of polymer compacts using a microsyringe. The contact angle was 
determined by measuring the tangent to the curve of the droplet on the surface of the 
compact using a Goniometer (Model No. 100-00-115, Ramé-Hart Inc., Mountain Lakes, 
NJ). The measurements were performed in triplicate at 20ºC.  
 
4.3.6 Drug release study 
 
 The drug release rate of CPM and theophylline from powder-coated tablets was 
investigated using a modified USP 29 Drug Release Standard for Enteric-Coated Articles, 
Method B. In vitro dissolution testing was performed in 900 mL 0.1N HCl for the first 
two hours, followed by 4 hours in 900 mL pH 6.8, 50 mM phosphate buffer solution 
maintained at 37 °C and agitated at 50 rpm using a USP 29 Apparatus 2 (Vankel VK 
7000; Vankel Industries Inc., Cary, NC). The dissolution properties of the coated tablets 
were determined by placing three tablets into each of either three or six dissolution 
vessels respectively (n = 3 x 3 tablets/vessel or n = 6 x 3 tablets/vessel). Samples were 
withdrawn by an autosampler over a 6 hour period (Vankel VK 8000; Vankel Industries 
Inc., Cary, NC). Samples were analyzed for CPM content using a HPLC system with a 
photodiode array detector (Model 996, Waters, Milford, MA) at a wavelength of 260 nm. 
Prior to analysis, the samples were filtered using 0.45 μm nylon filters. The autosampler 
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(Model 717plus) was set to inject 50 μL samples. The data were collected and analyzed 
using Empower® Version 5.0 software. An ODS-3 3 μm, 150 mm × 4.6 mm column 
(Alltech Inertsil™, Deerfield, IL, USA) was used. The column temperature was kept at 
40 ± 2ºC. The mobile phase contained a mixture of water:methanol:triethylamine in 
volume ratios of 675:325:4.5. The retention time of the CPM was 9.5 min. Linearity was 
demonstrated from 2 to 50 μg/mL (R2 > 0.999). The quantitative analysis for theophylline 
was conducted using the HPLC method described by Zheng et al. 2004 [12]. The same 
equipment was used as for the quantitative analysis of CPM. The injection volume was 
40μL. The mobile phase consisted of water:acetonitrile:glacial acid in volume ratios 
845:150:5 and 1.156 g/L of sodium acetate trihydrate. The flow rate was 1 mL/min, and 
the retention time was 4 minutes. Linearity was confirmed from 1 to 60 μg/mL (R2 > 
0.999). 
 
4.3.7 Film preparation 
 
 The ground extrudate containing varying amounts of PEG 3350 was pressed into 
polymeric films in Teflon coated aluminum dishes with a Teflon coated lid by applying a 
small weight. A compression force of 45 g per cm2 during the curing process was used to 
prepare the polymeric film to facilitate polymer particle fusion and film formation. This 
pressure minimized the formation of voids in the film due to an increase in the packing 




4.3.8 Scanning electron microscopy 
 
 The morphology of the surface and cross-section of powder-cast films and coated 
tablets was analyzed by scanning electron microscopy (SEM) using a Hitachi, Model S-
4500 FE (Hitachi, London UK) operated at 10 kV and 20 mA. The samples were sputter 
coated with gold/palladium (60:40) using a Ladd Benchtop Sputter Coater (Ladd 
Research, Winston, VT) at 2.5 kV and 20 mA for 75 seconds.  
 
 
4.4 RESULTS AND DISCUSSION 
 
4.4.1 Coating powder preparation 
 
  Due to the high glass transition temperature of the bulk polymer and to reduce the 
melt viscosity, the Eudragit® L 100-55 was pre-plasticized with up to 40% TEC using 
hot-melt extrusion. The pre-mixing of polymer and plasticizer under high shear 
conditions allowed for a homogeneous distribution of the plasticizer in the extrudate. The 
temperature in the metering zone of the extruder (zone 3) was maintained at 115ºC. 
Processing temperatures for Eudragit® L 100-55 should generally not exceed 130ºC as a 
decrease in functional groups was reported above temperatures of approximately 130ºC, 
with depolymerization occurring at temperatures exceeding 300ºC [15].  
  The TEC content recommended for aqueous coating dispersions of Eudragit® L 
100-55 is 10-15% based on the dry polymer weight. In previous reports, Obara et al. and 
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Pearnchob et al. demonstrated that dry powder coating of tablets and pellets required 
polymers with higher plasticizer levels than normally employed in aqueous coating 
processes [6-9]. The extrusion of Eudragit® L 100-55 containing 10% TEC (based on the 
polymer weight) was unsuccessful due to the high melt viscosity of the polymer. A 
thermal glidant could be used to aid in processing, but may impact dissolution. Thus, the 
current study investigated plasticizer ratios of 20, 30, and 40% TEC.  
  The glass transition temperature of the polymer was dependent on the amount of 
plasticizer in the extrudate, as seen in Table 4.2. A homogeneous distribution of the 
plasticizer throughout the polymer was verified for all TEC concentrations, as evidenced 
by the low standard deviation of the TEC recovery values. The higher the plasticizer 
level, the more difficult was the feeding of the polymer-plasticizer mixture from the 
hopper into the extruder barrel due to the poor flow properties of the powder-plasticizer 
mixture. The low glass transition temperatures of the pre-plasticized polymeric extrudates 
required a cryogenic grinding process to obtain a fine powder suitable for powder coating 
applications. 
  The loss on drying of the coating powder was analyzed to determine the moisture 
content since water is a known plasticizing agent for acrylic polymers [16] and adsorbed 
moisture has been shown to significantly impact the glass transition temperature for 
Eudragit® L 100-55 [13]. The loss on drying of the processed polymer ranged from 3.1 to 
3.8%, which was slightly lower than the value of 4.5% for the bulk polymer (Table 4.2). 
Before the analysis, it was demonstrated by thermogravimetric analysis that TEC was not 
volatile at the 110ºC storage temperature used in this study (data not shown). However, 
TEC exhibited a distinct weight loss at temperatures above 200ºC.  
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  The particle size distributions of the unprocessed Eudragit® L 100-55 and ground, 
pre-plasticized polymer after sieving are presented in Table 4.2. The particle sizes of the 
processed polymers were significantly higher than the commercially available Eudragit® 
L 100-55 powder but equivalent to particles used in previous powder coating studies [12]. 
Due to identical processing conditions and the same sieving process, no influence of the 
plasticizer level on the particle size distribution of the cryogenic ground powders was 
observed.  
  
4.4.2 Powder coating 
 
 The coating powder mixture was composed of the processed polymer, 10% talc, 
and 10% PEG 3350. Both the weight of talc and the weight of PEG 3350 were based on 
the weight of the ground extrudate. A talc content of 10% effectively prevented tablet 
aggregation during the powder coating process with pre-plasticized Eudragit® L 100-55.  
Comparably low levels of talc as an anti-tack agent were sufficient due to the absence of 
liquids during the coating operation, and low talc levels had previously been successfully 
employed in a powder coating process with Eudragit® E PO and Eudragit® RS/RL PO 
[11, 12].  
  Powder adhesion to the core tablets of pre-plasticized Eudragit® L 100-55 
combined with 10% talc was not possible without the presence of a primer subcoat. 
Several primers were investigated including cetyl alcohol, poloxamer 407, and PEG 
3350. All investigated priming agents had a melting point below the coating temperature 
in order to generate a liquid priming layer covering the core tablets. The interfacial 
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interactions between the tablet surface and the pre-plasticized polymer particle are 
complex and are dependent on interfacial tension, wetting and adhesion [17, 18]. Another 
factor influencing the adhesion of the coating powder is the hydrophilicity of the tablet 
surface. PEG 3350, which is characterized by a small contact angle with purified water, 
increases the hydrophilic surface properties of the tablet [12]. The use of low melting 
point hydrophobic primers, such as cetyl alcohol, were not effective in powder-coating 
with pre-plasticized Eudragit® L 100-55, although they were successfully employed for 
Eudragit® RS/RL PO [12]. Since Eudragit® L 100-55 was characterized by a contact 
angle with water of 61.0 ± 2.6º (n = 3), while the contact angle of Eudragit® RS PO and 
RL PO was determined to be 87.7 ± 2.1º and 86.7 ± 0.6º respectively (n=3), Eudragit® L 
100-55 is a more hydrophilic polymer which required a more hydrophilic priming agent.  
  PEG 3350 was not only employed as a priming agent, but it was also incorporated 
into the coating powder at the 10% level based on the weight of the ground extrudate. 
When PEG 3350 was utilized as the priming agent but was not present in the powder 
coating formulation the maximum polymer weight gain that could be achieved was 5%, 
which was insufficient to pass the gastric phase of the USP enteric test for all TEC levels 
investigated. To investigate the miscibility of PEG 3350 and Eudragit® L 100-55 and to 
study the influence of PEG 3350 on the thermal properties of Eudragit® L 100-55, 
polymeric films were powder-cast and cured for 24 hours at 60ºC. The presence of the 
PEG 3350 at the 10% level reduced the glass transition temperature of Eudragit® L 100-
55 by about 30ºC for all TEC levels as shown in Table 4.2. The thermograms indicated 
complete miscibility of Eudragit® L 100-55 and PEG 3350 at this ratio, as evidenced by a 
single detectable glass transition and the absence of the distinct melting peak of PEG 
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3350. These findings correlate well with previously published solubility parameters, 
which suggest a high affinity between PEGs and the Eudragit® L polymers [19]. 
  The influence of PEG 3350 on film formation was additionally investigated in a 
second free film study. The SEM micrographs of cross-sections of Eudragit® L 100-55 
films containing 30% TEC and various levels of PEG 3350 are presented in Figure 4.1. 
PEG 3350 levels of 5 and 10% promoted polymer particle fusion and facilitated film 
formation during the curing process at 60ºC for 24 hours. However, the addition of 5% 
PEG 3350 to the coating powder in combination with a primer did not promote polymer 
adhesion. In contrast, a 3% weight gain of PEG 3350 as primer and the additional 
incorporation of 10% PEG 3350 into the coating powder allowed high coating levels with 
polymer weight gains above 15% for all employed TEC levels.  
  The bed temperatures for the powder coating process were 80-85ºC, 70-75ºC, or 
70-75ºC for powder blends containing 20, 30, and 40% TEC, respectively. These 
temperatures are above the glass transition temperature of the pre-plasticized Eudragit® L 
100-55 for the respective TEC concentrations.  
  The influence of TEC content and coating level on the release rate of CPM from 
powder-coated tablets is presented in Figure 4.2. Tablet samples were withdrawn during 
the coating process after each designated coating level was reached and cured for 24 
hours in a static oven. The applied polymer weight gain had a significant impact on the 
drug release properties of the powder-coated tablets. The USP 29 Drug Release Standard 
for Enteric-Coated Articles requires a drug release of less than 10% after 2 hours 
dissolution testing in 0.1N HCl. In addition, the gastric stability was found to be 
significantly dependent on the TEC concentration in the film coating. A coating level of 
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10% polymer weight gain on powder-coated CPM tablets met the USP dissolution 
specifications at a TEC content of both 30 and 40%. However, a polymer weight gain of 
15% was needed to maintain the release of CPM in acid below the 10% level for a TEC 
content of 20%. Higher plasticizer levels will enhance the coalescence between the 
polymer particles and were previously demonstrated to decrease drug release rates [20]. 
This trend was observed both in the gastric as well as the buffer phase of the enteric test.  
  To investigate the surface morphology of the coating, powder-coated tablets with 
a 15% polymer weight gain were subjected to microscopic examination as seen in Figure 
4.3. The highest coating level was chosen to evaluate the dependence of film formation 
on the plasticizer level in the coating powder. All TEC concentrations resulted in the 
formation of a dense polymer film as seen in the micrographs of the cross sections. The 
surfaces of all films, however, were characterized by the presence of voids and non-fused 
large particles of polymer. The number of flaws in the film coating decreased with 
increasing TEC levels, thereby demonstrating improved film formation at elevated 
plasticizer concentrations in the polymeric film. The results of the microscopic analysis 
supported the observed differences in CPM dissolution rates at different plasticizer levels. 
  Swelling of the enteric coating was observed for the powder-coated CPM tablets 
during dissolution testing after immersion in 0.1N HCl for 2 hours. Following the acid 
stage of the enteric test, the tablets were characterized by an increase in size and a soft 
consistency compared to the dry tablets. These results may be partially attributed to the 
high level of water-soluble components in the film coating. TEC has been shown to be 
slowly released from Eudragit® L film coatings due to strong interactions with Eudragit® 
L compared to other plasticizers [21]. PEGs have been studied by other researchers to 
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increase the permeability of poly(meth)acrylate films. Due to its high water solubility, 
PEG can act as a pore forming agent during dissolution testing depending on the 
miscibility with the polymer and can cause an increase in the drug diffusion rate [22-24]. 
Since water molecules are strongly bound to the ether groups in the PEG molecule by 
hydrogen bonds [19], the PEG remaining in the polymeric film causes swelling of the 
polymer coating, resulting in the release of a small amount of CPM during the acid stage 
of the enteric test. This level of drug release did not exceed the maximum allowance of 
the USP test for enteric-coated articles at coating levels of 10% polymer weight gain and 
above.  
 High levels of plasticizer also increase the tackiness of a polymeric film. This effect 
improves adhesion of the polymer film to the tablet core, but represents an undesired 
phenomenon in coating operations and during storage, and may result in agglomeration 
of coated dosage-forms [25, 26]. Increasing tackiness with high TEC levels (40%) was 
also observed for the powder coating of tablets with pre-plasticized Eudragit® L 100-55 
following curing. Tackiness was eliminated with the application of a 2% talc overcoat in 
the spheronizer after the curing step.  
  A TEC content of 30% in the processed polymer and a coating level of 10% 
polymer weight gain were determined to be the ideal coating parameters for CPM tablets 
since tablets coated with Eudragit® L 100-55 containing 20% TEC required high coating 
levels, while a TEC content of 40% resulted in slightly tacky tablets. Tablets powder-
coated using these conditions were further studied to investigate the optimal curing 
conditions and the physical stability of the powder-coated tablets at accelerated storage 




4.4.3 Curing conditions 
 
 In Figure 4.4, the scanning electron micrographs are presented which show the 
surface and cross-section of an uncured tablet that was powder-coated with pre-
plasticized Eudragit® L 100-55. Film formation was incomplete following the application 
of the coating material using the dry powder coating process. The upper layer of the 
polymer film is characterized by separate polymer particles, while the lower layer 
exhibited a dense polymeric film. Without curing, the quantity of drug released in the 
acidic medium was higher than 10%, which is the maximum allowance by the USP 29 
Release Standard for Enteric-Coated Articles, and exhibited a large standard deviation. 
Since a curing time of 24 hours in a static oven resulted in a continuous polymeric film in 
previous powder-coating studies [11, 12], all tablets used in the dissolution studies 
presented in Figure 4.2 were cured for 24 hours at 60ºC. Curing at 80ºC resulted in 
yellow discoloration of the tablets, due to the oxidation of PEG at this high temperature 
[27, 28]. A curing condition at 60ºC for 24 hours prevented the discoloration. A curing 
study was performed to determine the necessary curing time at 60ºC to reduce the drug 
release in 0.1N HCl to less than 10%.  
  The tablets were coated with pre-plasticized Eudragit® L 100-55 containing 30% 
TEC based on the polymer weight with a 10% polymer weight gain. After the completion 
of the coating process, the tablets were either cured in a static oven at 60ºC or were 
tumbled in the spheronizer at 60ºC at 220 rpm. The gastric stability of the powder-coated 
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tablets was investigated, which was characterized by the percent of CPM released in 0.1N 
HCl after 2 hours using USP 29 Apparatus 2. The data in Figure 4.5 show the influence 
of curing time and conditions on the CPM release rate from tablets powder-coated with 
pre-plasticized Eudragit® L 100-55.  
 Curing of powder-coated CPM tablets at 60ºC improved gastric stability and 
decreased the variability in the dissolution data since curing eliminated the residual voids 
between the polymer particles. In prior studies, curing was shown to be an essential step 
in a dry-powder coating process to improve polymer particle fusion and complete film 
formation [6-9, 11, 12]. Curing in the spheronizer was demonstrated to be an efficient 
curing method with a small standard deviation and a lower average CPM release rate in 
the acidic medium than the oven cured tablets. Due to the strong centrifugal forces and 
the resulting impact of the tablets on the spheronizer wall, the polymer particles were 
compressed, deformed, and fused. The surface was leveled and defects were corrected 
faster resulting in a shiny surface compared to the oven cured tablets, even after short 
curing times. Curing in the spheronizer also reduced the influence of gravity on the 
polymer flow during film formation. Generally, the flow of polymeric films with a 
thickness of 25 - 75 μm or above is controlled by gravity [29]. In the case of powder-
coated tablets, this effect caused the direction of flow of the polymer to the bottom of the 
tablet. As a result, tablets stored on trays at 60ºC for 24 hours developed a flat base which 
resulted in the loss of the round tablet shape. After rotating for 12 hours, tablets cured in 
the spheronizer showed signs of deformation and grey discoloration of the tablet edges. 
Curing in the spheronizer should therefore generally not exceed 6 hours to prevent this 
phenomenon. 
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 Curing in both a static oven and the spheronizer was shown to be effective for 
tablets powder-coated with pre-plasticized Eudragit® L 100-55, to achieve sufficient 
gastric stability. However, curing in the spheronizer reached equilibrium faster than 
curing the powder-coated tablets in a static oven.  
   
4.4.4 Properties of powder-coated theophylline tablets 
 
  Dosage forms containing theophylline were shown to require a lower Eudragit® L 
30 D-55 coating weight gain applied from an aqueous dispersion compared to those 
containing CPM to provide sufficient gastric stability [2]. This phenomenon was 
attributed to the lower water solubility of theophylline and decreased migration rate of 
the API into the film. Thus, theophylline was selected for this study to compare and 
characterize its release rate from tablets powder coated with pre-plasticized Eudragit® L 
100-55 using the same parameters as for CPM.  
  Theophylline containing tablets (Table 4.1) were powder-coated with a pre-
plasticized blend of Eudragit® L 100-55 containing 30% TEC. The tablets were coated to 
polymer weight gains of 7, 10, and 15% and then subsequently cured in a static oven for 
24 hours. The static oven and not the spheronizer was used for curing to compare the 
results to the CPM tablets. The influence of weight gain on the release rate of 
theophylline from tablets powder-coated with pre-plasticized Eudragit® L 100-55 
containing 30% TEC based on the polymer weight is seen in Figure 4.6. A polymer 
weight gain of 7% provided gastric stability with the amount of drug released after two 
hours in 0.1N HCl being approximately 10%. A 10 and 15% polymer weight gain 
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reduced the amount of drug released after two hours in 0.1N HCl to less than 5 and 2% 
respectively. The drug release from theophylline tablets could be controlled with a lower 
polymer weight gain. The differences in the drug release rates are mainly caused by the 
higher water solubility of CPM and higher drug diffusion from CPM tablets compared to 
the theophylline tablets in acidic media. It has been reported that the drug release rate 
from theophylline tablets was slower compared to tablets containing a more water soluble 
API [30]. Drug release during the acid phase is a result of swelling of the film coating, 
water penetration into the core, drug dissolution, and subsequent diffusion through the 
hydrated polymeric film [31]. Penetrated water increases the polarity and molecular 
mobility inside the tablet [30]. Both water influx and drug solubility are factors which 
increase the drug release rate through enteric polymer films [31]. The transfer of drug 
through polymeric films is not only controlled by diffusion, but is also modulated by 
osmotic pressure [32]. Osmotic forces that are generated by the dissolution of drug and 
excipients in the tablet matrix increase the influx of water and the diffusion of electrolyte, 
which result in faster drug release [33]. 
  The theophylline core tablets were characterized by a significantly shorter 
disintegration time compared to the CPM tablets. The tablet size, weight, hardness, and 
friability were similar for both formulations. To investigate possible API migration into 
the polymer film during the powder coating process or curing, the interactions between 
the model drugs and the molten PEG 3350 were studied using conventional DSC. The 
first heating cycle was used to investigate the effects of the molten PEG 3350 on each 
crystalline drug. The DSC profiles of the raw materials were characterized by distinct 
melting peaks as seen in Figure 4.7. PEG 3350 melted at a temperature of 61ºC. The 
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melting points of CPM and theophylline occurred at 136ºC and 274ºC, respectively, 
which were above the coating and curing temperature conditions. The melting point as 
well as the heat of fusion of PEG 3350 was not influenced by the presence of either CPM 
or theophylline. In contrast, the DSC profiles of the physical mixtures, exhibit lower or 
no distinct melting points for both APIs, depending on the mixing ratio. Additionally, 
PEG 3350 influenced the heat of fusion of both APIs. Table 4.3 shows the heat of fusion 
values of the individual components calculated based on the mixing ratio of the model 
drug and PEG 3350. All physical mixtures exhibited a lower heat of fusion for both CPM 
and theophylline in a physical mixture compared to the pure drugs, indicating changes in 
the crystal lattice of the model compounds. Both theophylline and CPM were shown to 
interact with PEG 3350. The melting point of CPM is lower than that of theophylline and 
hence closer to the processing conditions. Consequently the effect of PEG 3350 could be 
more pronounced on CPM than on theophylline.  
 The theophylline release rate in buffer was faster compared to the CPM release rate. 
The dissolution of enteric polymeric films during the buffer phase of the enteric test was 
demonstrated to occur primarily at the polymer/bulk interface rather than by bulk erosion 
throughout the coating layer [31]. As a result, the thickness of the polymeric film was 
shown to decrease under simulated intestinal conditions. The drug CPM was previously 
shown to adsorb to Eudragit® L 30 D-55 as a function of the pH of the dissolution 
medium [2]. Consequently the theophylline release rate in pH 6.8 buffer was expected to 
be faster and less dependent on the coating level.  
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4.4.5 Stability of powder-coated CPM tablets  
 
  Powder-coated tablets have been reported to demonstrate excellent physical 
stability during storage [6-8, 12]. The physical stability of CPM tablets powder-coated 
with a 10% weight gain of pre-plasticized Eudragit® L 100-55 containing 30% TEC 
based on the polymer weight was determined. These tablets were cured in the rotating 
spheronizer at 170 rpm for 6 hours. After the completion of the curing step, a 2% talc 
overcoat was applied onto the coated tablets in the spheronizer to reduce the tackiness of 
the film coating. The powder-coated tablets were stored in induction-sealed HDPE 
containers with desiccant to exclude the influence of humidity during storage at both 
25ºC/60% RH and 40ºC/75% RH. Before dissolution testing, the samples were 
equilibrated to ambient temperatures for 24 hours.  
  As shown in Figure 4.8, CPM powder-coated tablets demonstrated 
excellent stability over 12 weeks at 25ºC/60% RH with no detectable difference in the 
drug release profiles. The drug release rate from powder-coated tablets stored at 
40ºC/75% RH was characterized by an initial increase over 4 weeks followed by a slight 
decrease after 8 and 12 weeks. The drug release profiles that were obtained from tablets 
stored at 40ºC/75% RH after one and eight weeks were excluded from Figure 4.8 for 
better clarification between the single profile curves. Both deleted graphs were similar to 
the initial drug release curve. This aging phenomenon was attributed to the additional 
plasticization of the Eudragit® L 100-55 by PEG 3350 during storage. The glass transition 
temperature of the coating powder containing 30% TEC based on the polymer weight and 
10% PEG based on the ground extrudate was approximately 28ºC as shown in Table 4.2. 
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This temperature was below the storage temperature. The changes in dissolution rate 
during storage can be explained by changes in the permeability of the coating that 





 Dry powder coating, a completely liquid free process, was demonstrated to be 
an efficient method to enterically coat tablets with Eudragit® L 100-55. Unlike aqueous 
coating, powder coating minimized partitioning of the drug into the film coating during 
the coating process. The choice of primer significantly impacted the film formation and 
drug release properties. PEG 3350 was determined to be an ideal priming material for 
powder coating of tablets with pre-plasticized Eudragit® L 100-55. Curing is a necessary 
step to ensure the complete film formation and drug release stability. The drug release 
properties of powder-coated tablets were dependent on the curing time, coating level and 
plasticizer content. Higher TEC levels in the acrylic polymer reduced the polymer weight 
gain required to control the drug release in 0.1N HCl. The drug release rate from powder-
coated theophylline tablets was controlled with slightly lower coating levels. The stability 
of the powder-coated CPM tablets was confirmed at 25ºC/60% RH over a storage time of 
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4.7 TABLES AND FIGURES 
 
Table 4.1: Chlorpheniramine maleate and theophylline tablet formulations and tablet 
characteristics (standard deviation, n = 6). 
 
 CPM tablets Theophylline tablets
 Tablet formulations 
API 15%





 Tablet characteristics (n = 6) 
Diameter (d) [mm] 5.0 ± 0.0 5.0 ± 0.0 
Height (h) [mm] 4.2 ± 0.0 4.2 ± 0.0 
Weight [mg] 81.2 ± 0.5 82.6 ± 0.3 
Hardness [kg] 7.8 ± 0.6 7.8 ± 0.4 
Disintegration time [min] 21 1 
Tablet friability [%] 0.04 0.01 
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Table 4.2: Coating powder characteristics: TEC recovery, inflection glass transition 
temperature (Tg) (standard deviation, n = 3), and particle size distribution.  
 
TEC content 0 (bulk) 20 30 40 
TEC recovery - 98.5 ± 0.3% 97.5 ± 0.2% 97.5 ± 0.3%
Tg 123.7 ± 0.6ºC 73.7 ± 0.6ºC 61.3 ± 3.1ºC 37.0 ± 2.2ºC
Loss on drying 4.50 ± 0.05% 3.07 ± 0.08% 3.77 ± 0.18% 3.25 ± 0.09%
Tg after addition of 
10% PEG 3350 
122.2 ± 3.0ºC 47.4 ± 9.0ºC 29.2 ± 0.9ºC 11.1 ± 2.9ºC
Particle size distribution 
Dv 10 0.37 μm 0.33 μm 35.13 μm 38.42 μm
Dv 50 43.63 μm 74.18 μm 77.50 μm 81.94 μm
Dv 90 83.25 μm 148.33 μm 147.58 μm 151.07 μm
Span 1.900 1.995 1.451 1.375 




Table 4.3: Heat of fusion of CPM, theophylline, and PEG 3350 and their mixtures. 
  CPM/PEG mixtures Theophylline/PEG mixtures 
  CPM PEG 3350 Theophylline PEG 3350 
Heat of 
fusion [J/g] 
Bulk 121.2 194.6 167.1 194.6
1:1 86.5 194.2 79.0 206.6
1:2 73.7 196.4 69.8 202.5
1:10 33.1 193.7 19.3 200.9
 78
Figure 4.1: Influence of PEG 3350 content on morphology of free films prepared from 
HME processed Eudragit® L 100-55 pre-plasticized with 30% TEC (based on the 
polymer weight) after curing at 60ºC for 24 hours. A: 0% PEG 3350. B: 1% PEG 3350. 







Figure 4.2: Influence of TEC content and coating level on the release of CPM from 
tablets powder-coated with pre-plasticized Eudragit® L 100-55 using USP 29 apparatus 2. 
Dissolution in 900mL of 0.1N HCl for 2 hours followed by 4 hours in 900mL pH 6.8 
50mM phosphate buffer at 37ºC and 50 rpm. ♦: 7% polymer weight gain. ■: 10% 
polymer weight gain. ▲: 15% polymer weight gain. (Standard deviation, n = 6 x 3 
tablets/vessel.) (A) 20% TEC based on the polymer weight. (B) 30% TEC based on the 






























































































Figure 4.3: SEM micrographs of cross-section (CS) and surface (SF) of powder-coated 
tablets (15% polymer weight gain) after curing in a static oven at 60ºC for 24 hours. A: 
20% TEC based on the polymer weight (CS). B: 30% TEC based on the polymer weight 
(CS). C: 40% TEC based on the polymer weight (CS). D: 20% TEC based on the 
polymer weight (SF). E: 30% TEC based on the polymer weight (SF). F: 40% TEC based 







Figure 4.4: SEM micrographs of cross-section (A) and surface (B) of tablets powder-







Figure 4.5: Influence of curing time and conditions on the release of CPM from powder-
coated tablets (30% TEC based on the polymer weight, 10% polymer weight gain) in 
900mL 0.1N HCl using USP Apparatus 2 at 50 rpm and 37ºC after 2 hours. ▲: 60ºC, 

































































Figure 4.6: Influence of coating level on the release of theophylline from tablets powder-
coated with pre-plasticized Eudragit® L 100-55 containing 30% TEC based on the 
polymer weight using USP 29 apparatus 2. Dissolution in 900mL of 0.1N HCl for 2 
hours followed by 4 hours in 900mL pH 6.8 50mM phosphate buffer at 37ºC and 50 rpm. 
♦: 7% polymer weight gain. ■: 10% polymer weight gain. ▲: 15% polymer weight gain. 














































Figure 4.7: DSC profiles of CPM (A) and theophylline (B) and their physical mixtures in 
ratios of 1:1, 1:2, and 1:10 PEG 3350. 
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Figure 4.8: 12 week stability of CPM tablets powder-coated with pre-plasticized 
Eudragit® L 100-55 containing 30% TEC based on the polymer weight using USP 29 
apparatus 2. Dissolution in 900mL of 0.1N HCl for 2 hours followed by 4 hours in 
900mL pH 6.8 50mM phosphate buffer at 37ºC and 50 rpm. Polymer weight gain: 10%. 
♦: initial. ■: 1 week. ▲: 4 weeks. □: 8 weeks. ∆: 12 weeks (Standard deviation, n = 6 x 6 


































































Chapter 5: Investigate the Influence of Polymeric Subcoats on the Drug 
Release Properties of Tablets Powder-coated with Pre-plasticized 




 The aim of the study was to investigate the properties of sodium valproate tablets 
that were dry powder coated with pre-plasticized Eudragit® L 100-55. Polyethylene 
glycol 3350 (PEG 3350) was used as primer to facilitate initial coating powder adhesion. 
Solubility parameters were employed to determine the wetting properties of the PEG 
3350 primer. Additional PEG 3350 within the powder coating formulation was required 
to enable powder adhesion to the tablet cores. The application of a subcoat of either 
Eudragit® E PO or Eudragit® RL PO facilitated adhesion of the enteric polymer to the 
tablet cores and reduced the amount PEG 3350 required in the coating formulation. Since 
reduction of the PEG 3350 content produced less hydrophilic films, the enteric coating 
level necessary to control the drug release was decreased. The storage stability of the 
coated tablets was also improved by the use of an acrylic subcoating material. PEG 3350 
and Methocel® K4M were incorporated in both Eudragit® E PO and Eudragit® RL PO 
subcoating formulations as pore forming agents. The influence of the pore forming 
excipients on physicochemical properties of free powder-cast films was investigated. The 
miscibility of the PEG 3350 and Methocel® K4M in the film coating was correlated with 




Dry powder coating of pharmaceutical dosage forms was first investigated by 
Obara and coworkers in the late 1990s [1]. The process was later modified by Pearnchob 
et al. and Kablitz et al. [2, 3]. Recently a new liquid free coating technique for tablets was 
developed by Cerea et al. and Zheng et al. using the acrylic polymers Eudragit® E PO and 
mixtures of Eudragit® RL PO and RS PO [4, 5]. The process did not require the use of 
organic solvents or water. Powder coating is a suitable technique for water-sensitive 
drugs and can reduce interactions between the API and functional polymers in aqueous 
coating applications. Powder coating has been shown to significantly reduce processing 
times [2], prevent aging of polymer films [5], and reduce the migration of drugs into 
functional coatings [6].  
Sodium valproate is a very water-soluble, heat-stable, deliquescent salt with a 
pKa of 4.8 [7]. It has been reported that sodium valproate tablets and pellets required 
high coating levels of an enteric polymer, even with the application of either a Methocel® 
E5 or Opadry® AMB subcoat [8]. Several mechanisms have been proposed in the 
literature to explain why cores containing highly soluble model drugs require high 
coating levels of a functional polymer to control the drug release. In aqueous coating 
operations, highly water-soluble active pharmaceutical ingredients (APIs) can dissolve 
and partition into the film coating, which may compromise film integrity during 
dissolution [9]. In this case, an elevated polymer weight gain is required to control the 
drug release. Other researchers have found that high levels of an enteric polymer are 
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necessary to delay drug release of an alkaline API in acidic media [10, 11]. The presence 
of a weak base in the core formulation of an enteric coated dosage form was shown to 
cause high absorption of simulated gastric fluid and premature drug release at low 
coating levels [10]. Dissolution of sodium valproate, as a weak base, may increase the 
microenvironmental pH at the film interface causing partial polymer ionization and 
premature drug release. A decrease in the drug release in acidic media was observed 
following the addition of small amounts of organic acids to the sodium valproate core 
formulation [8].  
Subcoating materials have been widely used in combination with enteric polymers 
to promote adhesion of the functional polymer [1], function as a moisture barrier [12], 
and prevent interactions between an API and enteric coating [13]. Other researchers 
described an increased gastric resistance of enteric coated dosage forms in the presence 
of a polymeric subcoat [14-16]. 
Eudragit® L 100-55 is an anionic copolymer based on methacrylic acid and ethyl 
acrylate. The ratio of free carboxyl groups to the ester groups is approximately 1:1. The 
carboxylic groups ionize in aqueous media at pH 5.5 and above. Eudragit® E PO is a 
copolymer of dimethylaminoethyl methacrylate and neutral methacrylic esters, and, due 
to its solubility below pH 5.5, is mainly used for taste-masking or moisture protection. 
Eudragit® RL PO is a water-insoluble polymer based on ethyl acrylate, methyl 
methacrylate, and trimethylammonioethyl methacrylate chloride in a ratio of 1:2:0.2 and 
used for sustained release applications. Eudragit® L 100-55, Eudragit® E PO, and 
Eudragit® RL PO have been used in previous studies of dry powder coating applications 
[4-6]. 
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The objective was to study the influence of the sub-coating materials Eudragit® E 
PO and Eudragit® RL PO on the level of enteric coating required for enteric protection. 
The effect of pore forming agents on the permeability and thermal properties of the 





 Eudragit® L 100-55, Eudragit® RL PO, and Eudragit® E PO were donated by 
Degussa Corp. (Piscataway, NJ). Sodium valproate USP/NF and magnesium stearate NF 
were obtained from Spectrum Chemical Mfg. Corp. (Gardena, CA). Triethyl citrate NF 
(TEC) was supplied by Morflex Inc. (Greensboro, NC). Talc USP (Imperial 500) was 
donated by Luzenac America, Inc. (Centennial, CO). Polyethylene glycol (PEG) 3350 NF 
and hydroxypropyl methylcellulose (Methocel® K4M) were supplied by The Dow 
Chemical Company (Midland, MI). Microcrystalline cellulose (MCC, Avicel® PH-200 
and PH-101) was donated by FMC BioPolymer (Newark, DE). Polyvinylpyrrolidone K-
30 (PVP, Kollidon® 30) was supplied by BASF Corp. (Mt. Olive, NJ). Colloidal silicon 






5.3.1 Coating powder preparation 
 
 Eudragit® L 100-55 and Eudragit® RL PO were pre-plasticized by hot melt 
extrusion using the method described by Zheng et al. for mixtures of Eudragit® RS and 
Eudragit® RL PO [5]. The process was later adapted for the pre-plasticization of 
Eudragit® L 100-55 [6]. Prior to extrusion, both Eudragit® L 100-55 and Eudragit® RL 
PO were combined with TEC in a high shear mixer (RSI 3VG, Robot Coupe Scientific-
Industrial Division, Joliet, IL). For the extrusion of Eudragit® L 100-55 containing 30% 
TEC based on the polymer weight, the temperature zones of the single screw extruder 
(Randcastle Model RC 0750, Cedar Grove, NJ) were set to: zone 1 = 80ºC, zone 2 = 
110ºC, zone 3 = 115ºC, die = 120ºC. Eudragit® RL PO with a TEC content of 10% based 
on the polymer weight was extruded at slightly different temperatures: zone 1 = 80ºC, 
zone 2 = 105ºC, zone 3 = 115ºC, die = 125ºC. For both extrusion processes, a cylindrical 
die with an inner diameter of 6mm was used. A Randcastle RCP-2.0 pelletizer was 
employed to cut the extrudate into pellets which were subsequently ground into a fine 
powder using a cryogenic milling process (CF Mikro-Bantam Cryogenic Grinder, Micron 
Powder Systems, Summit, NJ).  The ground extrudate was sieved by mechanical shaking 
for 15 minutes to exclude the particle size fractions below 200 and above 100 mesh 
(below 75 μm and above 150 μm respectively) as recommended in previous publications 
[5, 6]. 
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5.3.2 Tablet preparation  
 
 Sodium valproate (15%), Avicel® PH-200 (81.25%), and Kollidon® 30 (3%) were 
blended in a Yoke V-shape blender (Patterson-Kelley Co., East Stroudsburg, PA) for 15 
minutes. The formulation was mixed for an additional 5 minutes after the addition of the 
magnesium stearate (0.5%) and colloidal silicon dioxide (0.25%). Tablets with a weight 
of 74.8 ± 0.3 mg (n = 6, standard deviation) were directly compressed on a single stage 
press (Stokes F press, Bristol, PA) using deep concave 5 mm punches. A breaking load of 
74.5 ± 5.3 N (n = 6, standard deviation) was measured using a WTP-3 tablet tester 
(Heberlein &. Co. AG, Wattwil, Switzerland). The disintegration time was determined to 
be 22 min, according to USP 29 using a USP Disintegration Tester (Vankel Industries 
Inc., Chatham, NJ). 
 
5.3.3 Powder coating process 
 
 A modified laboratory scale spheronizer (Model 120, G.B. Caleva, Dorset, UK) 
was used for powder coating of 40 g batches of tablets, as previously described in the 
literature [4-6]. The processing conditions varied according to the coating formulation 
and are presented in Table 5.1. Eudragit® E PO and Eudragit® RL PO were employed as 
subcoating materials, while Eudragit® L 100-55 was used as the enteric polymer. The 
temperature of the coating bed was monitored using a Fluke 61 Infrared Thermometer 
(Fluke Corporation, Everett, WA). Talc was added as an anti-tack agent at 10% of the 
ground extrudate weight. The addition of talc considerably affected the adhesion of 
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Eudragit® E PO onto the tablet cores and was thus excluded in formulations of this 
polymer. Methocel® K4M and PEG 3350 were each added to the coating powder as pore 
forming agents at 10% of the ground extrudate weight. It was necessary to adjust the 
feeding rate of the coating powder onto the tablets cores according to the ability of the 
coating powder to adhere, which decreased with increasing coating levels. Following the 
application of the molten primer PEG 3350, the polymer mixture adhered well and was 
therefore applied onto the tablet cores at a feeding rate of about 3 g/min until a polymer 
weight gain of 5% was obtained. The powder feeding rate was then reduced to 
approximately 0.5 g/min. Eudragit® E PO formulations did not require a primer and the 
coating powder was fed at a rate of approximately 0.5 g/min throughout the process. 
Since all coating formulations exhibited poor flow properties, the powder mixtures were 
manually fed onto the tablet surfaces. After completion of the coating process, tablets 
were subsequently cured either in the operating spheronizer or in a static oven on Teflon 
trays. To prevent sticking during storage at 25ºC/60% RH and 40ºC/75% RH, the cured 
tablets were over-coated with 2% talc based on the weight of the coated tablets in the 
spheronizer. 
 
5.3.4 Film preparation 
 
 Powder cast films were prepared by placing the ground extrudate into Teflon 
coated aluminum dishes with a Teflon coated lid. The Eudragit® L 100-55 films were 
stored in a static oven at 80ºC for 3 hours and 24 hours at 60ºC to simulate the coating 
and the curing process. Eudragit® E PO and Eudragit® RL PO films required higher 
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curing temperatures and were cured at 80ºC for 24 hours also in a static oven. A 
compression force of 9.8 N was applied on 22 cm2 of film during the curing process to 
facilitate polymer particle fusion and to reduce the formation of voids in the film. 
 
5.3.5 Drug release study and quantitative TEC analysis 
 
 The dissolution test was performed according to the USP Drug Release Standard 
for Enteric Coated Articles Method A which was recently proven to generate results that 
are comparable with data that were obtained using Method B [17]. Following dissolution 
in 750 mL 0.1N HCl for two hours, 250 mL of 0.2M tribasic sodium phosphate solution 
were added to the dissolution vessel. After the dissolution medium was adjusted to pH 
6.8 ± 0.05, the test was continued for 2 additional hours.  The dissolution media were 
maintained at 37 °C and agitated at 50 rpm using a USP 29 Apparatus 2 (Vankel VK 
7000; Vankel Industries Inc., Cary, NC). Six tablets were placed into each of either three 
or six dissolution vessels respectively (n = 3 x 6 tablets/vessel or n = 6 x 6 tablets/vessel). 
Samples were withdrawn by an autosampler over the 4 hour period (Vankel VK 8000; 
Vankel Industries Inc., Cary, NC). All samples were filtered using 0.45 μm nylon filters. 
A HPLC system with a photodiode array detector (Model 996, Waters, Milford, MA) at a 
wavelength of 210 nm was employed to analyze the sodium valproate concentration in 
the dissolution samples. The HPLC method was adapted from a method described by 
Bruce et al. [8]. The 50 μL samples were injected using an autosampler (Model 717plus). 
Data collection and analysis were performed using Empower® Version 5.0 software. A 
Phenomenex Luna C18(2), 3 μm, 150 mm × 4.6 mm column (Phenomenex 
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Inc., Torrance, CA) was used at a column temperature of 30 ± 2ºC. The mobile phase 
contained a mixture of sodium phosphate monobasic and acetonitrile in a volume ratio of 
63:37. The pH of the mobile phase was adjusted to 2.3 using phosphoric acid. A flow rate 
of 1 mL/min resulted in a retention time of 18 min for sodium valproate. Linearity was 
demonstrated from 4 to 100 μg/mL (R2 > 0.999). 
 The TEC content of the coating powder and powder cast films was determined 
with the same equipment used in the quantitative analysis of sodium valproate according 
to a method previously described in the literature at a detection wavelength of 210 nm 
[6]. 500 mg of the coating powder or powder cast films were dissolved in 50 mM pH 7.4 
buffer and then diluted 1:2 with 50 mM pH 2.5 phosphate buffer to precipitate the 
polymer (n = 3). The samples were then filtered using 0.2 μm nylon filters to remove the 
polymer from solution. The injection volume was set to 50 μL. An ODS-3 3 μm, 150 mm 
× 4.6 mm column (Alltech Inertsil™, Deerfield, IL, USA) was employed at a column 
temperature of 30 ± 2ºC. The mobile phase contained a mixture of acetonitrile and pH 2.5 
10 mM phosphate buffer in a volume ratio of 55:45. The flow rate of 1 mL/min resulted 
in a retention time of 4.0 min for TEC. Linearity was demonstrated in the concentration 
range of 100 to 500 μg/mL (R2 > 0.999).  
 
5.3.6 Differential scanning calorimetry 
 
 Modulated differential scanning calorimetry (MDSC) was employed to 
investigate the thermal properties of polymeric films and melt extrudates using a Thermal 
Advantage Model 2920 (TA Instruments, New Castle, DE) equipped with Universal 
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Analysis 2000 software. The samples were sealed in aluminum pans (Kit 0219-0041, 
Perkin-Elmer Instruments, Norwalk, CT). The flow rate of the ultrahigh pure nitrogen 
purge gas was 150 ml/min. The temperature ramp rate was set to 3°C/min to characterize 
the interactions occurring between subcoat and enteric coat or 5°C/min at a modulation 
rate of ±1.00°C every 60 seconds to study the thermal properties of the subcoating 
materials containing pore formers. The inflection glass transition temperatures (Tg) were 
determined using the reverse heat flow of the second heating cycle. The heat of fusion 
(Qf) was determined by linear peak integration from 40 to 70ºC. The first heating cycle 
was used for PEG 3350, the second heating cycle was used for the powder-cast polymer 
films. 
   
5.3.7 Mechanical testing 
 
 The mechanical testing of powder-cast Eudragit® L 100-55 films containing 10% 
PEG 3350 based on the ground extrudate was performed using a puncture test that was 
adapted from a method previously described by Bodmeier et al. [18]. A Chatillon 
Universal Tension / Compression Tester Model TCD-200 (Ametek, Largo, FL) was used 
with a DFGS 50 digital force gauge to determine the puncture strength and elongation of 
powder-cast polymer films as a function of storage time. The film specimen was mounted 
onto the open mouth of a film holder that consisted of an aluminum cup with an inner 
diameter of 15 mm and an upper mounting plate. The puncture probe (length, 31mm; 
diameter, 6mm; dome shaped probe end) was lowered toward the center of the film 
specimen at a crosshead speed of 10 mm/min. The load (N) and deflection (mm) at 
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maximum were used to determine the maximum puncture strength (MPa) and % 
elongation (puncture strength = F/Acs, where F is the load and Acs is the cross-sectional 
area in the path of the cylindrical opening; % elongation = [{(R2 + D2)1/2 – R}/R]·100, 
where R is the radius of the film and D is the deflection of the probe). SPSS Version 15.0 
was used for the statistical analysis of the data.  
 
5.3.8 Scanning electron microscopy 
 
 Scanning electron microscopy (SEM) was used to examine the morphology of the 
surface of powder-cast films and tablet cores at 10 kV and 20 mA (Model S-4500 FE, 
Hitachi, London UK). The samples were sputter coated with platinum/palladium (80:20) 
using a Cressington Sputter Coater 208 HR equipped with a Thickness Controller MTM 
20 (Cressington Scientific Instruments Ltd., Watford, UK) at 20 mA until a coating 
thickness of 15 nm was obtained.  
 
5.3.9  1H and 13C nuclear magnetic resonance spectroscopy and fourier transform 
infrared spectroscopy 
 
1H and 13C Nuclear magnetic resonance spectroscopy (1H and 13C NMR) as well 
as Fourier transform infrared spectroscopy (FTIR) were performed to investigate possible 
interactions between sodium valproate and PEG 3350 after heating at 80ºC for 3 hours 
followed by 24 hours at 60ºC to simulate the temperatures occurring during the coating 
and curing processes. For NMR analysis, 10 mg of sample was dissolved in deuterium 
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dioxide containing 3-(trimethylsilyl)-propionic acid-D4, sodium salt (TSP) as the internal 
standard. The NMR spectra were obtained using a Varian Inova 500 (Varian Inc., Palo 
Alto, CA). Prior to FTIR analysis, the single components and the heat-treated physical 
mixture were compressed with potassium bromide into pellets under vacuum using a 
compression pressure of 10 tons. A Nicolet Magna IR-560 FT-IR spectrometer was used 
to acquire the transmittance spectra of the materials. 
 
 
5.4 RESULTS AND DISCUSSION 
 
5.4.1 Surface properties of sodium valproate tablets  
 
Interfacial properties of polymeric coating materials and the substrate surface 
such as interfacial tension and wetting have been described as key factors for polymer 
adhesion [19]. Obara and coworkers demonstrated that the addition of acetylated 
monoglycerides to the plasticizer significantly improved coating powder adhesion 
compared to the plasticizer alone due to a reduced contact angle for the polymer [1]. 
Zheng et al. reported that the application of a molten layer of cetyl alcohol enhanced the 
adhesion of pre-plasticized Eudragit® RS / RL PO mixtures onto the surface of 
theophylline tablets [5]. A PEG 3350 primer and the additional incorporation of PEG 
3350 into the coating powder formulation as a low melting, hydrophilic material was 
necessary to facilitate adhesion of pre-plastiziced Eudragit® L 100-55 [6].  
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In the current study, the coating process used for chlorpheniramine maleate 
(CPM) tablets with pre-plasticized Eudragit® L 100-55 [6] was unsuccessful due to 
insufficient sticking of the enteric polymer to the sodium valproate tablets. Poor adhesion 
of pre-plasticized Eudragit® L 100-55 in the current study was initially thought to be due 
to less efficient spreading of the molten PEG 3350 primer over microcrystalline cellulose 
(MCC) compared to more hydrophilic diluents such as lactose. Upon further study, it was 
shown that coating powder can be successfully applied to CPM tablets containing solely 
MCC as filler, proving MCC is not limiting adhesion (data not shown). Additional SEM 
studies demonstrated that tablets containing high MCC levels were characterized with 
smoother surfaces compared to lactose containing cores (data not shown). Surface 
roughness is an important factor for particle adhesion. Smooth surfaces generally 
improve adhesion due to increased molecular attractions [20].   
To exclude the possibility of chemical binding of PEG 3350 and sodium valproate 
at elevated temperatures, 1H and 13C NMR as well as FTIR spectroscopy were performed. 
Both NMR and FTIR spectra of the single components and the annealed physical mixture 
were identical with no detectable new peaks or peak shifts occurring (data not shown). 
Consequently binding interactions of PEG 3350 and sodium valproate were not 
considered as a cause for the poor coating powder adhesion. 
 
5.4.2 Prediction of interaction parameters based on solubility parameters  
 
The spreading of the PEG 3350 priming layer over the tablet cores was described 
to be crucial in the powder coating process [6]. Solubility parameters of materials have 
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been used to predict cohesive and adhesive properties of APIs and pharmaceutical 
excipients. The method which is based on the Lennard-Jones pair potential function was 
initially introduced for pharmaceutical applications by Rowe [21]. In the simplified 
model, hydrogen bonding forces were combined with polar forces to form polar 
components of the solubility parameter. The interaction parameter (Φ) was calculated 
using the harmonic mean equation derived by Wu [22] to determine the relative strength 
of interaction (σ).  
The Hoftyzer, van Krevelen 3D solubility parameters and the corresponding 
interaction parameter for theophylline, CPM, valproic acid, and PEG 3350 are presented 
in Table 5.2. The solubility parameter of valproic acid was used in the calculations since 
it is not possible to calculate the solubility parameters of salts using the group 
contribution method. According to Rowe, the adhesive strength between materials A and 
B needs to be larger than the cohesive strength of interaction of B in order to facilitate 
spreading of substance B over substance A. The calculated values in Table 5.2 suggest 
that the spreading of PEG 3350 over dosage forms containing valproic acid is not 
favored, whereas CPM and theophylline promote spreading of the priming agent. The 
latter two APIs have been previously used in dry powder applications [6]. 
 
5.4.3 Powder coating process 
 
In a method previously used to powder coat with Eudragit® L 100-55, PEG 3350 
was incorporated into the coating powder [6]. In this study, to overcome adhesion 
difficulties, the pre-plasticized Eudragit® L 100-55 and PEG 3350 were fed separately 
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onto the sodium valproate containing tablet cores. A modified spheronizer was used for 
the process as previously described [4-6]. First, a PEG 3350 priming layer was applied 
onto the tablet cores with a weight gain of 3% based on the tablet weight. Then the pre-
plasticized Eudragit® L 100-55 was blended with talc as an anti-tack agent and fed onto 
the tablet cores at a rate of approximately 3 g/min in alternation with PEG 3350. The 
advantage of this modified dry powder coating technique is the high powder feeding rate 
throughout the coating process.  
The drug release profiles of powder-coated tablets that were prepared using the 
modified method are presented in Figure 5.1. A high level of enteric polymer was 
required to prevent drug release in acidic media. Polymer weight gains up to 20% 
resulted in a drug release of more than 10% after two hours in gastric conditions. A 
polymer weight gain of 28% Eudragit® L 100-55 delayed drug release in acid and 
allowed a fast release pH 6.8 buffer. The PEG 3350 level in the film coating for the 10, 
15, 20, and 28% polymer weight gain were approximately 41, 39, 32, and 26% based on 
the weight of the ground pre-plasticized Eudragit® L 100-55, respectively, compared to 
10% that was used in the previous study for CPM tablets [6]. The PEG 3350 content 
decreased in the polymer film with increasing coating levels due to an increased capacity 
for the Eudragit® L 100-55/talc mixture to adhere. The high PEG 3350 levels resulted in 
an increased hydrophilicity of the polymer film. The elevated water permeability of the 
enteric coat required high polymer weight gains to control the drug release.  
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5.4.4 Storage stability of powder-coated tablets 
 
The physical stability of the powder-coated tablets (28% polymer weight gain) 
was investigated during storage at either 25ºC/60% RH or 40ºC/75% RH for 12 weeks. 
After curing for 6 hours in the spheronizer at 60ºC and 170 rpm, an overcoat of 2% talc, 
based on the final tablet weight, was applied onto the tumbling tablets. The tablets were 
sealed in HDPE containers with desiccant. Prior to dissolution testing, all samples were 
equilibrated in the sealed container at ambient conditions for 24 hours. The drug release 
profiles of the enteric-coated sodium valproate tablets are presented in Figure 5.2. The 
powder-coated tablets exhibited excellent storage stability at 25ºC/60% RH with no 
detectable changes in drug release. In contrast, drug release decreased and became less 
consistent with a higher standard deviation over time when stored at 40ºC/75% RH. 
PEG 3350 is a known plasticizer for Eudragit® L 100-55, therefore, while it 
functions as a primer, it would also further plasticize the coating polymer during storage. 
DSC analysis revealed that the Tg of pre-plasticized Eudragit® L 100-55 containing an 
additional 25% PEG decreased to 13.9±3.8ºC (standard deviation, n = 3). The low Tg of 
the coating formulation was connected with a high molecular mobility of the polymer 
that resulted in physical instability of the film coating.  
 
5.4.5 Properties of subcoated sodium valproate tablets  
 
 In order to avoid large PEG 3350 levels in the Eudragit® L 100-55 coating, 
different subcoating materials were investigated. Eudragit® E PO and Eudragit® RL PO 
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were chosen as potential subcoating materials since both polymers were successfully 
used in previous dry-powder coating applications [4, 5]. Due to their solubility properties, 
both polymers would delay drug release in pH 6.8 buffer, a characteristic that is not 
desired for enteric coated dosage forms. Consequently, pore forming agents were added 
to the subcoating to increase water influx and hence drug dissolution in the buffer stage 
of the enteric test. Methocel® K4M and PEG 3350 were chosen as possible pore formers.  
 In Figure 5.3, the drug release profiles of sodium valproate tablets powder-coated 
with either Eudragit® E PO (A) or pre-plasticized Eudragit® RL PO (B) are presented. 
Both acrylic polymers were used alone and in combination with PEG 3350 and 
Methocel® K4M in a 10:1 ratio. A 10:2 ratio was also tested, but did not show any 
advantages compared to the lower pore forming content. The investigated polymer 
weight gains included 5 and 10% for subcoating formulations containing PEG 3350. The 
maximum weight gain for subcoating formulations containing Methocel® K4M did not 
exceed 7% due to insufficient coating powder adhesion.  The aim was to obtain a drug 
release of over 90% after 45 minutes in pH 6.8 50mM buffer as a benchmark to ensure 
that the subcoating material did not delay drug release in the buffer phase. The objective 
was met with a 5% weight gain of Eudragit® E PO, Eudragit® E PO in combination with 
PEG 3350, or Eudragit® RL PO in combination with Methocel® K4M. Both PEG 3350 
and Methocel® K4M demonstrated pore forming activity for Eudragit® E PO. Cerea et al. 
previously demonstrated that the addition of hydrophilic polymers to the coating 
formulation increased the drug release of tablets that were powder-coated with Eudragit® 
E PO in pH 6.8 50mM phosphate buffer [4].  
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The pore forming effect of Methocel® K4M in powder-layered Eudragit® RL PO 
films was stronger than the one of PEG 3350. At high coating levels, PEG 3350 reduced 
the drug release when compared with tablets that were powder-coated with Eudragit® RL 
PO without added pore forming agents. Similar results were obtained by Lippold et al. 
who described a decrease in the drug release from theophylline pellets that were coated 
with Eudragit® RS containing 10% PEG compared to a Eudragit® RS coating formulation 
without pore former or with a 10% admixture of HPMC [23].  
To better understand the influence of pore forming agents on the release of 
sodium valproate, polymer films were powder cast, cured, and the properties were 
investigated using dissolution testing, SEM, and DSC. The SEM micrographs of free 
films before and after 30 min in pH 6.8 buffer are presented in Figure 5.4. Both the 
incorporation of PEG 3350 and Methocel® K4M into Eudragit® E PO films resulted in 
pore formation after dissolution in pH 6.8 buffer. Since PEG 3350 has a melting point 
below the processing temperature, PEG 3350 containing films were characterized by 
numerous small pores while the dissolution of Methocel® K4M generated large openings 
within the Eudragit® E PO film. In contrast, the addition of PEG 3350 to Eudragit® RL 
PO did not produce any visible pores after 30 minutes in the dissolution media (pH 6.8 
buffer). Only the combination of Eudragit® RL PO with Methocel® K4M resulted in pore 
formation after exposure to dissolution media. The SEM results correlated well with the 
dissolution data. Miscibility and compatibility of coating excipients with the functional 
polymer were shown to influence the permeability of film coatings [24]. 
To further investigate the miscibility of the pore forming agents in the film 
matrix, the powder-cast films were analyzed using DSC. Eudragit® E PO did not show 
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miscibility with both PEG 3350 and Methocel® K4M. As a result, both materials act as 
pore former when combined with the polymer. The DSC profiles of the Eudragit® E PO 
films containing PEG 3350 showed a large endothermic peak due to the melting of the 
pore former (Figure 5.5). The melting peak of PEG 3350 was broadened and slightly 
shifted from 60.5 ± 0.3ºC (standard deviation, n = 3) for bulk PEG 3350 to 55.3 ± 0.2ºC 
(standard deviation, n = 3) when incorporated into Eudragit® E PO. Qf of PEG 3350 was 
slightly decreased (160.6 ± 5.8 J/g, standard deviation, n = 3) compared to Qf of bulk 
PEG 3350 that was determined to be 196.6 ± 24.4 J/g (standard deviation, n = 3). PEG 
3350 and Methocel® K4M did not produce a significant change in Tg of Eudragit® E PO 
(45.4 ± 2.0ºC, standard deviation, n = 3). Also the Tg of Methocel® K4M (179.5 ± 2.9ºC, 
standard deviation, n = 3) was not significantly influenced when combined with 
Eudragit® E PO.  
In combination with Eudragit® RL PO, PEG 3350 demonstrated partial miscibility 
or was present in an amorphous state in the polymer film (Figure 5.5). The melting point 
of PEG 3350 was shifted to 50.7 ± 1.2ºC (standard deviation, n = 3). Qf of PEG 3350 in 
the polymer films was reduced to 10.0 ± 4.8 J/g (standard deviation, n = 3). The Tg of 
Eudragit® RL PO (pre-plasticized with 10% TEC based on the polymer weight) was 
slightly decreased from 42.1 ± 0.1ºC (standard deviation, n = 3) for the bulk polymer to 
33.6 ± 5.9ºC (standard deviation, n = 3) when combined with PEG 3350. The miscibility 
of PEG 3350 in the acrylic polymer affected its function as pore former and improved 
film formation. DSC thermograms of Eudragit® RL PO films that contained Methocel® 
K4M showed two Tg and thus no miscibility. The Tg of Methocel® K4M did not change 
significantly whereas the Tg of Eudragit® RL PO increased to 50.2 ± 1.8ºC (standard 
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deviation, n = 3) due to possible interactions of the plasticizer TEC with the hydrophilic 
pore former.   
 
5.4.6 Properties of sub- and enteric-coated sodium valproate tablets  
 
 Three subcoating formulations at a 5% coating level were chosen for further 
investigation in an enteric powder-coating process: Eudragit® E PO without a pore 
former, Eudragit® E PO containing PEG 3350, and pre-plasticized Eudragit® RL PO in 
combination with Methocel® K4M. The selection criterion was a sodium valproate 
release of more than 90% in pH 6.8 buffer after 45 minutes of dissolution.  
 In Figure 5.6, the drug release profiles of sodium valproate tablets subcoated and 
subsequently enterically coated using a dry-powder coating technique are presented. All 
Eudragit® E PO subcoated tablets were cured in a static oven at 80ºC for 12 hours, while 
Eudragit® RL PO subcoated tablets were cured in the revolving spheronizer at 60ºC for 2 
hours prior to application of the enteric polymer. Curing of the Eudragit® E PO tablets in 
the spheronizer was not possible due to chipping of the functional coating. The Eudragit® 
L 100-55 film coating was applied using the same technique previously developed for the 
coating of CPM tablets [6]. The process involved the use of pre-plasticized (30% TEC) 
Eudragit® L 100-55 in combination with a PEG 3350 primer and the incorporation of a 
small amount of PEG 3350 into the coating formulation. The enteric-coated tablets were 
subsequently cured in the rotating spheronizer for 6 hours. 
A coating level of 20% Eudragit® L 100-55 was employed to control the drug 
release for all formulations. Both the Eudragit® E PO subcoating formulation with PEG 
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3350 and the Eudragit® RL PO composition with Methocel® K4M resulted in a delay of 
sodium valproate release in acid and a fast release in buffer. Both formulations passed the 
USP requirements for enteric coated tablets when overcoated with adequate levels of 
Eudragit® L 100-55. A Eudragit® E PO subcoat without the incorporation of a pore 
forming agent, Figure 5.6 (A), did not provide a rapid drug release during the buffer stage 
of the enteric test, because of the polymer’s insolubility in alkaline media. Additional 
curing after application of the enteric film coating and potential plasticizer migration 
from the pre-plasticized Eudragit® L 100-55 to the Eudragit® E PO improved subcoat 
film formation. As a result, the release in buffer was further delayed.  
 
5.4.7 Stability of sub- and enteric-coated sodium valproate tablets 
 
The physical stability of the sub- and enteric-coated sodium valproate tablets was 
investigated over 12 weeks at either 25ºC/60% RH or 40ºC/75% RH. Two different 
subcoating materials were investigated: Eudragit E PO containing PEG 3350 in a 10:1 
ratio and Eudragit® RL PO containing Methocel® K4M in a 10:1 ratio. All investigated 
tablets were subcoated to a polymer weight gain of 5% and enteric-coated to a polymer 
weight gain of 20%. The tablets were cured in the revolving spheronizer for 6 hours 
before they were overcoated with 2% talc based on the weight of the coated tablets and 
sealed in HDPE containers with desiccant. Both formulations demonstrated excellent 
storage stability at 25ºC/60% RH over 12 weeks. The drug release of the Eudragit® E PO 
subcoat formulation decreased continuously at 40ºC/75% RH over 12 weeks while the 
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drug release of the Eudragit® RL PO subcoat formulation stabilized after four weeks 
(Figure 5.7). 
Important factors that affect the storage stability of coated dosage forms are 
plasticizer content and change in the mechanical properties of the polymeric films. The 
TEC content in the coating powder and in powder-cast films initially and after 4 and 12 
weeks is presented in Table 5.3. Free Eudragit® L 100-55 films containing 30% TEC 
based on the polymer weight were either stored at 25ºC/60% RH or at 40ºC/75% RH in 
sealed HDPE containers with desiccant to determine the plasticizer loss. The TEC 
content in the polymeric films did not change significantly at 25ºC/60% RH. There was a 
significant decrease in TEC concentration (ANOVA, Tukey’s HSD, p<0.05) after storage 
at 40ºC/75% RH for 4 and 12 weeks. The elongation of powder-cast films increased over 
storage and was significant after 12 weeks of storage compared to the initial value for 
both storage temperatures at 0% RH (ANOVA, Tukey’s HSD, p<0.05). However, there 
was no significant difference in elongation between storage at 25ºC compared to storage 
at 40ºC after 12 weeks. The puncture strength did not change significantly at 25ºC/0%RH 
and 40ºC/0%RH over the investigated storage time (ANOVA, Tukey’s HSD, p<0.05).  
Another theory included the aging of the subcoating layer and interactions 
occurring between subcoat and enteric coating. This hypothesis agreed with a previous 
study that investigated the physico-chemical stability of tablets that were powder-coated 
using pre-plasticized Eudragit® L 100-55 without prior application of subcoat [6]. The 
drug release fluctuated slightly around the initial profile, but did not drastically decrease 
over storage. Increased molecular mobility at high storage temperatures and additional 
plasticization by PEG 3350 were the suggested rationale [6]. 
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DSC was employed to investigate interactions between Eudragit® E PO and pre-
plasticized Eudragit® L 100-55. The thermogram of a physical mixture of bulk Eudragit® 
E PO and pre-plasticized Eudragit® L 100-55 containing 30% TEC was characterized by 
two Tg, one at 24.9 ± 0.9ºC (standard deviation, n = 3) and one at 73.6 ± 7.7ºC (standard 
deviation, n = 3), as presented in Figure 5.8. In contrast, the Tg of bulk Eudragit® E PO 
was 43.5 ± 0.8 ºC (standard deviation, n = 3), and that of pre-plasticized Eudragit® L 100-
55 containing 30% TEC was determined to be 61.3 ± 3.1ºC [6]. DSC analysis revealed 
that the Tg of Eudragit® E PO was lowered by approximately 20ºC, while the transition of 
Eudragit® L 100-55 was increased by approximately 10ºC. The same phenomenon was 
observed for physical mixtures of Eudragit® RL PO pre-plasticized with 10% TEC and 
Eudragit® L 100-55 pre-plasticized with 30% TEC. The DSC profile of Eudragit® RL 
PO containing 10% TEC was characterized by a glass transition at 44.3 ± 2.4 ºC 
(standard deviation, n = 3). The DSC profile showed two Tg: one for Eudragit® RL PO at 
29.5 ± 4.0ºC and one at 72.0 ± 3.5ºC for Eudragit® L 100-55. This corresponds to a shift 
of approximately 10ºC down for Eudragit® RL PO and 10ºC up for Eudragit® L100-55 
compared to the pre-plasticized bulk polymers. TEC can therefore migrate from the 
subcoat into the enteric coating layer at elevated temperatures, as demonstrated with the 
TEC loss over storage and change the physico-chemical properties of the powder-coated 






Sodium valproate tablets required high weight gains of powder-coated Eudragit® 
L 100-55 in order to pass the USP enteric test. The application of a Eudragit® E PO or 
Eudragit® RL PO subcoat assisted with adhesion of the enteric polymer onto the tablet 
cores, enhanced film formation, and therefore reduced the amount of enteric polymer 
required for enteric protection. High polymer weight gains of Eudragit® L 100-55, 
however, were still required for the tablets to pass the USP enteric test. PEG 3350 and 
Methocel® K4M were added to the subcoat to improve the release of sodium valproate in 
buffered media. Drug release was dependent on miscibility of the pore forming agents 
with the polymers. Storage stability was confirmed for powder-coated sodium valproate 
tablets at 25ºC/60% RH for all investigated formulations. Storage at 40ºC/75% RH 
resulted in fluctuations in sodium valproate release over 12 weeks. A Eudragit® RL PO 
subcoat resulted in the smallest change in the drug release over the storage period. A loss 
of plasticizer in the enteric film coating was shown to affect the storage stability of the 
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5.7 TABLES AND FIGURES  
 
Table 5.1: Processing parameters and formulations for the powder-coating of sodium 
valproate tablets. 
 



















55-60ºC 170 rpm D 10% PEG+ 

















Table 5.2: Hoftyzer, van Krevelen 3D solubility parameters and interaction parameters of 
theophylline, chlorpheniramine maleate (CPM), valproic acid, and PEG 3350. 
 
 PEG3350 Valproic acid CPM Theophylline
Hoftyzer, van Krevelen 3D solubility parameter (J/cm3)0.5
D 17.4 17.1 20.8 24.6
P 1.2 2.8 3.8 16.2
H bonding 9.3 8.1 8.8 13.6
Vm (cm3/mol) 2803.4 152.3 309.4 109.1
sol parameter (δ) 19.8 19.1 22.9 32.4
Φ with PEG  0.6 0.9 0.9
 
Strength of interaction J/cm3 (σ)
Cohesive (PEG) 98.3 98.3 98.3 98.3






Table 5.3: 12 week stability of powder-cast films of Eudragit® L 100-55 pre-plasticized 
with 30% TEC containing 10% PEG 3350 (standard deviation, n = 3).  
 
 TEC recovery [%] Puncture strength Elongation [%] 
Coating powder 100.4±0.3 % N/A N/A 
Initial 100.1±0.3 % 1.18±0.16 MPa 112.6±9.6 % 
4 weeks 
25ºC 99.4±0.3 % 1.04±0.28 MPa 140.3±24.9 % 
40ºC 97.2±0.7 %* 1.20±0.18 MPa 130.7±16.4 % 
12 weeks 
25ºC 98.9±0.1 % 0.90±0.10 MPa 164.0±23.0 %* 
40ºC 95.3±1.0 %* 1.05±0.21 MPa 160.8±27.5 %* 






Figure 5.1: Influence of coating level on the release of sodium valproate from tablets 
powder-coated with pre-plasticized Eudragit® L 100-55 using USP 29 apparatus 2. 
Dissolution in 750mL of 0.1N HCl for 2 hours followed by 2 hours in 1000mL pH 6.8 
50mM phosphate buffer after pH adjustment at 37ºC and 50 rpm. ■: 10% polymer 
weight gain. ♦: 15% polymer weight gain. ▲: 20% polymer weight gain. □: 28% 







































Figure 5.2: 12 week stability of sodium valproate tablets powder-coated with pre-
plasticized Eudragit® L 100-55 containing 30% TEC based on the polymer weight using 
USP 29 apparatus 2. Dissolution in 750mL of 0.1N HCl for 2 hours followed by 2 hours 
in 1000mL pH 6.8 50mM phosphate buffer after pH adjustment at 37ºC and 50 rpm. 
Polymer weight gain: 28%. ■: initial. ♦: 4 weeks at 25ºC / 60% RH. ▲: 4 weeks at 40ºC / 
75% RH. □: 12 weeks at 25ºC / 60% RH. ◊: 12 weeks at 40ºC / 75% RH. (Standard 




































Figure 5.3: Influence of polymer weight gain (PWG) and pore formers on the release of 
sodium valproate from powder-coated tablets using USP 29 apparatus 2. Dissolution in 
900mL pH 6.8 50mM phosphate buffer at 37ºC and 50 rpm. ×: core tablets. ♦: polymer / 
PEG 3350 ratio 10:1, 5% PWG. ▲: polymer / PEG 3350 ratio 10:1, 10% PWG. ■: 
polymer / Methocel® K4M ratio 10:1, 5% PWG. ◊: polymer / Methocel® K4M ratio 10:1, 
7% PWG. ∆: no pore former, 5% PWG. □: no pore former, 10% PWG. (A) Eudragit® E 






































































Figure 5.4: Surface morphology of powder cast polymer films before (A-D) and after 
dissolution in pH 6.8 buffer for 30 minutes (E-H). A and E: Eudragit® E PO / PEG 3350, 
ratio 10:1. B and F: Eudragit® E PO / Methocel® K4M, ratio 10:1. C and G: Eudragit® 









Figure 5.5: DSC thermograms of Eudragit® E PO and Eudragit® RL PO, pre-plasticized 
with 10% TEC based on the polymer weight containing either PEG 3350 or Methocel® 


































































Figure 5.6: Influence of coating level on the release of sodium valproate from tablets 
powder-coated with pre-plasticized Eudragit® L 100-55 using USP 29 apparatus 2. 
Dissolution in 750mL of 0.1N HCl for 2 hours followed by 2 hours in 1000mL pH 6.8 
50mM phosphate buffer after pH adjustment at 37ºC and 50 rpm. ■: 10% polymer 
weight gain. ♦: 15% polymer weight gain. ▲: 20% polymer weight gain. (Standard 
deviation, n = 6 x 6 tablets/vessel.) (A) 5% Eudragit® E PO subcoat, no pore former. (B) 
5% Eudragit® E PO subcoat containing 10% PEG 3350 based on the polymer weight. (C) 






































































































Figure 5.7: 12 week stability of sodium valproate tablets powder-coated with pre-
plasticized Eudragit® L 100-55 containing 30% TEC based on the polymer weight using 
USP 29 apparatus 2. Dissolution in 750mL of 0.1N HCl for 2 hours followed by 2 hours 
in 1000mL pH 6.8 50mM phosphate buffer after pH adjustment at 37ºC and 50 rpm. 
Polymer weight gain: 28%. ■: initial. ♦: 4 weeks at 25ºC / 60% RH. ▲: 4 weeks at 40ºC / 
75% RH. □: 12 weeks at 25ºC / 60% RH. ◊: 12 weeks at 40ºC / 75% RH. (Standard 
deviation, n = 6 x 6 tablets/vessel.) (A) Eudragit® E PO subcoat containing 10% PEG 
3350 based on the polymer weight. (B) Eudragit® RL PO subcoat containing 10% 







































































Figure 5.8: DSC thermograms of Eudragit® L 100-55, pre-plasticized with 30% TEC, 
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Chapter 6: Study of the Influence of Additives on Melt Viscosity, 
Surface Tension, and Film Formation of Dry Powder Coatings2 
 
Abstract: 
 The aim of this study was to characterize the film formation process of thermally 
cured Eudragit® L 100-55 dry-powder coatings. The main focus was to investigate the 
influence of film additives on melt viscosity and surface tension, the main parameters that 
influence polymer particle fusion and surface leveling of the polymeric film. The coating 
process employed no liquids and the plasticizer was combined with the polymer using hot 
melt extrusion. Thermogravimetric analysis confirmed thermal stability of all coating 
excipients at the investigated curing conditions. The influence of the level of triethyl 
citrate (TEC) as plasticizer and polyethylene glycol (PEG) 3350 in the polymer film on 
film formation was investigated. The rheological behavior of the coating formulations 
were characterized with the extrusion torque, and the surface energy parameters were 
determined from contact angle measurements. Increasing TEC levels and the addition of 
PEG 3350 as a low melting excipient in the coating reduced the viscosity of the polymer. 
In contrast, plasticization of the polymer with TEC increased the surface free energy, 
whereas the admixture of 10% PEG 3350 did not affect the surface free energy of 
Eudragit® L 100-55.  The spreading coefficient of the polymers over two sample tablet 
formulations was reduced with increasing surface free energy. During the curing process, 
                                                 
2 Significant portions of this chapter were taken from: Sauer D. and J.W. McGinity. Influence of Additives on Melt 
Viscosity, Surface Tension, and Film Formation of Dry Powder Coatings. This paper is under review by Drug 
Development and Industrial Pharmacy. 
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puncture strength and elongation of powder-cast films increased. The effect of curing 





  The mechanism of film formation occurring in dry coating processes has been 
described in the literature [1, 2]. However, there is little information available on the 
characteristics of thermally cured dry-powder coatings used for pharmaceutical solid oral 
dosage forms. The properties that have been used to evaluate film formation in 
pharmaceutical coatings included glass transition temperature and minimum film 
formation temperature of the polymers, dissolution data, and scanning electron 
micrographs [3-5]. The main parameters that influence film formation of such dry 
powder coatings, including melt viscosity and surface tension of the polymer have not 
been discussed in the pharmaceutical literature. 
 Huang and coworkers divided the film formation process for dry coating into four 
stages [2]. Initially, powders are deposited on the surface and packed together. Secondly, 
sintering and coalescence of the polymer particles occur. Film leveling mainly takes 
place during the curing process, and lastly, cooling of the film completes the process [2]. 
A high initial packing density of the coating powder is essential for polymer particle 
fusion. Johnson and coworkers introduced a model to determine the contact area between 
two spheres that were pressed into contact [6]. According to this theory the diameter of 
the contact spot was dependent on three main parameters: external force, surface 
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attractions, and elastic properties of the deformed particles [7]. The film forming process 
of powder coatings is dependent on coalescence of the polymer particles and wetting of 
the tablet surface [1]. The main driving force for coalescence and leveling is the surface 
tension of the polymer, with a low surface tension resulting in wavy surfaces and a high 
surface tension causing crater defects due to poor wetting properties [8]. The main 
resistance to fusion of polymer particles is the melt viscosity of the polymer. According 
to Nix and Dodge, the time needed to fuse two polymer particles increases with 
decreasing surface tension, as expressed in Equation 1 [9].  
t = f (η Rc/σ)                                                      (1) 
where t is the flow time, η is the melt viscosity, Rc is the average radius of curvature, and 
σ is the surface tension of the polymer.  
 Orchard developed a model for the surface leveling in viscous liquids and gels 
[10] that also describes the flow of powder coatings [1]. According to this model, the rate 
of leveling is increased for polymers with high surface tension, low melt viscosity, small 
particle size and for polymeric films with high film thickness. Additives including 
plasticizers can affect melt viscosity as well as the surface tension of polymers. The 
incorporation of plasticizers was shown to significantly reduce the melt viscosity of 
polymers [9, 11]. The effect of additives on the surface free energy was demonstrated to 
be dependent on the amount and type of additive, although small amounts of dibutyl 
sebacate and dibutyl phthalate to ethylcellulose films did not influence the surface free 
energy of cast polymer films [12]. In contrast, the inclusion of different grades of PEG 
increased the surface free energy of Eudragit® RS films [13]. 
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 The objective of this study was to characterize the curing process of dry-powder 
Eudragit® L 100-55 films and to investigate the influence of the plasticizer triethyl citrate 
(TEC) and the coating excipient polyethylene glycol 3350 (PEG 3350) on melt viscosity, 





Eudragit® L 100-55 was donated by Evonik Industries AG (Piscataway, NJ). 
Triethyl citrate (TEC) was supplied by Vertellus Materials Inc. (Greensboro, NC). 
Polyethylene glycol (PEG) 3350 NF was purchased from the DOW Chemical Company 
(Midland, MI). Lactose monohydrate NF, magnesium stearate, and the model drugs 
chlorpheniramine maleate (CPM) and sodium valproate (SoVa) were purchased from 
Spectrum Chemical Mfg. Corp. (Gardena, CA). Microcrystalline cellulose (Avicel® PH-
101 and PH-200) were supplied by FMC Corp. (Newark, DE). Kollidon® K 30 was 
donated by BASF Corp. (Mount Olive, NJ). Cab-O-Sil M-5P was supplied by Cabot 






6.3.1 Hot-melt extrusion 
 
Eudragit® L 100-55 was pre-plasticized with up to 40% triethyl citrate (TEC) by 
melt extrusion using a Randcastle Model RC 0750 with a 6 mm die that was connected to 
a  Randcastle Pelletizer RCP-2.0 (Randcastle Extrusion Systems, Inc., Cedar Grove, NJ). 
The temperature zones of the extruder were kept at 80ºC (zone 1), 110ºC (zone 2), 115ºC 
(zone 3), and 120ºC (die). The screw speed was set to 20 rpm and resulted in drive amps 
between 0.3 to 0.5 for the 20% TEC level and 0.1 to 0.2 at the TEC concentration of 
40%. The extruded pellets were subsequently ground into a fine coating powder using a 
cryogenic mill (Model CF, Micron Powder systems, Summit, NJ) and screened using 
mechanical shaking. The particle size fraction between 200 and 100 mesh (75 - 150 μm) 
was then used in this study for dry powder coating as recommended in a previous study 
[4]. 
 
6.3.2 Thermal analysis 
 
The thermal stability of the coating excipients and a powder-cast film was 
investigated using thermogravimetric analysis (TGA). A sample of approximately 10 mg 
was equilibrated to 50ºC and then heated at a rate of 10ºC/min to 800ºC. At isothermal 
conditions, the equilibration of the sample to 50ºC was followed by heating to 60ºC and 
the temperature was then kept constant for 6 hours. 
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6.3.3 Relative melt viscosity 
 
The mixing torque necessary to extrude Eudragit® L 100-55 containing various 
amounts of TEC and PEG 3350 was determined using a Haake MiniLab-Compounder 
(Thermo-Fisher Scientifc Inc., Waltham, MA) in the cycle mode. The screw speed was 
set to 10 rpm. The temperature range was adjusted for each formulation. The maximum 
temperature did not exceed 125ºC to avoid side chain degradation of the polymer [14]. 
The torque cut off value occurred at 550 Ncm and restricted measurements at low 
temperature values. 
 
6.3.4 Contact angle measurements 
 
A Carver Laboratory Press (Model M, ISI Inc., Round Rock, TX) was used to 
manufacture compacts from pre-plasticized Eudragit® L 100-55, PEG 3350, and three 
tablet formulations at a 1000 kg compression force (Table 6.1). 3 μL of water, ethylene 
glycol or diiodomethane were placed onto the surface of the compacts using a 
microsyringe with Teflon tip. The contact angle was determined by measuring the 
tangent to the curve of the sessile droplet using a Goniometer (Model No. 100-00-115, 
Ramé-Hart Inc., Mountain Lakes, NJ) within 5 seconds after drop deposition. The 
measurements were performed in triplicate at 25ºC. The apolar and the acid-base 
components of the surface free energy were calculated according to an approach by van 
Oss and coworkers using the following equation [12, 15] 




SL γγγγγγθγ                        (2) 
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where γ is the surface free energy, θ is the measured contact angle, γLW is the apolar 
component associated with the Lifshitz-van der Waals (LW) interactions, γ+ is the 
electron-acceptor parameter (Lewis acid) of the acid-base contributions, and γ- is the 
electron donor parameter (Lewis base) of the acid-base contributions. The subscripts S 
and L distinguish between the solid and the liquid used in the experiment. The surface 
free energy parameters of the liquids were taken from the literature [12, 16].  
 
6.3.5 Preparation and characterization of free films 
 
 Free films were prepared from the pre-plasticized Eudragit® L 100-55 that 
contained 20, 30, or 40% TEC based on the polymer weight. The polymer was blended 
with 10% PEG 3350 based on the weight of the ground extrudate using mortar and pestle. 
Prior to curing in a static oven at 60ºC, the coating powder was pressed into films using a 
compression force of 10 kN on a surface area of 22 cm2 for 3 minutes to ensure a dense 
powder packing (Carver Laboratory Press, Model M, ISI Inc., Round Rock, TX). The 
compression force was reduced during the curing process to 10 N. The mechanical 
properties of powder-cast Eudragit® L 100-55 films were investigated using a puncture 
test previously described by Bodmeier et al. [17, 18]. A Chatillon Universal Tension / 
Compression Tester Model TCD-200 (Ametek, Largo, FL) with a DFGS 50 digital force 
gauge was used to study puncture strength and elongation of powder-cast polymer films 
after up to 12 hours of curing at 60ºC. The puncture probe (length, 31 mm; diameter, 
6mm; dome shaped end) was lowered toward the center of the film specimen that was 
clamped into a film holder at a crosshead speed of 10 mm/min. The film holder consisted 
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of an open-mouth Aluminum cup with an inner diameter of 15 mm and an upper 
mounting plate. The load (N) and deflection (mm) at maximum was used to determine 
the maximum puncture strength (MPa) and % elongation at maximum (puncture strength 
= F/Acs, where F is the load and Acs is the cross-sectional area in the path of the 
cylindrical opening; % elongation = [{(R2 + D2)1/2 – R}/R]·100, where R is the radius of 
the film and D is the deflection of the probe). Statistical analysis of the data was 
performed using SPSS Version 15.0.  
 
 
6.4 RESULTS AND DISCUSSION 
 
6.4.1 Thermal stability 
 
 The raw materials Eudragit® L 100-55, TEC, and PEG 3350 as well as a powder 
cast film were subject to thermogravimetric analysis (TGA) to evaluate the thermal 
stability during the curing process. Two different TGA methods were evaluated. 
Incremental heating of the samples, as shown in Figure 6.1, demonstrated thermal 
stability with no signs of degradation occurring at the curing temperature 60ºC. TEC 
decomposed above 200ºC, whereas the polymers Eudragit® L 100-55 and PEG 3350 
showed signs of degradation above 300ºC. Petereit et al. employed TGA combined with 
mass spectroscopy to characterize the thermal degradation process of acrylic polymers 
[14]. It was demonstrated that Eudragit® polymers showed a loss of functional groups 
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above approximately 130ºC. Reactions of the main chain such as depolymerisation or 
cross-linking were noted at processing temperatures above approximately 300ºC. The 
TGA profile of a powder-cast film exhibited weight loss in the same temperature ranges 
and at ratios expected based on the raw materials. The polymer film contained 30% TEC 
based on the polymer weight and 10% PEG 3350 based on the weight of the ground 
extrudate and was cured for 24 hours in a static oven at 60ºC before analysis.  
 Isothermal TGA analysis at 60ºC over 6 hours revealed stability of the coating 
excipients with minimal weight loss occurring over the investigated time frame (Table 
6.2). The 6 hours time frame corresponded to the investigated curing time in this study. 
The weight loss of Eudragit® L 100-55 and PEG 3350 was negligible, with less than 
0.2%. The highest weight loss with a value of approximately 2% was noted for TEC. In a 
powder cast film as described in the previous paragraph the loss of TEC would result in a 
combined weight loss of less than 0.5%.  
  
6.4.2 Relative melt viscosity 
 
 Melt viscosity is considered to be the main resistance for polymer flow and 
polymer-particle fusion [9]. The temperature dependence can be expressed by the 
Arrhenius-Frenkel-Eyring equation [19]: 







Ea                                                   (3) 
where B is a polymer specific constant, Ea is the activation energy of the viscous flow, R 
is the gas constant, and T is the absolute temperature. The logarithm of the melt viscosity 
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plotted against the reciprocal value of temperature in an Arrhenius diagram results in a 
straight line at a constant shear rate when the activation energy is independent from 
temperature [20]. The surface tension is linearly temperature dependent, decreasing with 
increasing temperatures [8]. However, this effect is less pronounced compared to the 
temperature effect on melt viscosity. 
 Torque data have been widely used to characterize the rheological behavior of 
polymers under processing conditions [21-23] and to determine the relative melt viscosity 
of materials [24].  At constant rotor speed, the equilibrium torque was shown to be 
directly proportional to the apparent shear viscosity [25, 26]. The torque data for the 
circulation of each formulation in a twin-screw extruder were graphed in a direct plot and 
in an Arrhenius diagram (Figure 6.2). The plasticizer content had a strong effect on shear 
viscosity, with decreased viscosity noted with increasing plasticizer levels. It has been 
proposed that a decrease reduces the time needed for polymer-particle fusion and leveling 
of a polymer film [9, 10]. The incorporation of PEG 3350 into Eudragit® L 100-55 based 
powder coating formulations as a low melting coating excipient was previously 
recommended to assist with coating powder adhesion [4]. PEG 3350 is a known 
plasticizer for Eudragit® L 100-55 and additionally reduced the viscosity of Eudragit® L 
100-55. Therefore, the inclusion of PEG 3350 was expected to have a positive effect on 
film formation.  
 All investigated formulations followed a linear relation when the natural 
logarithm of the torque was plotted against the reciprocal absolute temperature in the 
investigated temperature range. The square of the correlation coefficient (R2) from 
regression analysis for Eudragit® L 100-55 containing 20, 30, or 40% TEC based on the 
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polymer weight was 0.943, 0.995, and 0.988 respectively. The addition of 10% PEG 
3350 based on the weight of the ground extrudate to the pre-plasticized polymer resulted 
in R2 values of 0.997, 0.997, and 0.977. This linear relationship can be used to predict the 
viscosity outside of the investigated temperature range [27]. Extrapolation to the curing 
temperature of 60ºC continued the trend of torque reduction with increasing plasticizer 
levels (data not shown).  
 The flow activation energy at constant shear rate can be obtained from the slope 
that was determined using regression analysis as described above [28]. Since only torque 
data were available to describe the rheological behavior of the dry powder coating 
formulations the slopes were compared relative to each other and no flow activation 
energy values were calculated. Figure 6.2 B does not show a clear trend on the slope for 
increasing TEC amounts in the coating formulation. The slope slightly declined for the 
TEC content of 30% compared to the 20% TEC ratio and increased again for the 40% 
TEC level. In contrast, a small decline of the slopes was observed for all TEC 
concentration after the addition of PEG 3350 as coating excipient and thus resulted in a 
small decrease of the flow activation energy.  
 
6.4.3 Surface free energy parameters 
 
One simple method to determine the surface free energy parameters in terms of 
the Lifshitz-van der Waals and acid-base contribution of multi-component systems is the 
analysis of contact angles with both hydrophilic and hydrophobic liquids [15]. This 
method has been used in pharmaceutical research to characterize adhesion between 
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polymer film and substrate surfaces [12, 29, 30] and wetting phenomena in a wet-
granulation process [31]. Young’s equation requires a smooth and homogeneous surface 
with no interactions or adsorption occurring in order to calculate the interfacial energy 
between two materials, 
    γsv = γsl + γlv cosθ                                  (4) 
where γ is the surface tension (or surface free energy) and θ is the contact angle. The 
subscripts sv, sl, and lv refer to the interfaces between solid and vapor, solid and liquid, 
and liquid and solid, respectively. Although these assumptions are often difficult to meet 
in practice, contact angle studies are acknowledged for the comparative determination of 
surface properties of materials [12, 30]. In this study, the contact angles decreased over 
time, a phenomenon that has previously been described for the sessile drop method [12, 
30]. Previous workers have reported that the advantage of the sessile drop method, 
compared to advancing contact angles, is the low prevalence of salvation, hydration, or 
swelling of the analyzed material, provided that the contact angle is immediately 
measured after deposition of the drop on the surface [30]. Oss et al. recommended the use 
of three different liquids of which two must be polar to determine the surface free energy 
parameters of surfaces [15]. 
The non-polar (dispersion) and polar components of the surface energy of 
compacts of pre-plasticized Eudragit® L 100-55, PEG 3350, and their physical mixtures 
are presented in Table 6.3. In a preliminary study with diiodomethane, ethylene glycol, 
and water all materials listed in Table 6.3 and Table 6.4 were determined to be Lewis-
bases and strongly monopolar with a Lewis acid component of surface interaction (γ+) of 
approximately zero (data not shown). The results correspond to literature values for the 
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acrylic polymer and PEG [32, 33]. Further studies were performed solely with 
diiodomethane and water with the assumption that γ+ equals zero to avoid negative 
square roots in the calculations as already described for materials with improved adhesion 
behavior, such as corona or flame treated polyolefins [32]. The equation for the 




LSLLSL γγθγγγ 2)cos1(2 / ++−=−
−+                                (5) 
where γ is the surface free energy, θ is the measured contact angle, γLW is the apolar 
component associated with LW interactions, γ+ is the electron-acceptor parameter, and γ- 
is the electron donor parameter of the acid-base contributions. The subscripts S and L 
distinguish between the solid and the liquid used in the experiment. The surface free 
energy parameters of the liquids were taken from the literature [12, 16]. Contact angles of 
materials were shown to decrease with temperature; however, not markedly [34, 35]. 
Since the temperature coefficient for PEG and acrylic polymers is less than 0.1 mJ/m2/K 
[33], the interfacial energies were determined at 25ºC as approximation although the 
coating temperature and curing temperature were 70-75ºC and 60ºC, respectively. No 
contact angle data could be obtained for compacts made from Eudragit® L 100-55 with a 
TEC content of 40%. At this high plasticizer concentration the contact angles decreased 
rapidly both for diiodomethane and water.  
The surface free energy can be calculated from the surface free energy parameters 
using the following equation [15]: 
)(2 −++= γγγγ LWTOT                                             (6) 
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where γLW is the apolar Lifshitz-van der Waals parameter. γ+ and γ- are the Lewis-acid 
and Lewis-base component of the surface free energy, respectively which describe 
electron donor/acceptor interactions. Since all materials from Table 6.3 were determined 
to be monopolar Lewis-bases, the surface free energy equaled the Lifshitz-van der Waals 
parameter. The surface free energy of Eudragit® L 100-55 increased with increasing TEC 
content. In contrast, the addition of PEG 3350 to the coating formulation did not show 
any influence on the surface free energy of the polymer, although PEG 3350 resulted in 
an increase of the Lewis-base component of the surface free energy.  
The spreading coefficient of material A over material B can be determined using 
the following equation [12, 36]: 
ABABS γγγ −−= >0                                                (7) 
where γ is the surface free energy. The interfacial energy γAB between two materials was 
calculated according to the following equation [15]: 




AAB γγγγγγγγγγγ          (8) 
where γLW is the apolar component, γ+ is the electron-acceptor, and γ- is the electron 
donor parameter. Since γ+ was set to zero, the interfacial energies were based on the 
Lifshitz-van der Waals (LW) interactions. The interfacial energy is the free energy 
change in expanding the interfacial area between two materials [36]. The interfacial 
energies between PEG 3350, three tablet formulations and various Eudragit® L 100-55 
powder coating formulations are presented in Table 6.4. Since PEG 3350 had a low 
interfacial energy with pre-plasticized Eudragit® L 100-55, which decreased with 
increasing TEC levels, PEG 3350 was an effective priming material and has been used as 
 138
low melting coating excipient for the powder-coating with pre-plasticized Eudragit® L 
100-55.  
 The chlorpheniramine maleate and sodium valproate formulations were chosen 
since they have been used previous in dry coating studies with Eudragit® L 100-55 [4]. 
The contact angles for water and diiodomethane were 21.3 ± 1.5º and 48.7 ± 1.2º for 
chlopheniramine maleate tablets (formulation 1), 40.0 ± 3.6º and 60.3 ± 1.2º for 
chlopheniramine maleate tablets (formulation 2), and 41.3 ± 2.1º and 69.3 ± 1.5 for 
sodium valproate tablets (formulation 3). These contact angles resulted in γLW and γ- 
values of 35 mJ/m2 and 71 mJ/m2 for chlorpheniramine maleate tablets (formulation 1), 
28 mJ/m2 and 61 mJ/m2 for chlorpheniramine maleate tablets (formulation 2), and 23 
mJ/m2 and 67 mJ/m2 for sodium valproate tablets (formulation 3). The interfacial energy 
between the tablet formulations and pre-plasticized Eudragit® L 100-55 increased with 
increasing TEC levels and thus affected spreading over the investigated tablet 
formulations, whereas PEG 3350 did not have a strong impact (Table 6.4). Using the 
interfacial energies the spreading coefficients of PEG 3350 and pre-plasticized Eudragit® 
L100-55 over the tablet cores were determined and the results are presented in Figure 6.3. 
The spreading coefficients of PEG 3350 over tablet formulation 1 through 3 were -12 
mJ/m2, -20 mJ/m2, and -27 mJ/m2, respectively. Positive spreading coefficients result in 
spreading of one material over the other. In this study, most spreading coefficients are 
negative but it should be noted that only Lifshitz-van der Waals interactions were 
considered in the model. The calculated spreading coefficients for the sodium valproate 
tablets are highly negative and therefore more difficult to compensate with other aspects 
of adhesion compared to the chlorpheniramine maleate tablets. Tablet formulation 1 and 
 139
2 differ in the filler composition. Tablets with higher microcrystalline cellulose content 
were characterized by a lower spreading coefficient compared to tablets containing 
lactose monohydrate in the formulation. 
 
6.4.4 Mechanical properties 
 
 After powder deposition and packing, sintering, coalescence, and film leveling 
occur during the curing process of dry-powder coatings [2]. In this study the progress of 
film formation and extent of polymer particle fusion was studied using a puncture test on 
free films and the results are shown in Figure 6.4. The data were then analyzed using a 
One-way ANOVA followed by Tukey’s HSD (p<0.05) of all possible paired 
comparisons and the results are presented in Table 6.5. The glass transition temperature 
of Eudragit® L 100-55 pre-plasticized with 20 to 40% TEC has been previously shown to 
be below the curing temperature of 60ºC and thus in a rubbery state for all TEC levels 
after admixture of PEG 3350 [4]. The powder-cast films were characterized by an initial 
maximum load of less than 0.6 N which corresponded to a puncture strength of less than 
0.1 MPa for all investigated plasticizer levels (data not shown). Eudragit® L 100-55 films 
containing TEC concentrations of 30% and 40% based on the polymer weight were 
characterized by an increase of puncture strength over time, whereas it did not change for 
films containing 20%, as shown in Figure 6.4. The puncture strength plateaued after 6 
hours of curing while the elongation continuously increased over 24 hours. The 
elongation increased for all TEC levels. It has been demonstrated that increasing 
plasticizer levels result in an increase in elongation of polymer films but a decrease in 
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tensile strength and elastic modulus [37, 38]. Interestingly, both the elongation and the 
puncture strength of the Eudragit® L 100-55 dry-powder films increased with increasing 
TEC levels over a curing time of 12 hours. Plasticizer molecules that are embedded in a 
polymer matrix generally reduce interactions between polymer chains and number of 
entanglements, and hence increase the flexibility and decrease the mechanical strength of 
polymer films. The increase in puncture strength for powder-cast films with rising TEC 
levels over 12 hours hence demonstrated that polymer particle fusion and film formation 





The thermal characterization of the curing process revealed stability of the 
components at the investigated curing conditions. Both viscosity and surface free energy 
of Eudragit® L 100-55 coating formulations were shown to be a function of the TEC 
content. The plasticizer reduced the viscosity and increased the surface free energy of the 
polymer. Both low viscosity and high surface free energy were previously shown to 
accelerate polymer particle fusion in dry coating processes. The addition of PEG 3350 
can improve film formation due to an additional reduction of viscosity. PEG 3350 did not 
affect the surface free energy of Eudragit® L 100-55. Mechanical testing of powder-cast 
films showed an increase of both elongation and puncture strength over the curing 
process as criterion for polymer particle fusion, where film formation progressed faster at 
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6.7 TABLES AND FIGURES 
 
Table 6.1: Tablet formulations. 
 
 Formulation 1 Formulation 2 Formulation 3
Model drug CPM CPM Sodium valproate15% 15% 15% 
Avicel® PH-101 46.25%  




Kollidon® 30 3% 3% 3% 
Magnesium stearate 0.5% 0.5% 0.5% 
Cab-O-Sil 0.25% 0.25% 0.25% 
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Table 6.2: Cumulative percent weight loss of Eudragit® L 100-55, PEG 3350, and TEC 
after isothermal TGA analysis at 60ºC for 6 hours. 
 
Material Eudragit® L 100-55 TEC PEG 3350
Weight loss after 6 
hours at 60ºC 0.13% 2.19% 0.07% 
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Table 6.3: Influence of plasticizer content and the addition of PEG 3350 on the surface 
free energy parameters of Eudragit® L 100-55 that were determined using contact angle 
measurements (standard deviation, n = 3). 
 
 Contact angles for liquids (º) 
Surface free energy 
parameters (mJ/m2) 
 Water Diiodomethane γ+ γ- γLW 
PEG 3350 22.0±2.6 24.3±2.1 0 58 46 
Eudragit® 
L 100-55 
0 TEC (bulk) 63.0±3.6 50.0±1.0 0 26 34 
20 TEC 58.7±1.2 31.0±1.0 0 23 44 
30 TEC 58.7±2.1 26.0±2.0 0 22 46 
0 TEC/10PEG 60.3±1.2 48.7±1.5 0 28 35 
20 TEC/10PEG 49.0±1.5 29.0±1.0 0 33 45 
30 TEC/10PEG 21.3±1.5 16.7±1.5 0 56 49 
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Table 6.4: Interfacial energies (γ) between PEG 3350 and Eudragit® L 100-55 containing 
various amounts of TEC and PEG 3350 as well as between PEG 3350, Eudragit® L 100-
55 and two model tablet formulations. 
 
 










Polymer (P) γP-PEG (mJ/m2) γP-CPM (mJ/m2) γP-CPM (mJ/m2) γP-SoVa (mJ/m2) 




(bulk) 1 0 0 1 
20 TEC 0 1 2 3 
30 TEC 0 1 2 4 
0 TEC/ 
10PEG 1 0 0 1 
20 TEC/ 
10PEG 0 1 2 4 
30 TEC/ 
10PEG 0 1 3 5 
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Table 6.5: Results of Tukey’s HSD post hoc test (p<0.05) for mechanical properties of 
Eudragit® L 100-55 powder-cast films with 20, 30, or 40% TEC after 3, 6, 12, and 24 
hours of curing at 60ºC. 
 
 20TEC 30TEC 40TEC 
3h 6h 12h 24h 3h 6h 12h 24h 3h 6h 12h 24h
20TEC 3h -   * * * *
6h ** -  * * * *
12h ** ** - * * * *
24h   ** - * * * *
30TEC 3h   ** - * * * *
6h   ** - * * * *
12h    ** - *   *
24h    - * * * 
40TEC 3h   ** -   *
6h ** **  ** ** ** ** -  
12h ** ** ** ** ** ** ** ** ** ** - 
24h ** ** ** ** ** ** ** ** ** ** ** -
 
** Significant difference elongation [%]. * Significant difference puncture strength 
[MPa].  
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Figure 6.2: Influence of plasticizer content and the addition of 10% PEG 3350 based on 
the weight of the ground extrudate on the shear viscosity of Eudragit® L 100-55. ♦ 
Eudragit® L 100-55 containing 20% TEC. ■ Eudragit® L 100-55 containing 30% TEC. ▲ 
Eudragit® L 100-55 containing 40% TEC. ◊ Eudragit® L 100-55 containing 20% TEC 
and PEG. □ Eudragit® L 100-55 containing 30% TEC and PEG. Δ Eudragit® L 100-55 
containing 40% TEC and PEG. The TEC content was based on the polymer weight. A: 












































Figure 6.3: Spreading coefficients for Eudragit® L 100-55 containing different levels of 
TEC. ■: PEG 3350 over Eudragit® L 100-55. □ PEG 3350 over Eudragit® L 100-55 
containing 10% PEG 3350. ▲: Eudragit® L 100-55 over CPM tablets (Formulation 1). Δ: 
Eudragit® L 100-55 containing 10% PEG 3350 over CPM tablets (Formulation 1). x: 
Eudragit® L 100-55 over CPM tablets (Formulation 2). -: Eudragit® L 100-55 containing 
10% PEG 3350 over CPM tablets (Formulation 2). ♦: Eudragit® L 100-55 over sodium 
valproate tablets (Formulation 3). ◊: Eudragit® L 100-55 containing 10% PEG 3350 over 















































Figure 6.4: Influence of curing time at 60ºC on the puncture strength and elongation of 



































































Chapter 7: Characterize the Properties of Theophylline Tablets Dry 
Powder Coated with Eudragit® E PO and Eudragit® L 100-55 
 
Abstract:  
The aim of the present study was to investigate the influence of Eudragit® E PO in 
Eudragit® L 100-55 film coatings applied to theophylline tablets by a dry powder coating 
technique on the drug release mechanism. The process was entirely liquid-free. 
Calculation of the Flory-Huggins interaction parameter based on solubility parameters 
suggested immiscibility of the copolymers. MDSC thermograms were characterized by 
two glass transitions for the investigated Eudragit® E PO/Eudragit® L 100-55 ratios and 
confirmed immiscibility of the copolymers at processing conditions. FT-IR analysis was 
employed to study binding interactions of the polymers. Due to the higher affinity of the 
plasticizer, triethyl citrate, for Eudragit® E PO compared to Eudragit® L 100-55, 
redistribution of the plasticizer was observed during the curing phase of the process. 
Plasticizer migration also affected the initial phase of drug release from powder-coated 
theophylline tablets that were stored for 4 weeks. The particle size of the coating powder 
influenced the microstructure of the film coating. Drug release from powder-coated 
tablets was dependent on the polymer blend ratio, coating thickness, and the pH of the 
dissolution medium. A broad range of pH dependent theophylline release profiles were 




Polymer blends have been widely used in liquid based coating applications to 
adjust the drug release rate, to improve processing [1] and to enhance the physical 
stability of coated dosage forms upon storage. The presence of Eudragit® L 100-55 in 
Eudragit® RS 30 D film coatings was demonstrated to stabilize the drug release rate from 
theophylline pellets [2]. Eudragit® NE 30 D film coatings that contained Eudragit® L 30 
D-55 were shown to prevent agglomeration of coated pellets during processing and upon 
storage [3]. The increase of the glass transition temperature in the presence of Eudragit® 
L 30 D-55 compared to Eudragit® NE 30 D alone was reported as the mechanism of 
stabilization. The addition of polymers that are immiscible with the film forming polymer 
were also shown to stabilize polymeric film coatings by prevention of further coalescence 
of the film forming polymer [4]. The combination of polymers that are used for sustained 
release coatings such as ethylcellulose, Eudragit® NE 30 D or Eudragit® RS with enteric 
polymers including Eudragit® L 100-55 and Eudragit® L 30 D-55, have been widely 
investigated to compensate for pH dependent solubility of active ingredients [1, 5]. 
Sustained release film coatings became more permeable following dissolution of the 
enteric polymer after passage from the stomach. Generally, it has been reported that the 
drug release kinetics was altered as a function of the mixing ratio of the two polymers 
due to changes in the permeability of film coatings [4, 5]. 
Eudragit® E PO/Eudragit® L 100-55 coprecipitates have been investigated for 
sustained drug release applications [6]. The cationic polymer Eudragit® E PO contains 
dimethylaminoethyl methacrylate and neutral methacrylic esters. The anionic copolymer 
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Eudragit® L 100-55 is based on methacrylic acid and ethyl acrylate. The ratio of free 
carboxyl groups to ester groups is approximately 1:1. Eudragit® E PO is soluble up to pH 
5.0 and swellable and permeable above pH 5.5 whereas Eudragit® L 100-55 is only 
soluble above pH 5.5 in aqueous media due to ionization of the carboxylic groups. 
Moustafine et al. characterized Eudragit® E PO/Eudragit® L 100-55 coprecipitates as 
interpolyelectrolyte complexes [6]. Such complexes contain interacting chains as well as 
defects of non-interacting chains which affect swelling behavior and drug release. 
Turbidimetry, viscosity measurements, and elementary analysis demonstrated that in 
aqueous solution, at pH 5.5, the binding ratio was approximately 1:1. FT-IR analysis 
revealed that ionic bonding was the primary binding force. Matrix tablets were prepared 
from the physical mixture and coprecipitate of Eudragit® E PO and Eudragit® L 100-55. 
Tablets prepared from the physical mixture disintegrated quickly, whereas matrixes of 
interpolyelectrolyte complexes were characterized by pH-dependent swelling and 
sustained drug release profiles. Similar results were obtained, when Eudragit® E 100 was 
coprecipitated with Eudragit® L 100 from aqueous solutions [7].  
The combination of Eudragit® E and Eudragit® L has not been investigated for the 
film coating of dosage forms. However, layering of the two polymers onto each other was 
studied by different researchers. A colon-targeted delivery system was developed when 
prior to coating with Eudragit® L 100, tablets were first subcoated with Eudragit® E 100 
and hydroxypropyl methylcellulose [8]. In contrast, a Eudragit® E overcoat was 
employed to layer an initial dose onto Eudragit® L containing films [9].  
Both Eudragit® E PO and Eudragit® L 100-55 have been used separately in dry 
coating processes of tablets. Dry powder coating, a water and organic solvent free 
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process, was developed to circumvent limitations of liquid based coating techniques for 
pharmaceutical dosage forms. The process has been successfully employed for various 
acrylic polymers [10-12]. Layering of Eudragit® E PO onto tablet cores was feasible 
without employing additional coating excipients [10]. In contrast, Eudragit® L 100-55 
required pre-plasticization with triethyl citrate and the use of polyethylene glycol 3350 as 
primer to facilitate coating powder adhesion [12]. The drug release rate was increased 
when Eudragit® E PO coatings contained hydrophilic polymers [10]. 
The aim of the present study was to investigate the influence of Eudragit® E PO in 
Eudragit® L 100-55 film coatings applied by a dry powder coating technique on the drug 
release mechanism of theophylline from coated tablets. Dry powder coating was used for 
a polymer mixture which showed incompatibilities in solution [13]. The miscibility of 
Eudragit® L 100-55 was studied and Eudragit® E PO and the physiochemical properties 





Eudragit® L 100-55 and Eudragit® E PO were donated by Evonik Industries AG 
(Piscataway, NJ). Triethyl citrate (TEC) was supplied by Vertellus Materials Inc. 
(Greensboro, NC). Talc USP (Imperial 500) was donated by Luzenac America, Inc. 
(Centennial, CO). Polyethylene glycol (PEG) 3350 NF was obtained from the DOW 
Chemical Company (Midland, MI). Lactose, monohydrate, NF, magnesium stearate, and 
the model drug theophylline (anhydrous) were purchased from Spectrum Chemical Mfg. 
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Corp. (Gardena, CA). Microcrystalline cellulose (Avicel® PH-101) was supplied by FMC 
Corp. (Newark, DE). Kollidon® K 30 was donated by BASF Corp. (Mount Olive, NJ) 





7.3.1 Preparation of coating powders 
 
 Eudragit® L 100-55 was pre-plasticized employing a method that was first 
reported by Zheng et al. [11] for Eudragit® RS and Eudragit® RL PO and later adapted 
for the pre-plasticization of Eudragit® L 100-55 [12]. Eudragit® L 100-55 was pre-mixed 
with 30% TEC, based on the polymer weight using a high shear mixer. The powder blend 
was subsequently extruded employing a single screw extruder using a cylindrical die with 
an inner diameter of 6 mm (Randcastle Model RC 0750, Cedar Grove, NJ). The 
processing temperatures were set to 80ºC (zone 1), 110ºC (zone 2), 115ºC (zone 3), and 
120ºC (die). The extrudate was cut into pellets using a Randcastle RCP-2.0 pelletizer and 
ground employing a cryogenic process (CF Mikro-Bantam Cryogenic Grinder, Micron 
Powder Systems, Summit, NJ).  The pre-plasticized polymer powder was sieved for 15 
minutes and particle size fraction between 100 and 200 mesh (75 - 150μm) was used for 
the dry powder coating experiments. The same process was used when Eudragit® L 100-
55 was extruded in combination with Eudragit® E PO. Eudragit® L 100-55 was pre-
blended with 30% TEC based on the weight of the enteric polymer using a mortar and 
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pestle before Eudragit® EPO was added. Different ratios of Eudragit® E PO and 
Eudragit® L 100-55 that contained 30% TEC were investigated including 3:7, 1:1, and 
7:3. The temperature zones of the extruder were set to: zone 1 65ºC, zone 2 110ºC, zone 3 
115ºC, and die 120ºC. The Eudragit® E PO/L 100-55 extrudate was processed identically 
as the pre-plasticized Eudragit® L 100-55 to obtain a fine powder. 
 
7.3.2 Preparation of core tablets  
 
 Theophylline anhydrous (15%), Avicel® PH 101 (66.25%), lactose monohydrate 
(15%), and Kollidon® K 30 (3%) were mixed in a low shear blender for 15 minutes. 
Subsequent to the addition of the magnesium stearate (0.5%) and colloidal silicon dioxide 
(0.25%), the mixture was blended for 5 more minutes. The tablets were compressed using 
a single stage press (F-press, Stokes, Bristol, PA) employing deep concave 5 mm 
punches. The tablet weight was 79.2±1.2 mg (n = 6, standard deviation). The tablet 
hardness (9.1±0.6 kg, n = 6, standard deviation) was determined using a tablet tester 
(WTP-3, Heberlein &. Co. AG, Wattwil, Switzerland).  
 
7.3.3 Powder coating of tablets 
 
 Theophylline tablets were powder-coated in a modified laboratory scale 
spheronizer (Model 120, G.B. Caleva, Dorset, UK) as first reported by Cerea et al. and 
Zheng et al. [10, 11]. The anti-tack agent talc and the low-melting coating excipient PEG 
3350 were each added in a 10% ratio to the processed polymer, based on the weight of 
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the Eudragit® E PO/pre-plasticized Eudragit® L 100-55 mixture. PEG 3350 was also used 
as primer with a 2% weight gain, based on the tablet weight, to promote coating powder 
adhesion as previously recommended [12]. The batch size was 40 g of tablets. The 
coating conditions for the different Eudragit® E PO/pre-plasticized Eudragit® L 100-55 
ratios are presented in Table 7.1. The temperature of the coating bed was monitored 
employing a Fluke 61 Infrared Thermometer (Fluke Corporation, Everett, WA). The 
feeding rate of the coating powder onto the tablets cores was adjusted according to the 
capacity of the coating powder to adhere. Subsequent to the application of the primer, the 
coating powder was manually applied at a rate of about 3 g/min until a polymer weight 
gain of approximately 10% was obtained and then reduced to 0.5 g/min. Following 
coating powder layering, the tablets were thermally treated in the operating spheronizer at 
60ºC for 6 hours.  
 
7.3.4 Particle size distribution 
 
 The particle size distribution of Eudragit® E PO was analyzed using laser light 
diffraction (Malvern Mastersizer S, Malvern Instrument Limited, Malvern, 
Worcestershire, UK). Dv 10, Dv 50, and Dv 90, the cumulative percent undersize, were 
determined using the approximate diffractive index of Eudragit® E PO (nD20 = 1.3899) in 
purified water (nD20 = 1.3300).  
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7.3.5 Modulated differential scanning calorimetry 
 
 Modulated differential scanning calorimetry (MDSC) was performed using a 
Thermal Advantage Model 2920 (TA Instruments, New Castle, DE) to characterize the 
thermal properties of Eudragit® E PO, pre-plasticized Eudragit® L 100-55, their physical 
mixtures, their melt extrudates, and free films of their mixtures. Universal Analysis 2000 
software was employed to determine the inflection glass transition temperature using the 
reverse heat flow of the second heating cycle. Prior to analysis, the samples were sealed 
in aluminum pans (Kit 0219-0041, Perkin-Elmer Instruments, Norwalk, CT). The 
temperature ramp rate was 3°C/min at a modulation rate of ±1.00°C every 60 seconds. 
Ultrahigh pure nitrogen was employed as purge gas at a flow rate of 150 ml/min.  
 
7.3.6 Drug release study 
 
 In vitro dissolution testing was conducted to investigate the release rate of 
theophylline from powder-coated tablets in either 900 mL of 0.1N HCl or in 900 mL pH 
6.8, 50 mM phosphate buffer for 12 hours. Furthermore, the USP Drug Release Standard 
for Enteric Coated Articles Method A was used to characterize the enteric release 
properties of the coated tablets. Following two hours dissolution in 750 mL, 0.1N HCl, 
250 mL of 0.2M tribasic sodium phosphate solution were transferred to the dissolution 
vessel to adjust the pH of the dissolution medium to 6.8 ± 0.05. The drug release study 
was then resumed for 2 more hours. All dissolution media were maintained at 37 °C and 
agitated at 50 rpm using USP 30 Apparatus 2 (Vankel VK 7000; Vankel Industries Inc., 
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Cary, NC). The dissolution properties of the coated tablets were investigated by placing 
three tablets into each of three dissolution vessels respectively (n = 3 x 3 tablets/vessel). 
Samples were withdrawn by an autosampler (Vankel VK 8000; Vankel Industries Inc., 
Cary, NC). 
 UV Analysis was performed to analyze the dissolution samples for theophylline 
content using a μQuant (Bio-Tek® Instruments Inc., Winooski, Vermont) at the detection 
wavelength 278 nm. Prior to analysis, the samples were filtered using 0.45 μm nylon 
filters and diluted with an equal volume of dissolution medium. Linearity was 
demonstrated from 1 to 25 μg/mL (R2 > 0.999). One-way ANOVA followed by Tukey’s 
HSD post-hoc test was conducted using SPSS Version 15.0. 
 
7.3.7 Film preparation and dissolution 
 
Free films were prepared from mixtures of Eudragit® E PO and pre-plasticized 
Eudragit® L 100-55 that contained 30% TEC based on the polymer weight. The polymer 
mixture was blended with 10% PEG 3350 using a mortar and pestle. Following 
compression into films using a compression force of 10 kN on 22 cm2 of film for 3 
minutes to ensure a dense powder packing (Carver Laboratory Press, Model M, ISI Inc., 
Round Rock, TX), the samples were cured in a static oven at 60ºC for 24 hours. The 
compression force was reduced during the thermal treatment to 10 N. 
Film samples of 3x3 mm were immersed in 15 mL of 0.1N HCl and shaken at 100 
rpm at 37ºC for 2 hours using a Lab-Line® Orbit Environ-Shaker (Lab-Line Inctruments 
Inc., Melrose Park, IL). Following the addition of 5 mL of 0.2M tribasic sodium 
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phosphate solution to adjust the pH of the dissolution medium to 6.8 ± 0.05, the film 
dissolution was continued for 2 more hours. 
 
7.3.8 Scanning electron microscopy 
 
 The surface morphology of powder-cast films prior to and after dissolution and 
coated tablets was analyzed using a LEO 1530 Gemini scanning electron microscope 
(Zeiss/LEO, Oberkochen, Germany) operated at 10 kV. The samples were sputter coated 
with platinum/palladium (80:20) using a Cressington Sputter Coater 208 HR equipped 
with a Thickness Controller MTM 20 (Cressington Scientific Instruments Ltd., Watford, 
UK) at 20 mA to a coating thickness of 15 nm.  
 
7.3.9 Fourier transform infrared spectroscopy 
 
To characterize interactions occurring between Eudragit® E PO and pre-
plasticized Eudragit® L 100-55 Fourier transform infrared spectroscopy was conducted 
using a Nicolet Magna IR-560 FT-IR spectrometer. Eudragit® E PO, Eudragit® L 100-55, 
pre-plasticized Eudragit® L 100-55, their physical mixtures and their heat-treated 
physical mixtures were compressed with potassium bromide into pellets under vacuum 





7.4 RESULTS AND DISCUSSION 
 
7.4.1 Powder coating of theophylline tablets 
 
 The Hoftyzer/van Krevelen 3-D solubility parameters solubility parameter 
of Eudragit® E PO and Eudragit® L 100-55 were determined to be 21.8 (J/cm3)0.5 and 
23.1 (J/cm3)0.5 respectively at 25ºC. It has been reported that differences in drug/excipient 
solubility parameters of <7 MPa0.5 were used to predict significant miscibility between 
the components [14]. Due to the restricted mobility of polymer segments, the Flory-
Huggins theory has been widely used for the mixing of polymers [15, 16]. The interaction 
parameter χ12 can be calculated using the following equation: 
                                                     χ12 = (Vr / RT)(δ1 – δ2)2                                                                 (1) 
where Vr is the reference volume (100 cm3/mol for polymers [16]), R is the universal gas 
constant, T is the absolute temperature, δ are the solubility parameter, and indices 1 and 2 
refer to the blended polymers. If the interaction parameter χ12 is smaller than the critical 
value of the interaction parameter, the polymer blend was considered miscible [16]. The 
critical value of the interaction parameter (χ12)cr can be calculated from the degree of 
polymerization (N): 
                                                   (χ12)cr = 0.5 (N1-0.5 + N2-0.5)                                             (2) 
According to the calculated interaction parameter 0.1 at 25ºC and the critical interaction 
parameter 0.0, Eudragit® E PO and Eudragit® L 100-55 were expected to be immiscible.  
Theophylline tablets were powder coated with Eudragit® E PO/Eudragit® L 100-
55 powder mixtures in a modified spheronizer as used for the single polymers [10, 12]. 
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Previously, Eudragit® E PO was coated onto theophylline tablets at a bed temperature of 
55-60ºC, whereas pre-plasticized Eudragit® L 100-55 containing 30% TEC based on the 
polymer weight was layered onto tablets using a bed temperature of 70-75ºC. A priming 
layer of PEG 3350 was required for the powder coating of tablets with pre-plasticized 
Eudragit® L 100-55 as well as the addition of PEG 3350 in a 10% ratio to the coating 
powder [12]. Talc has been commonly used in a 10% ratio in powder coating applications 
[11]. Depending on the polymer ratio of the physical mixtures, the coating conditions 
were adjusted as presented in Table 7.1. Increasing Eudragit® E PO amounts required 
lower coating temperatures. However, the curing conditions were unchanged for all 
investigated formulations. The coating powders prepared from the physical polymer 
mixtures adhered well onto the tablet cores. 
Depending on the polymer ratio, powder coating with hot-melt extruded mixtures 
of Eudragit® E PO and Eudragit® L 100-55 containing 30% TEC based on the weight of 
the enteric polymer resulted in no or uneven coating powder adhesion. Different 
formulation factors and processing parameters were varied to improve adhesion of the 
hot-melt extruded powders, including reduction of talc concentration in the coating 
formulation as suggested by Kablitz et al. [17], the increase of the TEC and PEG 3350 
levels in the coating powder, the elimination of PEG 3350 as primer, and the variation of 
the coating bed temperature from 55ºC to 90ºC. However, sticking of the extruded 
coating powder formulations to the tablet cores was not enhanced at the investigated 
processing conditions. There was no coating powder adhesion observed for the hot-melt 
extruded 3:7 ratio whereas formulation of the 1:1 and 7:3 ratio resulted in uneven coating 
powder layering onto the tablet cores. Free film studies revealed, that there was no film 
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formation occurring for a powder-cast film containing an extruded 3:7 mixture of 
Eudragit® E PO and Eudragit® L 100-55 that was plasticized with 30% TEC based on the 
weight of the enteric polymer when cured at 60ºC for 24 hours (data not shown). In 
contrast, film formation was observed for the 1:1 and 7:3 ratios.  
DSC analysis was performed to investigate the distribution of the plasticizer 
within the extruded polymer mixtures. As shown in Figure 7.1, Eudragit® E PO and 
Eudragit® L 100-55 were not miscible at the employed ratios and extrusion conditions. 
The thermograms were characterized by two glass transition temperatures. Eudragit® E 
PO did not plasticize the enteric polymer. In contrast, thermal analysis of coprecipitates 
of Eudragit® E PO and Eudragit® L 100-55 demonstrated miscibility [6, 18]. However, 
Gallardo et al. proposed that Eudragit® L 100-55 was plasticized by Eudragit® E PO, 
whereas Moustafine et al. detected glass transition temperatures at significantly higher 
temperatures than calculated values using the Gordon-Taylor equation. Hot-melt extruded 
mixtures of Eudragit® E PO and Eudragit® L 100-55 that were plasticized with TEC were 
characterized by an uneven distribution of the plasticizer and a higher affinity of TEC for 
Eudragit® E PO (Figure 7.1 B). At the 1:1 and 7:3 ratio the glass transition corresponding 
to Eudragit® L 100-55 was approximately the same as of pure bulk polymer 
(123.7 ± 0.6°C, [12]). Non-miscibility of the polymers and uneven distribution of the 
plasticizer resulted in a large difference of the two glass transition temperatures and thus 
in insufficient coating powder adhesion of the hot-melt extruded mixtures.  
The DSC thermograms of the physical mixtures also showed some redistribution 
of the plasticizer (Figure 7.1 A), however, not as strong as for the hot-melt extruded 
mixtures. Eudragit® L 100-55 containing 30% TEC based on the polymer weight was 
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characterized with a glass transition at 65.29ºC, whereas Eudragit® E PO showed a 
transition at 43.20ºC. The glass transitions of Eudragit® E PO occurred at lower 
temperatures and the glass transitions of Eudragit® L 100-55 were increased in the 
physical mixtures. Uneven plasticizer distribution in film coatings prepared from aqueous 
dispersions of different polymers has been reported in the literature. Lecomte et al. 
reported a higher affinity of dibutyl sebacate to ethylcellulose than to Eudragit® L 30 D-
55 [19]. Different affinity of the plasticizer to the film forming polymers may result in 
redistribution within the polymer mixture and may affect the physical stability upon 
storage. Adequate curing and sufficient pre-plasticization time prior to coating to ensure 
“equilibrated” plasticizer uptake by the polymers were shown to prevent changes of the 
drug release profiles during storage [19]. Generally, a homogeneous plasticizer 
distribution throughout the polymer is recommended [20]. 
DSC profiles of powder cast films from Eudragit® E PO/Eudragit® L 100-55 
physical mixtures that also contained 10% PEG 3350 as low melting coating excipient 
are presented in Figure 7.1 C. The addition of PEG 3350 was shown to be essential for 
film formation of powder-coated Eudragit® L 100-55 films [12]. Due to curing at 60ºC 
for 24 hours and the PEG 3350 content, different thermograms were expected compared 
to the physical mixtures. The glass transitions of Eudragit® E PO occurred at lower 
temperatures due to repartitioning of TEC. Due to the plasticizing effect of PEG 3350 on 
the enteric polymer, the glass transitions of Eudragit® L 100-55 were also reduced for the 
3:7 and 1:1 ratio. For the 7:3 ratio the TEC redistribution effect was more pronounced 
than the plasticizing effect of PEG 3350, and thus the glass transition of Eudragit® L 100-
55 was increased to 106.79ºC. The thermogram of Eudragit® L 100-55 containing 30% 
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TEC and 10% PEG 3350 was characterized by one glass transition and the disappearance 
of the PEG 3350 melting peak due to complete miscibility [12]. The thermograms of 
powder-cast films from the 1:1 and 3:7 ratio both showed an endothermic transition due 
to melting of the PEG 3350 between 52 and 54ºC. The melting point was decreased 
compared to the one of bulk PEG 3350, which occurred at approximately 61ºC [12] and 
was characterized by a low heat of fusion. Increasing Eudragit® E PO concentrations in 
the powder-cast films hence resulted in a decreasing miscibility of PEG 3350 in the 
polymer mixture. 
 
7.4.2 Theophylline release study 
 
The drug release profiles of theophylline tablets that were powder coated are 
presented in Figure 7.2. The core tablets disintegrated quickly and theophylline was 
completely released after 30 minutes of dissolution in both 0.1N HCl and pH 6.8 
phosphate buffer. The drug release from the powder-coated tablets was strongly 
dependent on the pH of the dissolution medium. As expected, in 0.1 N HCl the drug 
release rate increased with increasing Eudragit® E PO concentration in the film coating. 
Since Eudragit® L 100-55 is soluble above pH 5.5, increasing fractions of the enteric 
polymer in the film coating resulted in an accelerated release in pH 6.8 phosphate buffer. 
Not only the ratio of the polymers but also the polymer weight gain affected the drug 
release rate. The variability of the dissolution profiles decreased with higher polymer 
weight gains. Since thicker film coatings result in longer diffusion pathways for 
dissolution medium to penetrate into the core, for drug molecules to exit the core, and for 
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dissolved polymer molecules to leave of the film, higher polymer weight gains resulted in 
a decrease in drug release rate. The effect of weight gain was most pronounced for films 
with high concentration of Eudragit® E PO in pH 6.8 buffer. During film dissolution in 
pH 6.8 buffer, strong swelling was observed for the powder-cast films and approximately 
doubled its size, whereas the films did not swell in acid. Water imbibition in the 
Eudragit® E PO matrix may weaken the mechanical strength of the film coating and 
result in a fast release at low coating levels. The energy at break of Eudragit® L 30 D-55 
films was shown to increase after immersion in 0.1N HCl [21].  
SEM micrographs in Figure 7.3 of the surface of theophylline tablets that were 
powder-coated with physical mixtures of Eudragit® E PO and pre-plasticized Eudragit® L 
100-55 show a dense film. As in previous powder-coating studies, the film surface of 
powder coated films is not as even as the one of film coatings that were prepared using 
aqueous or organic coating processes and is characterized by some individually visible, 
non-fused polymer particles [10, 12, 22].    
Figure 7.4 shows the dissolution profiles of powder-coated theophylline tablets in 
pH 6.8 phosphate buffer following dissolution in 0.1N HCl for two hours. The 7:3 ratio 
was not tested, since more than 90% of theophylline were release after 2 hours in 0.1N 
HCl. After the pH change of the dissolution medium, the drug release rate increased for 
both investigated formulations. To further investigate the drug release mechanism, SEM 
studies were performed. The powder-cast film of Eudragit® E PO and pre-plasticized 
Eudragit® L 100-55 in a 7:3 ratio was initially characterized by a dense and smooth 
surface (Figure 7.5 A). After dissolution in 0.1N HCl for 1 hour, pore formation was 
observed that did not change noticeably after immersion for an additional hour in acidic 
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medium (Figure 7.5 B and C). Following two hours in 0.1N HCl, the pH of the 
dissolution medium was increased to pH 6.8. Change of the pH of the medium resulted in 
dissolution of the remaining Eudragit® L 100-55, noticeable swelling of the film and loss 
of integrity.   
As presented in Figure 7.5 B and C, large polymer domains were dissolved out of 
the film, leaving large cavities in the film coating. The influence of the preparation 
technique for films made from polymer blends was previously shown to significantly 
affect the microstructure of polymer films and thus drug release profiles [23]. Due to the 
different film forming mechanism, polymer films prepared from organic solution are 
characterized by a high degree of polymer-polymer interpenetration while separate 
polymer domains were present in films based on aqueous dispersions. This phenomenon 
affected the swelling behavior of polymer films that were composed of ethylcellulose and 
Eudragit L and thus the drug release kinetics of coated propranolol HCl pellets. Swelling 
of Eudragit® L was decreased in films prepared from organic solution due to a high 
degree of polymer interpenetration [23]. The particle size distribution of Eudragit® L 
100-55 that was pre-plasticized with 30% TEC was previously analyzed using laser light 
diffraction [12]. The Dv10, Dv50, and Dv90 values were 35.13 μm, 77.50 μm, and 147.58 
μm, respectively. The span index was 1.451. In contrast, bulk Eudragit® E PO was 
characterized by a much smaller particle size using the same analytical technique. The 
Dv10, Dv50, and Dv90 values were determined to be 0.69 μm, 7.13 μm, and 15.93 μm, 
respectively. The span index was 1.451. The mean particle size of Eudragit® L 30 D-55, 
Eudragit® RS 30 D, and Eudragit® NE 30 D latexes was shown to be between 100 and 
200 nm [24]. The coating powder particle size used for the dry coating of theophylline 
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tablets was higher, thus the degree of polymer interpenetration of blended polymers is 
expected to be lower in dry coating applications compared to aqueous and organic 
coating processes. As a result larger polymer domains are dissolved out of the film 
coating during dissolution.  
 
7.4.3 FT-IR results 
 
The characteristic bands of the FT-IR transmittance spectrum of Eudragit® E PO 
were at 2770 cm-1 and 2820 cm-1 for the absorption of the dimethyl amino group [20]. 
The spectrum of Eudragit® L 100-55 was characterized by one band at 1705 cm-1 that is 
assigned to the C=O vibration of the carboxylic acid group [20]. Both spectra showed a 
band at 1730 cm-1 corresponding to the C=O vibration of the esterified carboxyl group 
[20]. In FT-IR spectra of copolymer complexes, the characteristic bands of the carboxylic 
acid and the ternary amino group were reduced in intensity or disappeared, whereas new 
bands appeared at 1560 cm-1 and at 2560 cm-1 [6, 18]. The new bands were assigned to 
the formation of carboxylate groups and ionized dimethylamino groups and were not 
observed in the current study. As shown in Figure 7.6, no new band or band shifts were 
detected when the FTIR spectra of the single components, physical mixture, and the 
annealed physical mixture of different ratios were compared. Although the intensity of 
the bands decreased for the annealed physical mixture, the relative band intensity was 
unchanged. Upon heating, the plasticizer redistributed within the polymer mixture. The 
incorporation of plasticizers into a polymer was shown influence the density of the 
polymer [25] and thus may affect the transmittance. TEC could not be detected due to 
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structural similarity such as ethyl ester. The only difference in relative band intensity of 
physical mixture and annealed physical mixture was observed for bands at 1470cm-1 and 
1460cm-1 which can be assigned to CH2 and CH3 bending corresponding to a minor 
variation in ratio of the copolymers. Consequently binding interactions and complex 
formation between Eudragit® E PO and Eudragit® L 100-55 were not expected during 
film formation from the physical mixtures. The bands at 2370cm-1 and 2350cm-1 were 
attributed to atmospheric carbon dioxide.  
 
7.4.4 Physical stability of powder coated tablets  
 
 The physical stability of theophylline tablets that were powder-coated with a 25% 
weight gain of Eudragit® E PO and pre-plasticized Eudragit® L 100-55 in a 1:1 ratio was 
investigated using dissolution testing. The application of a talc overcoat was not 
necessary since the film coating did not show tackiness. The powder-coated tablets were 
sealed in HDPE containers with desiccant to exclude the influence of humidity during 
storage at 25ºC/60% RH or 40ºC/75% RH for 4 weeks. Prior to dissolution testing, the 
samples were equilibrated to ambient temperatures for 24 hours. The theophylline release 
profiles as function of storage time and conditions are presented in Figure 7.7. One-way 
ANOVA was employed to determine statistical differences of the cumulative 
theophylline release percentage from powder-coated tablets stored either at 25ºC/60% 
RH or at 40ºC/75% RH for 4 weeks at different time points. The ANOVA p values are 
listed in Table 7.2. Only the first time point demonstrated a statistical difference in the 
data both for dissolution in 0.1N HCl and pH 6.8 phosphate buffer. At the remaining time 
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points there was no statistical difference in the cumulative drug release percentage data 
(p<0.05). Tukey’s HSD revealed a statistical difference of the initial cumulative drug 
release at 1 hour compared to 4 weeks of storage at either 25ºC/60% RH or 40ºC/75% 
RH (p<0.05). However, there was no significant difference between the cumulative 
theophylline release between the samples stored at 25ºC/60% RH or 40ºC/75%. The drug 
release profiles were shown to be identical, besides the first time point which was taken 
after one hour of dissolution. Storage with desiccant can affect the hydration state of the 
polymer film and thus influence the drug release rate. The cumulative theophylline 
release at 1 hour was slightly more reduced in pH 6.8 medium than in 0.1N HCl. In 
buffered medium Eudragit® L 100-55 dissolved out of the film coating, whereas 
Eudragit® E PO was the film forming matrix. Plasticizer migration from the enteric 
polymer phase to Eudragit® E PO phase stabilized the film matrix. However, there was 





Powder coating technology was successfully employed for polymer blends that 
demonstrated incompatibilities in solution. Coating with Eudragit® E PO/Eudragit® L 
100-55 mixtures provided dosage forms with pH-dependent release profiles. The results 
of MDSC and SEM demonstrated non-miscibility of Eudragit® E PO and Eudragit® L 
100-55 in different ratios and for diverse processing methods. The calculated Flory-
Huggins interaction parameter based on solubility parameters supported the data. Due to 
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the film formation process and particle size of the copolymers the degree of polymer 
interpenetration of the blended polymers powders was less than expected in liquid based 
coating processes. The theophylline release rate from coated tablets was significantly 
controlled by the ratio of Eudragit® E PO and Eudragit® L 100-55 and the coating level. 
Different affinity of the plasticizer to the film forming polymers resulted in redistribution 
of the plasticizer during the curing phase of the coating process and slightly affected the 
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7.7 TABLES AND FIGURES  
 




Formulation I Formulation II Formulation III
Eudragit®  EPO 30% 50% 70% 
Eudragit® L 100-55 (pre-
plasticized with 30% TEC based 
on the polymer weight) 
70% 50% 30% 
PEG 3350 10% w/w based on polymer powder weight
Talc 10% w/w based on polymer powder weight
Primer 2% PEG 3350* 
Rotation speed 170 rpm
Coating bed temperature 70-75ºC 70-75ºC 65-70ºC
Curing rotation speed  120 rpm
Curing bed temperature 60ºC





Table 7.2: p values from One-way ANOVA for percent theophylline released from 
powder-coated tablets initially and after one month of storage.   
 
Dissolution time 1h 2h 3h 4h 5h 6h
p value for drug release in 0.1N HCl 0.001 0.199 0.334 0.057 0.931 0.863





Figure 7.1: MDSC thermograms of different ratio Eudragit® E PO / pre-plasticized 
Eudragit® L 100-55 mixtures. A: Physical mixture. B: Hot-melt extruded mixture. C: 















































































































































Figure 7.2: Influence of Eudragit® E PO / pre-plasticized Eudragit® L 100-55 ratio and 
coating level on the release of theophylline from powder-coated tablets using USP 30 
apparatus 2. (A) Dissolution in 900mL of 0.1N HCl. (B) Dissolution in 900mL pH 6.8 
50mM phosphate buffer. ◊: 3:7, 15% weight gain. ♦: 3:7, 25% weight gain. □: 1:1, 15% 
weight gain. ■: 1:1, 25% weight gain. Δ: 7:3, 15% weight gain. ▲ 7:3, 25% weight gain. 

























































































Figure 7.3: Influence of Eudragit® E PO / pre-plasticized Eudragit® L 100-55 ratio on 















Figure 7.4: Influence of Eudragit® E PO / pre-plasticized Eudragit® L 100-55 ratio on the 
release of theophylline from powder-coated tablets using USP 30 apparatus 2. 
Dissolution in 750mL of 0.1N HCl for 2 hours followed by 2 hours in 1000mL pH 6.8 
50mM phosphate buffer after pH adjustment at 37ºC and 50 rpm. Total weight gain: 










































Figure 7.5: SEM micrographs of surface of Eudragit® E PO / pre-plasticized Eudragit® L 
100-55 (ratio: 3:7) powder-cast film. Dissolution 0.1N HCl for 2 hours followed by 2 
hours pH 6.8 50mM phosphate buffer after pH adjustment at 37ºC. A: Initial. B: after 1 
hour in 0.1N HCl. C: after 2 hours in 0.1N HCl. D: after 2 hours in 0.1N HCl followed by 














Figure 7.6: FT-IR spectra of Eudragit® L 100-55, pre-plasticized Eudragit® L 100-55, 
Eudragit® E PO, and pre-plasticized Eudragit® L 100-55/Eudragit® E PO mixtures. I: 
physical mixtures. II: physical mixtures heated at 80ºC for 3 hours and 60ºC for 24 hours. 
A: Eudragit® EPO. B: 7:3. C: 1:1. D: 3:7. E: pre-plasticized Eudragit® L 100-55 (30% 
















































Figure 7.7: 4 week stability of theophylline tablets powder-coated with Eudragit® E PO / 
pre-plasticized Eudragit® L 100-55 in a 1:1 ratio using USP 30 apparatus 2 at 37ºC and 
50 rpm. Dissolution in 900mL of dissolution medium. Total weight gain: 25%. ▲: initial 
dissolution in 0.1N HCl. Δ: initial dissolution in pH 6.8 50mM phosphate buffer. ♦: 4 
weeks at 25ºC / 60% RH, 0.1N HCl. ◊: 4 weeks at 25ºC / 60% RH, pH 6.8 50mM 
phosphate buffer. ■: 4 weeks at 40ºC / 75% RH, 0.1N HCl. □: 4 weeks at 40ºC / 75% 













































Chapter 8: Summary and Conclusion 
 
 In this research project, I investigated the processing parameters and formulation 
factors influencing the dry-powder coating of tablets with pre-plasticized Eudragit® L 
100-55. The model drugs chlorpheniramine maleate (CPM) and sodium valproate were 
previously shown to require large weight gains of enteric polymer to delay the drug 
release in acidic media using aqueous coating techniques.  
 Unlike aqueous coating, powder coating reduced partitioning of the drug into the 
film coating during the coating process. Polyethylene glycol 3350 (PEG 3350) was used 
as primer for powder coating of tablets with pre-plasticized Eudragit® L 100-55 and was 
also added to the coating formulation to enhance coating powder adhesion and film 
formation. Following powder layering, the powder-coated tablets were thermally cured to 
ensure complete film formation and drug release stability. The drug release properties of 
powder-coated tablets were dependent on the curing time, coating level and plasticizer 
content. The stability of the powder-coated CPM tablets was confirmed at 25ºC/60% RH 
over a storage time of 12 weeks.  
Sodium valproate tablets were shown to require high weight gains of powder-
coated Eudragit® L 100-55 to pass the USP enteric test. The application of a Eudragit® E 
PO or Eudragit® RL PO subcoat assisted with adhesion of the enteric polymer onto the 
tablet cores and reduced the amount of enteric polymer required for enteric protection. 
PEG 3350 and Methocel® K4M were added to the subcoat formulation to increase the 
drug release in buffered media. Effectiveness as pore forming agent was a function of 
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miscibility of the excipient with the polymers. Storage stability was confirmed for 
powder-coated sodium valproate tablets at 25ºC/60% RH for all investigated 
formulations. Storage at 40ºC/75% RH resulted in fluctuations in drug release over 12 
weeks. Loss of plasticizer in the film coating at 40ºC affected the storage stability of the 
powder-coated sodium valproate tablets.  
Factors influencing film formation were investigated including thermal stability 
of the components, melt viscosity, and surface free energy of the copolymer. 
Thermogravimetric analysis revealed stability of the components at the investigated 
curing conditions. Low melt viscosity and high surface free energy were previously 
shown to accelerate polymer particle fusion and surface leveling in dry coating processes. 
The plasticizer triethyl citrate (TEC) reduced the relative melt viscosity and increased the 
surface free energy of the polymer. The addition of PEG 3350 resulted in a decrease in 
melt viscosity, however did not affect the surface free energy of Eudragit® L 100-55. 
Mechanical testing of powder-cast films demonstrated an increase in both the elongation 
and puncture strength with increasing curing times as criterion for polymer particle 
fusion. Film formation was shown to progress faster at high plasticizer levels. 
Powder coating with Eudragit® E PO/Eudragit® L 100-55 was used to 
manufacture dosage forms with pH-dependent release profiles. The Flory-Huggins 
interaction parameter based on solubility parameters as well as the results of differential 
scanning calorimetry, Fourier transform infrared spectroscopy and scanning electron 
microscopy demonstrated non-miscibility of Eudragit® E PO and Eudragit® L 100-55 in 
different ratios for diverse processing methods. The theophylline release rate from coated 
tablets was significantly controlled by the ratio of Eudragit® E PO and Eudragit® L 100-
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55. Lower affinity of the plasticizer to the enteric polymer influenced the plasticizer 
distribution within the film coating.   
 In conclusion, dry powder coating, a completely liquid free process, was 
demonstrated to be an efficient method to coat tablets with Eudragit® L 100-55. The 
coating formulations and processing parameters were adjusted for each model drug. 
Coating additives were shown to influence parameters for film formation such as melt 
viscosity and surface free energy. The incorporation of Eudragit® E PO in Eudragit® L 
100-55 film coatings provided dosage forms with a broad range of pH-dependent release 
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